https://theses.gla.ac.uk/

Theses Digitisation:
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/

This is a digitised version of the original print thesis.

Copyright and moral rights for this work are retained by the author

A copy can be downloaded for personal non-commercial research or study, without prior permission or charge

This work cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author

The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author

When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given

Enlighten: Theses
https://theses.gla.ac.uk/
research-enlighten@glasgow.ac.uk
An investigation of the innate inflammatory properties of immune stimulating complexes (ISCOMS) and their importance for the generation of adaptive immunity

Rosemary Elizabeth Smith
BSc. MSc.

This thesis is being submitted for the degree of PhD

University of Glasgow

Department of Immunology, Western Infirmary, Glasgow

March 2000
Acknowledgements

The time I spent working on my PhD has been one of the most enjoyable and happy times of my life. I feel extremely fortunate to have spent these few years in the inspiring and amiable environment that is the Department of Immunology, Western Infirmary, Glasgow. I now appreciate why so many former students strive to return to work in this wonderful city. By no means do I wish to detract from the blood, sweat and tears shed in the process of doing this study, but I would not have wished to have shared it with any other group of people.

In particular I would like to express my admiration and thanks to Allan Mowat, for cajoling, advising and grilling me throughout the course of this work, and teaching me the finer points of dancing at Scottish weddings! For my lab partners: Anne Donachie, who picked me at interview because I giggled, helped me with experiments and through our time working together has become a great and trusted friend; Tinni Sharma, a wonderful friend who has shared many times and even managed to drag me up one or two hills and Andrew Leishman who taught me almost everything I know about Rangers Football Club (and football in general) in between kicking my head in constantly! All of whom were true partners in crime, coffee and the odd gin and tonic! What laughs we had! I would also like to acknowledge the other members of staff in the department, especially Paul Garside for helpful advice and taking the mick on a regular basis, Christina Ross for FACS advice and the odd giggle or two!, Jane Hare for electron microscopy and Rod Ferrier for cutting all of my frozen sections, Sandra Scatter for attempting to teach me the finer points of RT-PCR and then consoling me when it didn’t work! In addition I would like to mention the admirable efforts of Maureen Deehan and Karen Smith who in addition to other things, got myself and Anne to the gym three times a week! Also not forgetting Annette, Steven Reid, Stephen Gauld, Elad, Kirsty, Clare, Dave Piedrafita, Dave Hunter, Damo, Will, Wanda, Jackie, Helen Arthur, Helen Goodridge, Kersten, Wei, Guil-jie, Bernard, Matt, Holger and Christina, Joan, Ana, Jeremy, David, Jimbo, Maggie, all the clinical immunologists, Helen Bailey and Anne McIlveen, who all made my time in Glasgow so jolly!

It just leaves me to express my thanks to Mum and Dad for starting me down this path in the first place and giving me such love and support, to Ed Carlyle who proof read my manuscript (brave lad!) and most importantly to Richard Humble, who has been there for me throughout, listened to my continuous moaning during the write up and kept me sane (well nearly!) - sweetheart, we can go and have some fun now!!
# List of Contents

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title Page</td>
</tr>
<tr>
<td>Acknowledgements</td>
</tr>
<tr>
<td>List of Contents</td>
</tr>
<tr>
<td>List of Figures and Tables</td>
</tr>
<tr>
<td>List of Publications</td>
</tr>
<tr>
<td>List of Abbreviations</td>
</tr>
<tr>
<td>Summary</td>
</tr>
</tbody>
</table>

**Chapter 1**

**Introduction**

| 1.0 Overview of the Immune Response | 2    |
| 1.1 Innate Immunity                | 2    |
| i) Triggers of the Innate Immune System | 2 |
| ii) The Innate Inflammatory Cascade | 3   |
| iii) Soluble Mediators of the Inflammatory Cascade | 4   |
| 1.2 The role of the Innate Cascade on the Development of Adaptive Immunity | 8   |
| 1.3 Protective Immunity            | 9    |
| 2.0 The Common Mucosal Immune System | 10   |
| 2.1 Immune Mechanisms of the GALT  | 11   |
| 2.2 Effector Immune Responses in the Mucosa | 12 |
| i) Humoral Immune Responses in the Mucosa | 13 |
| ii) Cellular Immune Responses in the Mucosa | 14 |
| 2.3 Immune Regulation in the GALT  | 15   |
| 2.4 Compartmentalisation of the GALT | 16   |
3.0 Mucosal Vaccination Strategies 17

3.1 Oral Vaccination Vectors 17
i) Live Attenuated Oral Vaccines 17
ii) Attenuated Organisms as Oral Vectors 18

3.2 Oral Adjuvants 19
i) Soluble Toxins as Adjuvants 19
ii) Particulate Oral Adjuvants 20

4.0 Immune Stimulating Complexes (ISCOMS) as Oral Vaccine Vectors 21

4.1 Structure of ISCOMS 21
4.2 ISCOMS as Parenteral Adjuvants 21
4.3 Induction of Protective Immunity by ISCOMS 23
4.4 ISCOMS as Mucosal Adjuvants 24
4.5 Mechanisms for ISCOMS Adjuvanticity 26

5.0 Specific Aims of Study 27

Chapter 2 29

Materials and Methods 29

2.1 Animals 29
2.2 Anaesthesia 29
2.3 Antigens 29
3.4 Adjuvants 30
2.5 Production of OVA ISCOMS 30
i) Palmitification of OVA 30
ii) Preparation of OVA ISCOMS 31
iii) Quantification of OVA ISCOMS Protein Content 32
iv) Quantification of Endotoxin Content in OVA ISCOMS 33

2.6 Administration of OVA ISCOMS in vivo 33
2.7 Isolation of Peritoneal Exudate Cells 33
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.8 Histological Analysis of PEC by Cytospin</td>
<td>34</td>
</tr>
<tr>
<td>2.9 Isolation of Lymphoid Cells</td>
<td>34</td>
</tr>
<tr>
<td>2.10 Flow Cytometry</td>
<td>34</td>
</tr>
<tr>
<td>2.11 Stimulation of Cytokine Production in vitro</td>
<td>35</td>
</tr>
<tr>
<td>2.12 Removal of Adherent Cells in vitro</td>
<td>35</td>
</tr>
<tr>
<td>2.13 Measurement of Reactive Oxygen Intermediate Production</td>
<td>36</td>
</tr>
<tr>
<td>2.14 Measurement of Nitric Oxide Production</td>
<td>36</td>
</tr>
<tr>
<td>2.15 Measurement of Systemic Delayed Type Hypersensitivity (DTH) Responses</td>
<td>36</td>
</tr>
<tr>
<td>2.16 Measurement of OVA-Specific Antibodies in Serum</td>
<td>37</td>
</tr>
<tr>
<td>i) Quantitation of Total IgG Antibodies</td>
<td>37</td>
</tr>
<tr>
<td>ii) Quantitation of OVA-Specific Serum IgG Antibody Isotypes</td>
<td>38</td>
</tr>
<tr>
<td>2.17 Measurement of Intestinal Secretory IgA Antibodies</td>
<td>38</td>
</tr>
<tr>
<td>2.18 Measurement of OVA-Specific Proliferative Responses</td>
<td>39</td>
</tr>
<tr>
<td>2.19 Measurement of Cytokines by ELISA</td>
<td>40</td>
</tr>
<tr>
<td>2.20 Measurement of OVA-Specific Cytotoxic T Cell Responses</td>
<td>40</td>
</tr>
<tr>
<td>2.21 Statistics</td>
<td>41</td>
</tr>
</tbody>
</table>

**Chapter 3**

**Parenteral and Oral Administration of ISCOMS induces an Inflammatory Cascade in vivo**

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>45</td>
</tr>
<tr>
<td>Experimental Protocol</td>
<td>45</td>
</tr>
<tr>
<td>Results</td>
<td>46</td>
</tr>
<tr>
<td>3.1 Recruitment of Local Inflammatory Cells after Intraperitoneal Administration of ISCOMS</td>
<td>46</td>
</tr>
<tr>
<td>3.2 Histological Examination of PEC after i.p. ISCOMS</td>
<td>46</td>
</tr>
<tr>
<td>3.3 Phenotypic Analysis of PEC Recruited by Parenteral Administration of ISCOMS</td>
<td>47</td>
</tr>
</tbody>
</table>
3.4 Parenteral Administration of ISCOMS Induces Production of Local Inflammatory Cytokines and Mediators

i) IL-1α

ii) IL-6

iii) Immunoreactive IL-12

iv) γIFN

v) TNFα

3.5 Stimulation of Nitric Oxide and Reactive Oxygen Intermediate Production after Parenteral Administration of ISCOMS

3.6 Secretion of Inflammatory Mediators by ISCOMS Induced PEC is Dependent on the Presence of Adherent Cells

3.7 Oral Administration of ISCOMS Induces Cellular Recruitment in the Gut Associated Lymphoid Tissues

3.8 Phenotypic Analysis of GALT Cells After Oral Administration of ISCOMS

i) Mesenteric Lymph Node

ii) Peyer’s Patch

3.9 Effects of Oral Administration of ISCOMS on the Production of Inflammatory Mediators by GALT Cells

i) Mesenteric Lymph Node

ii) Peyer’s Patch

Summary and Conclusions

Chapter 4

The Importance of ISCOMS Induced Inflammatory Mediators for the Generation of Antigen-Specific Immunity

Introduction

Experimental Protocol

Results
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1 Immune Responses to ISCOMS in Interleukin 12 Deficient Mice</td>
<td>73</td>
</tr>
<tr>
<td>4.1.1 Antigen-Specific DTH Responses</td>
<td>74</td>
</tr>
<tr>
<td>4.1.2 OVA-Specific Proliferative Responses</td>
<td>74</td>
</tr>
<tr>
<td>4.1.3 Antigen-Specific Cytokine Responses</td>
<td>74</td>
</tr>
<tr>
<td>4.1.4 OVA-Specific CTL Activity</td>
<td>75</td>
</tr>
<tr>
<td>4.1.5 Serum IgG Isotypes</td>
<td>75</td>
</tr>
<tr>
<td>4.1.6 Secretory Intestinal IgA Antibody Production</td>
<td>75</td>
</tr>
<tr>
<td>4.1.7 Summary</td>
<td>76</td>
</tr>
<tr>
<td>4.2 Immune Responses to ISCOMS in Interleukin 18 Deficient Mice</td>
<td>76</td>
</tr>
<tr>
<td>4.2.1 Antigen-Specific DTH Responses</td>
<td>77</td>
</tr>
<tr>
<td>4.2.2 Antigen-Specific Proliferative Responses</td>
<td>77</td>
</tr>
<tr>
<td>4.2.3 Antigen-Specific Cytokine Responses</td>
<td>77</td>
</tr>
<tr>
<td>4.2.4 OVA-Specific CTL Activity</td>
<td>78</td>
</tr>
<tr>
<td>4.2.5 Serum IgG Antibody Production</td>
<td>78</td>
</tr>
<tr>
<td>4.2.6 Summary</td>
<td>78</td>
</tr>
<tr>
<td>4.3 Immune Responses to ISCOMS in γ-Interferon-Receptor Deficient Mice</td>
<td>79</td>
</tr>
<tr>
<td>4.3.1 OVA-Specific DTH Responses</td>
<td>79</td>
</tr>
<tr>
<td>4.3.2 OVA-Specific Proliferative Responses</td>
<td>79</td>
</tr>
<tr>
<td>4.3.3 OVA-Specific Cytokine Responses</td>
<td>80</td>
</tr>
<tr>
<td>4.3.4 OVA-Specific CTL Activity</td>
<td>80</td>
</tr>
<tr>
<td>4.3.5 Antigen-Specific Serum IgG Production</td>
<td>81</td>
</tr>
<tr>
<td>4.3.6 OVA-Specific Intestinal IgA Production</td>
<td>81</td>
</tr>
<tr>
<td>4.3.7 Summary</td>
<td>81</td>
</tr>
<tr>
<td>4.4 Immune Responses to ISCOMS in Interleukin 4 Deficient Mice</td>
<td>81</td>
</tr>
<tr>
<td>4.4.1 Antigen-Specific DTH Responses</td>
<td>82</td>
</tr>
<tr>
<td>4.4.2 Antigen-Specific Proliferative Responses</td>
<td>82</td>
</tr>
<tr>
<td>4.4.3 Antigen-Specific Cytokine Responses</td>
<td>82</td>
</tr>
<tr>
<td>4.4.4 Antigen-Specific CTL Activity</td>
<td>83</td>
</tr>
<tr>
<td>4.4.5 Antigen-Specific Serum IgG Antibody Production</td>
<td>83</td>
</tr>
</tbody>
</table>
4.4.6 Secretory Intestinal IgA Antibody Production 83
4.4.7 Summary 83

4.5 Immune Responses to ISCOMS in Interleukin 6 Deficient Mice 84
4.5.1 Antigen-Specific DTH Responses 84
4.5.2 Antigen-Specific Proliferative Responses 84
4.5.3 Antigen-Specific Cytokine Responses 85
4.5.4 Antigen-Specific CTL Activity 85
4.5.5 Antigen-Specific Serum IgG Antibody Production 85
4.5.6 Summary 85

4.6 Immune Responses to ISCOMS in Inducible Nitric Oxide Synthase Deficient Mice 86
4.6.1 Antigen-Specific DTH Responses 86
4.6.2 Antigen-Specific Proliferative Responses 86
4.6.3 Antigen-Specific Cytokine Responses 87
4.6.4 Antigen-Specific Serum IgG Antibody Production 87
4.6.5 Summary 87

Summary and Conclusions 88

Chapter 5 121

Role of Inflammatory Mediators Induced by ISCOMS in Regulating Innate Immune Responses

Introduction 121
Experimental Protocol 121
Results 122
5.1 Innate Responses to ISCOMS in Interleukin 12 Deficient Mice 122
5.1.1 ISCOMS Induced Inflammatory Infiltrate 122
5.1.2 Phenotypic Analysis of PEC 122
5.1.3 Inflammatory Cytokine Production 124
5.1.4 Secretion of Nitric Oxide

5.1.5 Summary

5.2 **Innate Responses to ISCOMS in \(\gamma\)Interferon-Receptor Deficient Mice**

5.2.1 ISCOMS Induced Inflammatory Infiltrate

5.2.2 Phenotypic Analysis of PEC

5.2.3 Inflammatory Cytokine Production

5.2.4 Nitric Oxide Release

5.2.5 Summary

5.3 **Innate Responses to ISCOMS in Interleukin 18 Deficient Mice**

5.3.1 ISCOMS Induced Inflammatory Infiltrate

5.3.2 Phenotypic Analysis of PEC

5.3.3 Inflammatory Cytokine Production

5.3.4 Summary

5.4 **Innate Responses to ISCOMS in Interleukin 6 Deficient Mice**

5.4.1 Recruitment of PEC

5.4.2 Inflammatory Cytokine Production

5.4.3 Secretion of Nitric Oxide

5.4.4 Summary

5.5 **Innate Responses to ISCOMS in Interleukin 4 Deficient Mice**

5.5.1 Recruitment of PEC

5.5.2 Inflammatory Cytokine Production

5.5.3 Secretion of Nitric Oxide

5.5.4 Summary

**Summary and Conclusions**

125

126

126

127

128

129

129

130

130

130

131

132

132

133

133

134

134

134

134

135

135

136

136
Chapter 6
Discussion

ISCOMS Induce an Inflammatory Cascade

The Importance of ISCOMS Induced Inflammatory Mediator Production

Chapter 7
References
# List of Figures and Tables

## Chapter 1

| Figure 1.1 | Ultrastructural appearance of OVA ISCOMS | 28 |

## Chapter 2

| Table I | Phenotypic marker antibodies used for flow cytometry | 42 |
| Table II | Capture antibodies used for sandwich ELISA | 43 |
| Table III | Recombinant cytokine used in sandwich ELISA | 43 |
| Table IV | Detection antibodies used in sandwich ELISA | 44 |

## Chapter 3

| Figure 3.1 | ISCOMS Recruit Inflammatory Cells Following Local Injection | 59 |
| Figure 3.2 | Histological Examination of PEC after ISCOMS Injection | 60 |
| Figure 3.3 | Induction of Mast Cell Recruitment and Degranulation by ISCOMS | 61 |
| Figure 3.4 | Phenotypic Analysis of ISCOMS Recruited PEC | 62 |
| Figure 3.5 | ISCOMS Induce Local Secretion of Inflammatory Cytokines by PEC | 63 |
| Figure 3.6 | ISCOMS Induced Nitric Oxide Production from PEC | 64 |
| Figure 3.7 | ISCOMS Induced Production of Reactive Oxygen Intermediates | 65 |
| Figure 3.8 | Adherent Cells are Required for the Production of ISCOMS Induced Inflammatory Mediators | 66 |
| Figure 3.9 | Recruitment of Inflammatory Cells by a Single Feed of ISCOMS | 67 |
| Figure 3.10 | Phenotypic Examination of MLN Cells Induced by Oral Administration of ISCOMS | 68 |
| Figure 3.11 | Phenotypic Examination of PP Cells Induced by Oral Administration of ISCOMS | 69 |
Figure 3.12 Secretion of Inflammatory Cytokines by MLN After Oral Administration of ISCOMS

Figure 3.13 Secretion of Inflammatory Cytokines by PP After Oral Administration of ISCOMS

Chapter 4

Figure 4.1 Antigen-Specific DTH in OVA ISCOMS Immunised IL-12 KO mice

Figure 4.2 Antigen-Specific in vitro Proliferation in OVA-ISCOMS Immunised IL-12KO Mice

Figure 4.3 Antigen-Specific T Cell Cytokine Production in OVA ISCOMS Immunised IL-12KO Mice

Figure 4.4 Antigen-Specific MHC Class I -Restricted CTL Activity in OVA ISCOMS Immunised IL-12KO Mice

Figure 4.5 Antigen-Specific Serum IgG Isotype in OVA-ISCOMS Immunised IL-12KO Mice

Figure 4.6 Antigen-Specific Intestinal IgA Production in OVA ISCOMS Immunised IL-12KO Mice

Figure 4.7 Antigen-Specific DTH in OVA ISCOMS Immunised IL-18KO mice

Figure 4.8 Antigen-Specific in vitro Proliferation in OVA-ISCOMS Immunised IL-18KO Mice

Figure 4.9 Antigen-Specific T Cell Cytokine Production in OVA ISCOMS Immunised IL-18KO Mice.

Figure 4.10 Antigen-Specific MHC Class I -Restricted CTL Activity in OVA ISCOMS Immunised IL-18KO Mice

Figure 4.11 Antigen-Specific Serum IgG Isotype in OVA-ISCOMS Immunised IL-18KO Mice

Figure 4.12 Antigen-Specific DTH in OVA ISCOMS Immunised γIFNKO mice

Figure 4.13 Antigen-Specific in vitro Proliferation in OVA-ISCOMS Immunised γIFNKO Mice.
Figure 4.14 Antigen-Specific T Cell Cytokine Production in OVA ISCOMS Immunised γIFNKO Mice

Figure 4.15 Antigen-Specific MHC Class I-Restricted CTL Activity in OVA ISCOMS immunised γIFNKO Mice

Figure 4.16 Antigen-Specific Serum IgG Isotype in OVA-ISCOMS Immunised γIFNKO Mice

Figure 4.17 Antigen-Specific Intestinal IgA Production in OVA ISCOMS Immunised γIFNKO Mice

Figure 4.18 Antigen-Specific DTH in OVA ISCOMS Immunised IL-6KO mice

Figure 4.19 Antigen-Specific in vitro Proliferation in OVA-ISCOMS Immunised IL-6KO Mice

Figure 4.20 Antigen-Specific T Cell Cytokine Production in OVA ISCOMS Immunised IL-6KO Mice

Figure 4.21 Antigen-Specific MHC Class I-Restricted CTL Activity in OVA ISCOMS Immunised IL-6KO Mice

Figure 4.22 Antigen-Specific Serum IgG Isotype in OVA-ISCOMS Immunised IL-6KO Mice

Figure 4.23 Antigen-Specific DTH in OVA ISCOMS Immunised IL-4KO mice

Figure 4.24 Antigen-Specific in vitro Proliferation in OVA-ISCOMS Immunised IL-4KO Mice

Figure 4.25 Antigen-Specific T Cell Cytokine Production in OVA ISCOMS Immunised IL-4KO Mice

Figure 4.26 Antigen-Specific MHC Class I-Restricted CTL Activity in OVA ISCOMS Immunised IL-4KO Mice

Figure 4.27 Antigen-Specific Serum IgG Isotype in OVA-ISCOMS Immunised IL-4KO Mice

Figure 4.28 Antigen-Specific Intestinal IgA Production in OVA ISCOMS Immunised IL-4KO Mice

Figure 4.29 Antigen-Specific DTH in OVA ISCOMS Immunised iNOSKO mice
Figure 4.30  Antigen-Specific in vitro Proliferation in OVA-ISCOMS Immunised iNOSKO Mice

Figure 4.31  Antigen-Specific T Cell Cytokine Production in OVA ISCOMS Immunised iNOSKO Mice

Figure 4.32  Antigen-Specific Serum IgG Isotype in OVA-ISCOMS Immunised iNOSKO Mice

Chapter 5

Figure 5.1  ISCOMS Induced Recruitment of PEC in IL-12KO Mice

Figure 5.2  Phenotypic Analysis of ISCOMS Recruited PEC from IL-12KO Mice.

Figure 5.3  Phenotypic Analysis of ISCOMS Recruited PEC from IL-12KO Mice

Figure 5.4  ISCOMS Induced Inflammatory Cytokine Production by PEC from IL-12KO Mice

Figure 5.5  ISCOMS Induced Nitric Oxide Production from IL-12KO PEC

Figure 5.6  ISCOMS Induced Recruitment of PEC in γIFNRKO Mice

Figure 5.7  Phenotypic Analysis of PEC from γIFNRKO mice after Injection of ISCOMS

Figure 5.8  Phenotypic Analysis of ISCOMS Recruited PEC from γIFNRKO Mice

Figure 5.9  ISCOMS Induced Inflammatory Cytokine Production by PEC from γIFNRKO Mice

Figure 5.10  ISCOMS Induced Nitric Oxide Production by PEC from γIFNRKO Mice

Figure 5.11  ISCOMS Induced Recruitment of PEC from IL-18KO Mice

Figure 5.12  Phenotypic Analysis of ISCOMS Recruited PEC from IL-18KO Mice

Figure 5.13  Phenotypic Analysis of ISCOMS Recruited PEC from IL-18KO Mice

Figure 5.14  ISCOMS Induced Inflammatory Cytokine Production by PEC from IL-18KO Mice

Figure 5.15  ISCOMS Induced Recruitment of PEC in IL-4KO Mice

xv
List of Publications


<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>APC</td>
<td>antigen presenting cell</td>
</tr>
<tr>
<td>CFA</td>
<td>complete Freund’s adjuvant</td>
</tr>
<tr>
<td>CGD</td>
<td>chronic granulomatous disease</td>
</tr>
<tr>
<td>Cl2MDP</td>
<td>dichloromethane diphosphate</td>
</tr>
<tr>
<td>Con A</td>
<td>concanavalin A</td>
</tr>
<tr>
<td>CT</td>
<td>cholera toxin</td>
</tr>
<tr>
<td>CTL</td>
<td>cytotoxic T lymphocyte</td>
</tr>
<tr>
<td>DEA</td>
<td>diethanolamine</td>
</tr>
<tr>
<td>DMSO</td>
<td>dimethyl sulphoxide</td>
</tr>
<tr>
<td>DTH</td>
<td>delayed type hypersensitivity</td>
</tr>
<tr>
<td>ELISA</td>
<td>enzyme linked immunosorbant assay</td>
</tr>
<tr>
<td>eNOS</td>
<td>endothelial nitric oxide synthase</td>
</tr>
<tr>
<td>FAE</td>
<td>follicular associated epithelium</td>
</tr>
<tr>
<td>FCS</td>
<td>foetal calf serum</td>
</tr>
<tr>
<td>FLtSL</td>
<td>FIt3 ligand</td>
</tr>
<tr>
<td>GALT</td>
<td>gut associated lymphoid tissue</td>
</tr>
<tr>
<td>GC</td>
<td>germinal centre</td>
</tr>
<tr>
<td>HAO</td>
<td>heat aggregated ovalbumin</td>
</tr>
<tr>
<td>HBSS</td>
<td>Hank’s balanced salt solution</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>i.p.</td>
<td>intraperitoneal</td>
</tr>
<tr>
<td>ICE</td>
<td>interleukin-1 cleaving enzyme</td>
</tr>
<tr>
<td>IEL</td>
<td>intraepithelial lymphocyte</td>
</tr>
<tr>
<td>IFN</td>
<td>interferon</td>
</tr>
<tr>
<td>Ig</td>
<td>immunoglobulin</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>IL</td>
<td>interleukin</td>
</tr>
<tr>
<td>iNOS</td>
<td>inducible nitric oxide synthase</td>
</tr>
<tr>
<td>ISCOMS</td>
<td>immune stimulating complexes</td>
</tr>
<tr>
<td>KLH</td>
<td>keyhole limpet haemacyanin</td>
</tr>
<tr>
<td>KO</td>
<td>knockout</td>
</tr>
<tr>
<td>LP</td>
<td>lamina propria</td>
</tr>
<tr>
<td>LPS</td>
<td>lipopolysaccharide</td>
</tr>
<tr>
<td>LT</td>
<td>heat labile enterotoxin of <em>E. coli</em></td>
</tr>
<tr>
<td>LTB4</td>
<td>leukotriene B4</td>
</tr>
<tr>
<td>MADCAM-1</td>
<td>mucosal addressin adhesion molecule-1</td>
</tr>
<tr>
<td>MALT</td>
<td>mucosa associated lymphoid tissue</td>
</tr>
<tr>
<td>MCP-1</td>
<td>monocyte chemoattractant protein-1</td>
</tr>
<tr>
<td>Mega-10</td>
<td>N-methylglucamide</td>
</tr>
<tr>
<td>MHC</td>
<td>major histocompatibility complex</td>
</tr>
<tr>
<td>MLN</td>
<td>mesenteric lymph nodes</td>
</tr>
<tr>
<td>NK</td>
<td>natural killer</td>
</tr>
<tr>
<td>nNOS</td>
<td>neuronal nitric oxide synthase</td>
</tr>
<tr>
<td>NO</td>
<td>nitric oxide</td>
</tr>
<tr>
<td>NOS</td>
<td>nitric oxide synthase</td>
</tr>
<tr>
<td>NPS</td>
<td>N-(palmitoyloxy) succinamide</td>
</tr>
<tr>
<td>OVA</td>
<td>ovalbumin</td>
</tr>
<tr>
<td>PAMP</td>
<td>pathogen associated molecular pattern</td>
</tr>
<tr>
<td>PBS</td>
<td>phosphate buffered saline</td>
</tr>
<tr>
<td>PBST</td>
<td>phosphate buffered saline plus Tween 20</td>
</tr>
<tr>
<td>PEC</td>
<td>peritoneal exudate cells</td>
</tr>
<tr>
<td>PEG</td>
<td>polyethylene glycol</td>
</tr>
<tr>
<td>PGE2</td>
<td>prostaglandin E2</td>
</tr>
<tr>
<td>pIgR</td>
<td>poly immunoglobulin receptor</td>
</tr>
<tr>
<td>PLG</td>
<td>poly (lactide-co-glycosides)</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>PLN</td>
<td>popliteal lymph nodes</td>
</tr>
<tr>
<td>PMA</td>
<td>phorbol 12-myristate 13-acetate</td>
</tr>
<tr>
<td>PMSF</td>
<td>phenylmethylsulfonyl</td>
</tr>
<tr>
<td>PP</td>
<td>Peyer's patch</td>
</tr>
<tr>
<td>PRR</td>
<td>pattern recognition receptors</td>
</tr>
<tr>
<td>ROI</td>
<td>reactive oxygen intermediates</td>
</tr>
<tr>
<td>s.c.</td>
<td>subcutaneous</td>
</tr>
<tr>
<td>sIgA</td>
<td>secretory IgA</td>
</tr>
<tr>
<td>SOD</td>
<td>superoxide dismutase</td>
</tr>
<tr>
<td>TD</td>
<td>thoracic duct</td>
</tr>
<tr>
<td>TEM</td>
<td>transmission electron microscope</td>
</tr>
<tr>
<td>TGF</td>
<td>transforming growth factor</td>
</tr>
<tr>
<td>Th</td>
<td>T helper</td>
</tr>
<tr>
<td>TNF</td>
<td>tumour necrosis factor</td>
</tr>
</tbody>
</table>
Summary

Immune stimulating complexes (ISCOMS) are small cage-like particles which form spontaneously upon agitation of phospholipid, cholesterol and the saponin adjuvant Quil A. It is possible to incorporate protein antigen into the ISCOMS structure and ISCOMS have been used to stimulate antigen-specific immune responses by both parenteral and mucosal routes. However, the mechanisms that underlie these adjuvant effects have not been fully elucidated. This project was undertaken in order to expand the knowledge of the adjuvant properties of ISCOMS and to identify the influence that these had on the ability of ISCOMS to drive an antigen-specific immune response.

My initial experiments concentrated on performing a detailed study of the innate effects of ISCOMS in vivo, when given initially as an intraperitoneal injection and later orally. The results presented demonstrate that ISCOMS have an ability to stimulate an innate inflammatory cascade, comprised of the recruitment and activation of an inflammatory infiltrate, secretion of inflammatory cytokines and mediators. Secretion of these factors was dependent on the presence of adherent cells indicating the possible role of macrophages in their production. A similar pattern of cellular recruitment and activation was measured in gut associated lymphoid tissues after oral administration of ISCOMS, but this was much less dramatic than had been observed earlier.

I then undertook an examination of the influence that these inflammatory mediators had on the generation of antigen-specific immunity as determined by antigen-specific DTH, proliferation, cytokine production, CTL activity serum IgG isotype production and intestinal IgA production, using gene-targeted knockout mice including IL-12KO, IL-6KO, IL-18KO, IL-4KO, iNOSKO and γIFN-RKO. My experiments revealed that most of the components of the inflammatory response were not essential for the development of antigen-specific immunity to ISCOMS, but it did reveal that IL-12 played a particularly important role in the immunogenicity of ISCOMS, as immune responses were severely defective in these mice after either parenteral or oral immunisation with OVA ISCOMS.
I then went on to determine if the generation of normal antigen-specific immune response, in the absence of inflammatory cytokines, was due to the maintenance of the inflammatory cascade induced by ISCOMS. I therefore studied the cellular recruitment and inflammatory mediator release from ISCOMS injected gene targeted knockout mice. Despite most knockout animals retaining an intact innate cascade, the IL-12KO mice with decreased antigen-specific immune responses to ISCOMS also had an ablated innate response. However, unusually the γIFN-RRKO mice which had normal antigen-specific responses to ISCOMS also lacked an innate inflammatory cascade. This apparent dichotomy indicated that the role of the ISCOMS induced innate immune response for the generation of antigen-specific immunity is as complex as it is important and must be better understood if efficacious and potent vaccines are to be developed.
Infection with an invasive pathogen stimulates the development of a protective immune response and immunological memory. The purpose of vaccination is to mimic these effects of natural infection, without the morbidity and possible mortality associated with actual infection. Much time and energy has been invested in the development of vaccination strategies and, although there have been successes, such as measles, polio and smallpox, there is an ongoing need for effective vaccines that are readily available, easy to administer and capable of immunising against all the pathogens that endanger quality of life.

The majority of all antigenic encounters occur at mucosal surfaces such as the gut, nasal cavity and respiratory tract, eye and urogenital tract. These tissues have an extensive lymphoid system, which is distinct from the peripheral lymphoid system and so parenteral immunisations fail to generate protective immune responses in the mucosa, especially the gut. Therefore, it is important to generate vaccine strategies that are effective at mucosal sites. Subunit vaccines containing purified antigen are being investigated as immunisation strategies, as they retain the immunogenicity produced during a natural infection, but do not pose the threat of virulence. However, subunit vaccines are not efficacious when administered alone, especially by the oral route and therefore effective immunisation requires the co-administration of an adjuvant.

It has become clear recently, that the innate immune response has a strong, guiding influence over the initiation of adaptive immunity and determines the function of adjuvants. The purpose of the work described in this thesis was to explore the role of the innate immune response in the efficacy of the parenteral and oral vaccine vector ISCOMS.
1.0 Overview of the Immune Response

The mammalian immune response is a highly complex and delicately balanced process that comprises both innate and adaptive components. These two parts, although distinct from each other, are continually interacting.

1.1 Innate Immunity

Innate or natural immunity is considered phylogenetically to be the oldest form of host defence and forms of it exist in all species. It provides a rapid response to microorganisms which is not dependent on genetically variable, specific recognition elements. Instead this network exploits a mixture of highly conserved, invariant soluble factors and cell surface receptors, many of which can recognise non-protein structures such as carbohydrates or lipids, to monitor the normal environment and detect the presence of potentially harmful invading microorganisms.

i) Triggers of the Innate Immune System

The surface receptors on the host form a non-specific surveillance system for pathogen associated molecular patterns on invading organisms, a phenomenon that has been termed pattern recognition [Medzhitov and Janeway Jr, 1997b, Fearon and Locksley, 1996]. Three main families of pattern recognition receptors (PRRs) have been identified and classified according to their physical and functional properties. Firstly, there are PRRs that are plasma proteins and can opsonise microorganisms and therefore aid destruction by the complement membrane attack complex (C5-9). These include the collectins such as mannan binding lectin, conglutinin and lung surfactant proteins A and D [Sastry and Ezekowitz, 1993], or pentraxins such as C-reactive protein and serum amyloid protein [Gewurz et al., 1995]. The second family of PRRs comprises endocytic receptors which are found on the surface of cells such as macrophages and dendritic cells and bind directly to molecules present on invasive micro-organisms and activate entry into the endocytic pathway for
antigen processing and presentation, such as the macrophage mannose receptor [Stahl, 1992], macrophage scavenger receptor [Krieger and Herz, 1994]. The third family of PRRs is the Toll-like-receptors which are involved in both pattern recognition and signal transduction [Kopp and Medzhitov, 1999]. These were first identified in *Drosophila* and recently five Toll-like-receptor proteins have been discovered in humans [Rock et al., 1998]. Each contain a leucine rich extracellular domain and a cytoplasmic tail involved in signal transduction pathways, which activate NF-κB [Kopp and Medzhitov, 1999]. Although many of the ligands for the Toll-like-receptors have yet to be identified, all known ones are involved in expression of co-stimulatory molecules and cytokine or soluble mediator secretion, via the induction of NF-κB [Stancovski and Baltimore, 1997]. Most important of these is a receptor for LPS on monocytes and macrophages, which binds the lipopolysaccharide binding protein together with CD14 [Yang et al., 1998].

**ii) The Innate Inflammatory Cascade**

The ligation of PRRs on host cell surfaces or in serum, initiates a cascade of inflammatory events that comprises the release of chemotactic molecules, cellular recruitment and mediator release. These not only provide a rapid response to invasion, but also have a far reaching influence on subsequent antigen-specific immunity. The initial component is the release of chemokines, such as IL-8 or monocyte chemoattractant protein 1 (MCP-1), from activated phagocytes or inflamed endothelium, fibroblasts or platelets [Baggiolini, 1998]. Chemoattractants recruit neutrophils and monocytes, with neutrophils arriving first and being followed quickly by macrophages and dendritic cells, both of which are important for clearance of microbes and for processing and presentation of antigen to the lymphocytes which are the last of the recruited cells to arrive [Campbell et al., 1998]. The recruited neutrophils and macrophages become activated, increase their microbicidal activity, release soluble factors and macrophages show increased expression of co-stimulatory molecules, adhesion molecules and MHC class II. Mast cells are also involved in this early phase of the response. Classically these cells are described as the effector cells of IgE mediated immune responses, especially in the context of helminth infestations, but they are also capable of
secreting a number of preformed pro-inflammatory compounds, such as histamine, leukotriene B4 (LTB4), macrophage inflammatory protein-1α (MIP-1α) and MIP-1β as well as TNFα [Mekori and Metcalfe, 2000] which can enhance the recruitment of other inflammatory phagocytes and lymphocytes, by upregulating the expression of surface adhesion molecules and thus providing a suitable site for the extravasation of leukocytes [Galli et al., 1999].

iii) Soluble Mediators of the Inflammatory Cascade

Pro-inflammatory mediators released during the acute phase response also induce a cascade of events that trigger metabolic processes in the host in an attempt to control infection, minimise damage and initiate repair to inflamed tissues. TNFα is released immediately as a preformed molecule from mast cells [Gordon and Galli, 1990], or synthesised by macrophages after stimulation by LPS or ingestion of bacteria or viruses, and after the binding of C5a complement component to the p55 and p75 TNFα receptors which are present on a wide variety of target cells and tissues [Adolf et al., 1994]. TNFα induces the synthesis and release of IL-1, which together with TNFα, synergise to induce IL-6 secretion [Baumann and Gauldie, 1994]. In association with IL-1, TNFα is also a potent pyrogen and appetite suppressant, inducing these effects by binding to receptors present on the cells of the hypothalamus [Tracey et al., 1988, Plata-Salaman et al., 1988]. TNFα can also stimulate γIFN production by NK cells in synergy with IL-12 [Tripp et al., 1993]. Together with γIFN, TNFα acts in an autocrine fashion to amplify the production of inducible nitric oxide (iNOS) and thus nitric oxide (NO) release from macrophages, increasing the microbicidal activity of these cells and increasing the blood flow to the inflamed site [Oswald and James, 1996].

IL-1α and IL-1β are produced by activated macrophages and many other cell types in an inactive form that is activated by IL-1 converting enzyme (ICE) which cleaves off a regulatory region [Black et al., 1988]. Active IL-1 binds to the type I and type II IL-1 receptors which are present on a wide variety of cells including T cells, B cells, endothelium, hepatocytes and the hypothalamus [Dinarello, 1998]. Many of the inflammatory effects of IL-1 are induced in combination with TNFα, including the stimulation of IL-6, fever and the
secretion of amyloid precursor proteins, as well as the release of chemotactic signals such as IL-8 and MCP-1 by mononuclear phagocytes and endothelium [Baumann and Gauldie, 1994]. IL-1 in synergy with IL-6, acts as a growth factor for CD4 T cells, inducing secretion of IL-2 production by T cells [Holsti and Raulet, 1989, Houssiau et al., 1988] and expression of the IL-2 receptor α chain (CD25) [Houssiau et al., 1989].

IL-6 is secreted from as part of the acute phase response by macrophages, fibroblasts and mast cells after activation by TNFα and IL-1 [Baumann and Gauldie, 1994]. It induces hepatocytes to secrete plasma proteins such as fibrinogen as part of the acute phase response and has many effects which overlap with those of TNFα and IL-1, including increasing body temperature, the expression of adhesion molecules and chemotactic factors on the surface of inflamed endothelium which aids the entry of leukocytes. IL-6 also plays a role in the antigen-specific immune response, as it promotes the growth and maturation of B cells and stimulates plasma cell differentiation [Kishimoto, 1989]. Recent studies have also implicated the direct involvement of IL-6 in the secretion of IgA [Beagley et al., 1989, Kunimoto et al., 1989], and IL-6 together with IL-10 has also been shown to maintain the secretion of IgA in the gut of IL-4KO mice [Okahashi et al., 1996]. IL-6KO mice have been reported to have defects in sIgA production and the recruitment of neutrophils, as well as being susceptible to intracellular organisms such as *Candida albicans* [Romani et al., 1996] or *Listeria monocytogenes* [Kopf et al., 1994]. However, other studies have disputed the involvement of IL-6 in generating antigen-specific mucosal immune responses [Bromander et al., 1996].

IL-12 is a heterodimeric cytokine secreted from macrophages, dendritic cells and B cells [Trinchieri, 1995]. The bioactive p70 heterodimer is comprised of disulphide linked [Gubler et al., 1991], 35kD and 40kD subunits [Kobayashi et al., 1989, Stern et al., 1990] whose genes are found on chromosomes 3 and 5 respectively [Sieburth et al., 1992]. IL-12 production is induced directly by bacterial and parasitic products including endotoxins, superantigens and heat shock proteins [Trinchieri, 1995], but also after cognate interactions between the CD40 and CD40 ligand (CD40L) [Kennedy et al., 1996, Stuber et al., 1996], present on APC and activated T cells respectively. The best known effect of IL-12 is to induce γIFN production by NK cells and T cells and it is the principal factor controlling the
differentiation of Th1 CD4+ T cells [Wenner et al., 1996, Hsieh et al., 1993]. However, IL-12 also upregulates the expression of IL-8 and thus enhances the recruitment of neutrophils to an inflamed site and the establishment of an inflammatory cascade [Nuame et al., 1993]. In addition, IL-12 increases the growth and cytotoxic activity of NK cells [Kobayashi et al., 1989, Robertson et al., 1992] and acts as a growth factor for activated NK cells [Nuame et al., 1993]. It has similar effects on CD8+ T cells [Gately et al., 1994, Chouaib et al., 1994], probably in conjunction with γIFN. IL-12 alone can induce the upregulation of IL-2 and the expression of the IL-2 receptor α chain [Nuame et al., 1993], thus increasing responsiveness to IL-2 and the ability to clonally expand effector T cells.

The importance of IL-12 in infection has been shown in several models. Addition of rIL-12 enhances resistance to *Leishmania major* [Heinzel et al., 1993], *Listeria monocytogenes* [Hsieh et al., 1993, Tripp et al., 1994] and *Toxoplasma gondii* [Gazzinelli et al., 1993]. In the absence of IL-12, mice had defective protective immunity against *Mycobacterium tuberculosis* [Cooper et al., 1997]. IL-12 also protects against the pathology associated with normal granuloma response induced by *Schistosoma mansoni* eggs in liver and spleen [Wynn et al., 1994]. Because of its ability to enhance cytolytic activity, IL-12 has also been shown to be involved in the generation of anti-tumour CD8+ T cell activity in murine cancer models [Brunda et al., 1993].

IL-18 is a newly characterised cytokine which has several properties similar to IL-12 including the induction of γIFN production. However IL-18 resembles IL-1 structurally and requires enzymatic cleavage by ICE to release the biologically active cytokine [Ga et al., 1997, Ghayur et al., 1997]. First identified as a product of Kupffer cells in the livers of *Propionibacterium acnes* infected mice [Okamura et al., 1995], IL-18 is now known to be produced by a number of different cell types, including keratinocytes [Stoll et al., 1997], osteoblasts [Udagawa et al., 1997], and macrophages [Okamura et al., 1995]. Like IL-12, IL-18 increases the cytolytic activity and induces secretion of γIFN from NK cells and T cells [Okamura et al., 1998a] and enhances the development of Th1 cells [Kohno et al., 1997], and IL-12 and IL-18 may act together to generate a number of these effects. There is some recent
evidence that IL-12 may increase the expression of the IL-18Rβ2 gene which would also increase the pressure to drive a Th1 mediated immune response [Xu et al., 1998].

The gaseous free radical nitric oxide (NO) is produced by the enzymatic action of nitric oxide synthase (NOS) on the amino acid arginine [Palmer et al., 1988]. There are three isoforms of the NOS enzyme which have two separate functions. Neuronal cell NOS (nNOS) and endothelial cell NOS (eNOS) are involved in the Ca²⁺ dependent, constitutive production of small amounts of NO which acts as a signal transduction molecule in the nervous system and as a vasodilatory molecule [Meffert et al., 1994, Moncada and Higgs, 1991]. Inducible NOS (iNOS) on the other hand, is found in macrophages after stimulation by inflammatory signals such as the phagocytosis of bacteria or recognition of conserved molecules on pathogens such as LPS [Griscavage et al., 1996]. The other major inducer of iNOS transcription is γIFN [Kamijo et al., 1994], while TNFα, and IL-1β can have similar effects [Green and Nacy, 1993]. The high levels of NO produced by activated macrophages are toxic to intracellular pathogens or tumour cells. These effects are due to the ability of NO to interfere with several intracellular metabolic processes, by targeting iron binding proteins including mitochondrial NADPH-ubiquinone, the succinate-ubiquinone oxidoreductases of the electron transport chain and the Kreb's cycle enzyme aconitase [Oswald and James, 1996]. NO also targets iron containing molecules of pathogens, forming nitrosyl-Fe molecules which disrupt the metabolic and proliferative activity of intracellular pathogens and inhibit the superoxide dismutase enzyme (SOD), which is capable of protecting the pathogen against the lethal effects of free radicals such as H₂O₂ and NO [Oswald and James, 1996]. NO has also been implicated in a number of disease conditions, the most important of which is septic shock, where it is responsible for dilation of the local and then later the systemic vasculature [Green and Nacy, 1993]. Thus the regulation of such a dangerous molecule is tightly controlled and NO production is inhibited by TGFβ [Ding et al., 1990] and IL-10 [Cuncha et al., 1992] which decrease the stability of iNOS mRNA. Reactive oxygen intermediates (ROI) are a group of oxygen species including superoxide (O₂⁻), hydroxyl radicals (•OH), and singlet oxygen species (¹O) which are formed following activation of the NADPH oxidase enzyme present in the lysosomal membrane of phagocytes.
[Babior et al., 1988]. These molecules are all toxic and play an important part in the killing of intracellular pathogens, which is most clearly demonstrated in individuals with chronic granulomatous disease (CGD), who have a genetic defect in the ability to generate oxygen radicals. They are deficient in, or have an abnormal form of, one of the protein components that makes up the respiratory burst, for example NADPH oxidase [Clark, 1999]. These patients suffer recurrent infections of bacteria, parasites and fungal infections and develop widespread generation of granulomatous tissue which is formed in an attempt to control these infections [Clark, 1999].

1.2 The Role of the Innate Cascade on the Development of Adaptive Immunity

The mediators and cells described above not only play a crucial and often conclusive role in the early stages of infection, but also initiate and shape the ensuing antigen-specific immune response [Fearon and Locksley, 1996a]. Thus, the ligation of PRRs on resting dendritic cells increases the expression of costimulatory molecules, MHC class II and the antimicrobial activity of these cells [Medzhitov and Janeway Jr, 1997a, Medzhitov and Janeway Jr, 1997b, Janeway Jr, 1989], which enhances the ability to process and present antigen [Banchereau and Steinman, 1998]. In addition, these receptors and the pro-inflammatory cytokines IL-1, TNFα and IL-12, induces the migration of DC out of tissues and into the T cell dependent area of the secondary lymphoid organs where they can interact with naive T and B cells.

The nature of these ligand of PRR can also influence the ability of dendritic cells to polarise the eventual antigen-specific effector immune response. Recently it has been demonstrated that dendritic cells are capable of inducing both a Th1 and Th2 response from naive T cells, but this mechanism appears to be a consequence of the level of IL-12 production induced [Kalinski et al., 1999]. For example, a number of pathogens secrete IL-12 inhibiting factors such as prostancoids from some helminthias [Meyer et al., 1996], or IL-10 induced by Schistosoma mansoni eggs [Velupillai and Harn, 1994], disruption of IL-12
production is also observed in HIV [Yoo et al., 1996] and measles virus infection [Karp et al., 1996].

Depending on the stimulus dendritic cells can also be immunogenic or tolerogenic. When resting myeloid derived dendritic cells were pre-cultured with necrotic fibroblasts in vitro, the dendritic cells, increased surface expression of costimulatory molecules and were capable of inducing proliferation of naive T cell clones [Gallucci et al., 1999]. In contrast, when resting dendritic cells were pre-cultured with apoptotic fibroblasts, no elevation of costimulatory molecules expression or naive T cell proliferation was measured [Gallucci et al., 1999]. This phenomenon was also detected in vivo, as OVA+apoptotic fibroblast immunised mice produced significantly lower OVA-specific DTH responses than OVA+necrotic fibroblast immunised mice [Gallucci et al., 1999].

Thus it appears that the nature of the antigen has a profound influence on the outcome of the immune response induced, or in fact whether immunity is stimulated at all.

1.3 Protective Immunity

There are three arms of the antigen-specific protective immune response, firstly CD4+ T lymphocytes which recognise antigen presented by MHC class II molecules and secrete cytokines, whose profile determines the nature of the effector immune response that is generated. γIFN and IL-2 secretion are associated with Th1 CD4+ lymphocytes and the establishment of cell mediated immunity, whereas IL-4, IL-5, IL-10 and IL-13 are secreted by Th2 cells and promote humoral immune responses [Mosmann and Coffman, 1989, Mosmann, 1996]. Secondly, antigen-specific antibodies recognise structural patterns within the infecting agent, with CD4+ T cells assisting in the differentiation and antibody production by B cells [Parker, 1993]. Thirdly, antigen-specific CD8+ CTL, recognise and kill infected cells bearing processed antigenic peptides within MHC class I [Griffiths, 1995], by release of pore forming agents such as perforin and granzyme serine esterases that disrupt metabolic processes and induce apoptosis of the infected cell [Kagi et al., 1994]. CTL also induce apoptosis following ligation of the Fas ligand (FasL) expressed on CTL with Fas on the target.
The exact nature of the protective immune response depends on the infecting agent and thus if any vaccine immunotherapy is to be successful in generating a protective immune response it is vital that we understand and can mimic different immune mechanisms induced by various infecting organisms or disease processes. Viral infections generally involve the ability of MHC class I restricted CTL to kill infected cells, but also induce the production of neutralising antibodies to limit the dissemination of the viral pathogen. Intracellular pathogens other than viruses are either bacteria, protozoal parasites or fungi. Most of these organisms rely on active uptake into host cells following ligation of PRR and induction of phagocytosis and thus these pathogens generally target macrophages [Aderem and Underhill, 1999]. Because these organisms reside within the cell, they are concealed from immune surveillance, and most have evolved evasion strategies which not only prevents killing by normal antimicrobial processes of the cell but also prevents their discovery by the immune system [Brodsky et al., 1999]. However, after recognition by CD4+ T cells, the infected cells are activated by γIFN, with enhancement of microbicidal activity of the macrophage and clearance of the pathogen. In addition, there may be secretion of TNFα and IL-1 as well as activation of CD8+ CTL [Orme et al., 1993]. Extracellular pathogens are continuously exposed to potential attack by the adaptive immune response and Th2 dependent humoral immune responses are the major mechanism for the elimination of such organisms. Small extracellular pathogens such as bacteria can be opsonised and cleared by macrophage phagocytosis, while larger multicellular organisms such as helminths or nematodes which have been opsonised by antigen-specific antibody can be cleared by antibody dependent complement or cell mediated cytotoxicity. Extracellular organisms may also secrete toxins that are harmful, and thus neutralising antibodies are also a powerful mechanism for the capture and clearance of these soluble molecules, by immune complex formation and clearance in the liver [Schifferli et al., 1986].
2.0 The Common Mucosal System

The tissues of the mucosae encounter the majority of antigens that enters the host and infections of mucosal surfaces such as the digestive tract, nasal cavity, respiratory tract, eye and urogenital tract and breast are the most common cause of morbidity and mortality in humans [Bloom, 1989]. These infections are caused by viruses such as rhinoviruses, influenza virus, poliovirus, and human immunodeficiency virus (HIV), bacteria such as E. coli, S. typhi, V. cholerae, Borderella pertussis and Mycobacterium tuberculosis; protozoal parasites such as Giardia lamblia and Cryptosporidium parvum, as well as helminthic parasites such as Trichuris trichura, Ascaris lumbricoides, and Haematobium solis. The mucosal surfaces contain considerable amounts of mucosa-associated lymphoid tissue (MALT) that are anatomically and functionally distinct from the peripheral immune system [Mowat and Viney, 1997]. Of these, the gut associated lymphoid tissues (GALT) are the most intricate and specialised, containing organised lymphoid structures such as the Peyer’s patches (PP) and mesenteric lymph nodes (MLN), as well as large numbers of scattered lymphocytes both in the epithelium (intraepithelial lymphocytes (IEL)) and in the lamina propria (LP).

2.1 Immune Mechanisms of the GALT

The induction of intestinal immune responses is believed to occur first in the PP, which are submucosal nodules of organised lymphoid tissue in the small intestine, containing defined T and B cell areas including germinal centres (GC) [McGhee et al., 1992]. Above the T and B cell areas is the dome area of the PP which contains T and B cells, macrophages and dendritic cells, and bulges into the lumen of the small intestine, being covered by a single layer of follicular associated epithelium (FAE). This contains specialised epithelial cells (M cells), that have microfolds on their luminal surface and which are able to take up particulate materials such as bacteria and viruses from the intestinal lumen [Neutra et al., 1996]. M cells do not process antigen, but appear to transfer it to professional APC [Wolf and Bye, 1984],
which reside in an epithelial pocket created by the M cell, or in the dome area immediately below the FAE [Keren, 1992, Mowat and Viney, 1997]. The majority of these cells are dendritic cells, but they differ from those found in other tissues [Kelsall and Strober, 1996]. Most dendritic cells found beneath the M cells are immature and have been shown to capture antigenic peptides in vivo [Kelsall and Strober, 1996, Ruedl et al., 1996]. These cells are then thought to migrate to the MLN where they are able to present antigen to naive T and B cells [MacPherson et al., 1995]. Although the initial encounter with antigen is thought to occur in the PP, cells migrate away to other mucosal sites before becoming effector cells. For example B cells primed in the PP show preferential class switching to IgA production [McGhee et al., 1992], but before full differentiation, these leave the PP via the efferent lymphatics and recirculate to mucosal effector sites such as the LP, by which time they have differentiated into high affinity IgA secreting plasma cells [Brandtzaeg et al., 1999]. The production of IgA secreting cells occurs because of the influence of the local cytokine environment in the PP, with TGFβ being a crucial switch factor for IgA production [Brandtzaeg et al., 1999].

T cells are also primed in the PP and like B cells, migrate from the PP to the mesenteric lymph node (MLN) via the afferent lymphatics before differentiating fully [McGhee et al., 1992]. The MLN has a normal secondary lymphoid architecture and appears to form an interface between the mucosal and peripheral immune systems [Mowat and Viney, 1997]. After a few days, these T and B cells leave the MLN and gain access to the thoracic duct (TD), from where they enter the blood stream and exit preferentially in the mucosal surfaces because of expression of the α4β7 integrin which associates with the mucosal addressin adhesion molecule-1 (MADCAM-1), found predominantly only on mucosal vasculature [Mowat and Viney, 1997]. In addition to access via M cells, some soluble antigen may also cross the villus epithelium directly and be transported to the MLN in the lymphatics or carried on an APC such as dendritic cells, which can lead to the priming of T cells in the MLN itself [Mowat and Viney, 1997].
2.2 Effector Immune Responses in the Mucosa

The effector phase of the mucosal immune response occurs in the wall of the gut itself. Here are found B cells, T cells, macrophages, dendritic cells and mast cells, which are scattered within the LP or as dispersed T cells within the epithelium (IEL). These cells are capable of making a wide range of immune responses, which are able to combat the variety of pathogens encountered at this site.

i) Humoral Immune Responses in the Mucosa

The principal humoral immune defence in the gut is mediated by secretory IgA (sIgA) antibodies [Brandzaeg, 1989]. Over 90% of all antibody in the gut is sIgA, which is produced by plasma cells in the LP as a dimer linked by a joining (J) chain. This dimer binds to the poly Ig receptor (pIgR) on the basal surface of the enterocytes in the crypt, triggering endocytosis and then transport through the epithelial cell in a transport vesicle [Mostov, 1994]. This vesicle ultimately fuses with the luminal surface of the epithelial cell, where the pIgR is partially cleaved and releases sIgA that contains a small fragment of the pIgR still attached (secretory component)[Mostov, 1994]. sIgA is found only in mucosal secretions and because of its multivalent binding sites, is ideally suited to interfering with binding and entry of pathogens into mucosal tissues [Czinn et al., 1993, Mazanec et al., 1995]. sIgA bound to luminal antigen can either be excreted or taken back up through the epithelium, where it can enter the liver via the portal bloodstream and be cleared through phagocytosis by hepatic macrophages (Kupffer cells) or excreted in the bile. As IgA does not bind complement, sIgA mediated clearance of pathogens does not cause inflammation in the delicate tissues of the gut mucosa [Russell-Jones et al., 1981, Lamm et al., 1995].

Despite the predominance of sIgA in mucosal secretions, the absence of sIgA is a relatively common immunodeficiency and usually does not incur major complications or infection [Mbawuike et al., 1999]. In this situation the function of sIgA may be replaced by IgM, which also contains a J chain, and thus can bind to the pIgR and undergo transcytosis across the epithelium. IgG is found in secretions only under conditions of inflammation,
while IgE production may contribute to protective responses against helminth infection, by
binding to FcεR on eosinophils and mast cells elevated at times of expulsion and releasing
toxic granule contents into the lumen of the gut [Galli, 1997].

ii) Cellular Immune Responses in the Mucosa

Effector T cells are localised throughout the organised and diffuse compartments of
the GALT. The CD4+ T cells that are found within these tissues all show an activated
memory phenotype [Mowat and Viney, 1997] and they normally secrete cytokines such as
γIFN, IL-4, IL-5 and TGFβ [Mowat and Viney, 1997] which are thought to directly influence
the isotype switching of antibodies from B cells. IL-5 is a required cytokine if an augmented
sIgA response is to be generated [Harriman et al., 1988], and TGFβ also directs the class
switching to IgA [Brandtzaeg et al., 1999].

The T cells in the IEL are very different to those found in the periphery. Up to 80% of
these cells are CD8+, and conventional CD4αβ+ T cells are rare [Guy-Grand and Vassalli,
1993]. There are many different subsets of IEL and of the CD8+ IEL, only a small subset are
classical CD8αβ+ αβ TCR+ CTL, with another population of IEL being CD8αα+ [Guy-
Grand and Vassalli, 1993]. Of these cells some are αβ TCR+ but some are also γδ TCR+
[Lefrancois, 1991]. These γδ TCR+ cells are thought to have developed extrathymically
[Rocha et al., 1994] and some γδ TCR+ IEL exhibit NK cell like lytic activity but this is not
generated to MHC class I restricted antigens [McGhee et al., 1992]. The role, if any, that
these cells have in protective mucosal immune responses is yet to be fully defined as they
normally do not exhibit classical CTL activity and do not proliferate well to mitogens or
antigen [Mowat and Viney, 1997], even though a large expansion of CD8αα+ γδ TCR+ cells
is found in coeliac patients [Halstensen et al., 1989, Savilahti et al., 1990]. There is some
recent evidence that these γδ TCR+ IEL may play some regulatory role in maintaining gut
homeostasis and tolerance to intestinal antigens [Mowat and Viney, 1997], in addition to a
possible role in providing help for mucosal IgA secretion [Fujihashi et al., 1996]. Many of the
IEL have been identified as containing cytoplasmic granules and perforin [Guy-Grand et al.,
1991] and some CD8αβ+ IEL have been shown to have antigen-specific cytotoxic activities.
against Toxoplasma gondii [Charles et al., 1994b]. Nearly all subsets of IEL express the αβ7 integrin, which associates with E-cadherin on enterocytes and so is thought to be responsible for the accumulation and maintenance of IEL in the villus epithelium [Cepek et al., 1994].

2.3 Immune Regulation in the GALT

Although the immune apparatus of the gut must generate strong protective immune responses against pathogens, the majority of antigen encountered by the GALT is harmless, such as dietary proteins and commensal bacteria. Active immune responses against these materials would be dangerous as it can lead to chronic inflammatory diseases such as Crohn's disease, ulcerative colitis and coeliac disease [Mowat, 1987]. For these reasons, the default response to harmless antigen is the induction of systemic immunological unresponsiveness, known as oral tolerance [Mowat, 1987]. This long lasting phenomenon can affect all aspects of the systemic immune response and in addition to being of physiological importance, it is a potential obstacle to the development of orally active vaccines containing purified protein antigens [Mowat, 1987].

Several mechanisms have been implicated in mediating oral tolerance, but these may be dependent on the feeding regime used to induce tolerance. Thus it is proposed that single or continuous feeds of high doses of antigen may lead to clonal anergy or perhaps deletion of antigen-specific T cells, whereas multiple feeds of low doses of antigen may induce the generation of regulatory T cells such as the CD4+ Th3 subset or Tr1 subsets of T cells, which may suppress other T cell responses by secretion of TGFβ, IL-4 or IL-10 [Faria and Weiner, 1999]. In all cases, CD4+ T cells appear to be the most important targets and mediators of oral tolerance [Mowat and Viney, 1997]. The induction of tolerance is preceded by limited activation of these cells in tissues of the GALT such as the MLN, and it appears that orally administered soluble antigens may be presented by APC lacking the appropriate costimulatory molecules such as B7.1 and B7.2, which leads to partial activation of the CD4+ T cells, followed by unresponsiveness (anergy) upon subsequent restimulation with antigen in
an immunogenic form [Mueller et al., 1989]. Of the APC that might be involved, recent attention has focused on the resting dendritic cells present in the gut. Administration of the dendritic cell growth factor flt3 ligand (FLt3L) increases the numbers of dendritic cells in the GALT and other lymphoid organs and dramatically enhances the development of oral tolerance [Viney et al., 1998]. These FLt3L induced dendritic cells express low levels of B7 and CD40 costimulatory molecules, which may indicate dendritic cells in the gut are normally in a resting state and present antigen in a tolerogenic fashion [Viney et al., 1998]. In addition, recent evidence suggests that the gut is rich in immunomodulatory cytokines, such as IL-10, TGFβ, and PGE2, which may inhibit the activation of APC and thus suppress T cell induction [Khoury et al., 1992]. Overcoming or modulating these mechanisms is an important consideration for designing oral vaccines.

2.4 Compartmentalisation of the GALT

One of the most important features of the mucosal immune system is its compartmentalisation and isolation from the peripheral immune system. T and B cells primed in the GALT recirculate preferentially to mucosal surfaces, whereas T and B cells stimulated in other peripheral lymphoid tissues are unable to enter mucosal tissues [Phillips-Quagliata and Lamme, 1988]. This phenomenon is due to the fact that lymphocytes primed in the MALT lose L-selectin, and increase their expression of α4β7 which interacts with the mucosal addressin adhesion molecule-1 (MAdCAM-1), found mainly on endothelium of mucosal vasculature [Bargatze et al., 1995]. This provides the molecular basis of why a mucosally delivered vaccine is necessary to generate protective immune responses in these tissues. Despite this separation from the peripheral immune system, there is dissemination of lymphocytes between the different mucosal tissues, which all express MAdCAM-1. This is termed the common mucosal immune system and its existence is important for the development of mucosal vaccines as it implies that lymphocytes can be primed at an easily accessible mucosal site, such as the gut or nasal cavity, and then disseminate to other distant mucosal tissues as effector cells [Mestecky et al., 1994].
3.0 Mucosal Vaccination Strategies

It is important that a successful vaccine is able to prime all the arms of the immune response that would normally be stimulated by natural infection, as well as inducing effective memory. The majority of current vaccines are administered parenterally, but these are generally ineffective against mucosal pathogens, due to the inability of primed lymphocytes to enter the mucosal compartment [Phillips-Quagliata and Lamme, 1988]. Therefore there is a pressing need for the development of vaccines which are active at mucosal sites and it is widely accepted that a single, orally administered recombinant vaccine inducing long lasting mucosal and systemic immunity is a principal goal of vaccine research.

3.1 Oral Vaccination Vectors

i) Live Attenuated Oral Vaccines

The simplest means of generating an appropriate, long lasting immune response to a pathogen is by pre-exposure to the living organism. However, as the principle of vaccination is to protect the host without inducing disease, it is vital that the infecting micro-organism is made harmless before administration. Therefore, the first vaccines consisted of whole organisms which were killed, one of the most successful being the Salk polio vaccine [Smith, 1992]. However, although killed vaccines share most antigens with the live pathogen, they often do not induce the same range of innate and specific immune responses due to their inability to invade. Therefore several attenuated vectors have been investigated to induce protective responses. Of these, attenuated *Salmonella* strains, with mutations in growth genes such as *surA* have been very successful at generating protective immune responses [Sydenham et al., 2000], as have *Shigella* strains with mutated genes *aroA* and *virG* genes [Kotloff et al., 1996, Noriega et al., 1996].
ii) Attenuated Organisms as Oral Vectors

Attenuated bacteria and viruses have also been used as delivery vectors for the generation of immune responses against incorporated DNA of other pathogens. For example, *Salmonella* [VanCott et al., 1996, Steger and Pauza, 1997], *Shigella* [Fennelly et al., 1999], *Listeria* [Ikonomidis et al., 1997] and BCG bacteria [Fennelly et al., 1995] have been studied as potential mucosal vaccine vectors, after incorporation of genes from a number of different pathogens including influenza [Ikonomidis et al., 1997], measles [Fennelly et al., 1995], simian immunodeficiency virus (SIV) [Steger and Pauza, 1997], and *Tetanus* Toxoid [VanCott et al., 1996]. Viruses have also been used as vaccine vectors, for example attenuated vaccinia virus [Moss et al., 1984] and Venezuelan equine encephalitis virus [Caley et al., 1997] have been studied for their ability to deliver in the most part other viral genes. This strategy is particularly appropriate in the defence against viral pathogens as it is capable of generating CTL responses. However, there are several problems that have hindered the development of such recombinant bacterial and viral vectors. The bacterial carrier itself can induce an immune response in the GALT, which if a booster regime is required means that the second immunisation may be blocked by an anti-vector response [McGhee et al., 1992]. Also the expression of the foreign gene may be unstable and therefore lost and there is a possibility of a reversal of the attenuating processes of the carrier organism [McGhee et al., 1992]. These types of vaccines are also not particularly stable at fluctuating temperatures and so limit the potential market to that of more temperate climates. Finally, the use of the inactivated carrier limits the immune response generated to that normally induced to the carrier and so may not stimulate a response relevant for clearance of the pathogen [McGhee et al., 1992]. Thus research has been undertaken to search for non living mucosal vaccine carriers that generate all of the required protective immune responses, both mucosally and systemically, but which also avoid the problems associated with using attenuated organisms.
3.2 Oral Adjuvants

i) Soluble Toxins as Adjuvants

A number of non-viable mucosal adjuvants have been described, of which cholera toxin (CT) produced from *Vibrio cholerae* and the homologous heat labile enterotoxin from *E. coli* (LT) are the most widely studied. These toxins are comprised of five attachment units or B subunits surrounding the enzymatically active A subunit, which is divided into A1 and A2 [Spangler, 1992]. The B subunits bind to the GM1 ganglioside receptor found on the surface of many cells, including intestinal enterocytes and following binding, the A subunit can translocate into the cell [Holmgren, 1981]. The CTA1 and LTA1 subunits have ADP-ribosyl transferase activity, which activates GTP binding proteins and Gs proteins, thus increasing adenylate cyclase activity and cAMP levels [Holmgren, 1981]. In addition to being responsible for the massive fluid and electrolyte loss seen in the relevant infections, the ADP-ribosylase activity is crucial for the adjuvant activity of CT, although it may not be required for that of LT [Lycke, 1997].

CT was first recognised as a potential adjuvant when it was found that the holotoxin stimulated active mucosal and systemic immune responses, both to itself and to co-administered unrelated protein antigen when given orally [Lycke and Holmgren, 1986]. Since this discovery, the use of CT as an adjuvant has become more refined and it has been shown that CT is capable of increasing both humoral and cell mediated immunity mediated by both CD4 and CD8 T cells. For example, feeding of low doses of CT together with keyhole limpet haemocyanin (KLH), could induce both KLH-specific antibody and cell mediated immune responses. Feeding OVA+CT generates antigen-specific DTH, proliferation, Th1 and Th2 cytokine secretion as well as high levels of mucosal sIgA and IgG [Grdic et al., 1999].

There are several ways in which in which CT or LT may act as adjuvants, including increasing the uptake of luminal antigen via epithelial cells, increasing expression of B7.2 on APC [Cong et al., 1997] and stimulation of high levels of inflammatory cytokines such as IL-1 and IL-6 [Grdic et al., 1999]. However, the mucosal adjuvant effects of CT are dependent on the presence of IL-4 [Vajdy et al., 1995]. These results have been interpreted as showing
that the local adjuvant effects of CT require presentation of antigen in a manner which involves intimate cell-cell contacts in the follicular areas of Peyer's Patches (PP), which are defective in IL-4KO mice [Vajdy et al., 1995]. Despite the potent adjuvant effects of CT and LT, their practical use as vaccine vectors has been limited by their high toxicity in man. In addition, they also carry the same potential risk of inducing immune responses to themselves as with live vectors. Recent work has attempted to develop a variety of non toxic forms of CT and LT and these may prove useful in the future [Agren et al., 1997].

ii) Particulate Oral Adjuvants

A large number of orally active adjuvant systems are particulate in form. This may be because these are targeted preferentially to M cells, or because they protect protein antigen in the hostile environment of the gut. One such example are microspheres constructed from biodegradable polymers such as poly(lactide-co-glycosides) (PLG). These can be made to many different sizes, from ≥1μm up to 3 mm in diameter and can be formulated to degrade at different rates, releasing antigen in a constant flow over a few days to up to 2 years [Morris et al., 1994], which could eliminate the need for booster immunisations. Oral administration of microparticles induces a wide range of antigen-specific systemic and mucosal immune responses, including sIgA responses and systemic CTL and serum IgG responses [Maloy et al., 1994]. However, this approach has proved difficult as large amounts of antigen are required and the microencapsulation process may alter the antigenicity and stability of the incorporated antigen [Gupta and Siber, 1995].

Simple liposomes are another particulate vaccine carrier. Like PLG, their size can be varied and it is possible to incorporate protein antigen. Although preliminary studies have shown that sIgA responses can be stimulated by oral immunisation with liposomes containing antigen [Michalek et al., 1989], liposomes are fairly unstable in the intestine and thus it would be desirable to have other stable, non-living mucosal adjuvant systems that induce a wide range of immune responses by the oral route. This prompted the investigation of lipophilic immune stimulating complexes (ISCOMS) containing Quil A.
4.0 Immune Stimulating Complexes (ISCOMS) as Oral Vaccine Vectors

4.1 Structure of ISCOMS

ISCOMS were first described by Morein and colleagues in 1984. An ISCOM is a hydrophobically bonded micelle that forms spontaneously on mixing cholesterol, a lipid such as phosphatidyl choline and the mixture of saponins which comprise Quil A [Lovgren and Morein, 1988]. Each ISCOM particle consists of identical 12nm subunits which combine to form rigid icosahedral matrices of about 40nm diameter [Morein, 1988] (Figure 1.1). During formation of the ISCOMS, it is also possible to incorporate other hydrophobic molecules such as glycoproteins from cell membranes. The first ISCOMS to be described used crude mixtures of glycoproteins found in the membranes of viruses and bacteria. These included membrane glycoproteins of viruses such as parainfluenza-3 virus [Morein et al., 1984], influenza A virus [Sundquist et al., 1988] measles virus [Varsanyi et al., 1987], feline leukaemia virus [Osterhaus et al., 1985] and some bacterial antigens for example, Neisseria gonorrhoeae [Kersten et al., 1988a]. However, it was difficult to incorporate purified hydrophilic protein antigens, thus limiting the potential usefulness of the approach. This can be overcome by chemical modification of proteins by acidification to reveal hydrophobic groups [Morein et al., 1990], or by addition of hydrophobic regions by chemical linkage of palmitic acid tails [Mowat and Reid, 1992]. Using the latter approach, a variety of proteins have been incorporated into ISCOMS including ovalbumin (OVA) [Reid, 1992], cytochrome c [Reid, 1992] gp120 from HIV[Browning et al., 1992] and somatostatin-avidin complexes [Estrada et al., 1995].

4.2 ISCOMS as Parenteral Adjuvants

Initial experiments showed that parenteral immunisation with ISCOMS containing viral and bacterial membrane glycoproteins induced antigen-specific immune responses, but these were assessed mainly by the levels of serum antibody [Morein et al., 1984, Ertürk et al.,
1989, Lovgren et al., 1988, Kersten et al., 1988b, Nagy et al., 1990] The antibody levels stimulated by ISCOMS were at least equivalent to those found after immunisation with conventional adjuvants such as Complete Freund's Adjuvant (CFA) or alum, and parenteral immunisation with ISCOMS induced all subclasses of IgG [Lovgren, 1988]. Later studies investigated the effect of ISCOMS on other immunological parameters and found that cell mediated immune responses were also induced. These included delayed type hypersensitivity (DTH) reactions *in vivo* [Mowat et al., 1991a, Grdic et al., 1999], antigen-specific proliferative responses [Mowat et al., 1991a, Fossum et al., 1990, Maloy et al., 1995, Grdic et al., 1999] and cytokine production *in vitro* [Maloy et al., 1995, Sjolander et al., 1997] These responses are characteristically CD4+ T cell dependent and the profile of IgG isotypes secreted after immunisation with ISCOMS, indicated that both Th1 and Th2 subsets of CD4+ T cells were primed by parenteral immunisation [Maloy et al., 1995, Sjolander et al., 1997]. This finding was confirmed by the pattern of antigen-specific cytokine production which encompassed a Th1 and Th2 profile, including IL-2 [Fossum et al., 1990, Villacres-Eriksson et al., 1992, Maloy et al., 1995, Villacres-Eriksson, 1995], IL-4 [Maloy et al., 1995, Villacres-Eriksson, 1995, Sjolander et al., 1997], IL-5 [Maloy et al., 1995], IL-10 [Sjolander et al., 1997, Villacres-Eriksson, 1995] and γIFN [Villacres-Eriksson et al., 1992, Maloy et al., 1995, Sjolander et al., 1997, Villacres-Eriksson, 1995]. A surprising and important additional property of ISCOMS was the finding that antigen entrapped within the ISCOMS structure was able to enter the endogenous antigen processing pathway and hence prime class I MHC-restricted CTL. CTL activity has been shown with a number of antigens [Mowat et al., 1991a, Heeg et al., 1991, Jones et al., 1988, Trudel et al., 1992, Mowat et al., 1993], and the OVA-specific CTL have been identified as CD8+ lymphocytes that recognise the immunodominant epitope OVA 257-264 expressed from endogenously synthesised protein in H-2Kb cells [Heeg et al., 1991] The basis for this capacity of ISCOMS to prime for CTL activity is unknown, but could reflect the detergent effect of Quil A allowing direct entry of protein into the cytoplasm through the cell membrane or after ingestion into an endosomal compartment [Campbell and Peerbaye, 1992]. Previous studies have shown that the induction of CTL by ISCOMS requires functionally active macrophages, as CTL generation can be inhibited by
the lysosomal toxin dichloromethylene diphosphate (Cl\textsubscript{2}MDP), or with silica, both of which paralyse the function of macrophages [Maloy, 1996]. This is consistent with recent findings that the phagocytic pathway in macrophages is highly efficient at driving class I processing in other systems [Debrick et al., 1991, Kovacs-Oics-Bankowski and Rock, 1995, Harding and Song, 1994].

4.3 Induction of Protective Immunity by ISCOMS

The essential property of any vaccine is that it can generate a highly specific protective response to subsequent challenge infections. Although the primary response to ISCOMS peaks 2-3 weeks after immunisation, memory T cell responses can be recalled for up to 8 months after a single subcutaneous immunisation with OVA ISCOMS [Maloy, 1996] indicating their potential to generate long-lasting memory.

The ability of parenteral administration of antigen loaded ISCOMS to confer resistance to a challenge with a pathogen has been tested in a number of animal models of infection including influenza A [Lovgren et al., 1990], canine distemper virus [Visser et al., 1992, de Vries et al., 1988], pseudorabies virus [Tulman and Garmendia, 1994], rabies virus [Fekadu et al., 1992], simian immunodeficiency virus (SIV) [de Vries et al., 1994] and respiratory syncytial virus [Trudel et al., 1992], Salmonella [Charles et al., 1994a], Yersinia enterocolitica [Noll and Autenreith, 1996], Trypanosoma cruzi [Araujo and Moreira, 1991], Leishmania major [Papadopoulos et al., 1998] and Toxoplasma gondii [Ovemes et al., 1991]. Most encouraging is an ISCOMS based parenteral vaccine against equine influenza virus which is currently being used in Sweden. Trials of a human flu vaccine using ISCOMS technology have also been initiated. These findings have recently been published and indicate that a single intramuscular injection of an ISCOM based influenza vaccine was tolerated well and induced an increased level of influenza-specific CTL activity in 50-60% of the volunteers, as compared to those who received the standard influenza vaccine [Ennis et al., 1999]. Such positive outcomes of early human trials indicates that ISCOMS which retain immunogenicity can been formulated for human use.
4.4 ISCOMS as Mucosal Adjuvants

Early studies showed that intranasal administration of ISCOMS containing influenza A virus envelope glycoproteins stimulated serum antibody titres equivalent to those found after subcutaneous administration of ISCOMS [Lovgren, 1988]. Subsequent work using the same vector demonstrated local cellular and humoral immune responses in the lung after intranasal immunisation [Jones et al., 1988], as well as immunity to challenge with live influenza A virus [Lovgren et al., 1988]. By using a fusion peptide of paramyxovirus linked to a measles virus derived CTL epitope from measles nucleoprotein, ISCOMS were also shown to prime nucleoprotein-specific CTL after an intranasal immunisation [Hsu et al., 1996]. Although initial studies suggested that ISCOMS containing influenza proteins were ineffective when given by the oral route [Lovgren, 1988], ISCOMS are exceptionally stable structures, and can resist degradation by exposure to low pH and bile salts [Kersten, 1990]. Furthermore, it has been known for many years that the saponins themselves are effective adjuvants when given orally, inducing serum antibodies, antigen-specific proliferation and CTL activity [Chavali and Campbell, 1987b, Chavali and Campbell, 1987a]. These indications that ISCOMS could be an effective oral vaccine were confirmed by initial findings from this laboratory that a single feed of ISCOMS containing OVA could induce primary OVA-specific IgG, DTH and class I MHC-restricted CTL responses in mice [Mowat et al., 1991a]. In addition, feeding OVA ISCOMS did not induce the systemic tolerance to subsequent challenge which is the normal consequence of feeding equivalent amounts of soluble OVA. Thus ISCOMS appear to bypass the regulatory mechanisms which normally inhibit responses to orally administered proteins. Although the dose of OVA ISCOMS needed to induce primary systemic responses orally was ten fold greater than that given parenterally [Mowat et al., 1991a], as little as 50μg OVA could induce detectable DTH responses [Mowat et al., 1991a]. However, it was more difficult to prime serum antibody responses in this way and six feeds of 50μg - 100μg OVA ISCOMS were found to be optimal for inducing serum IgG antibody responses and CTL activity in the spleen. This protocol also
stimulates local immune responses, as shown by the fact that CTL could be demonstrated in draining mesenteric lymph node (MLN) and by the presence of high levels of secretory IgA antibodies in gut lavage fluid [Mowat et al., 1993]. Interestingly, optimal IgA production was dependent more on the frequency of oral immunisation, rather than the amount of antigen, as IgA levels increased progressively after 1, 3 or 6 feeds, but 10μg OVA/dose was as effective as 100μg [Mowat et al., 1993]. No IgA antibodies could be found in serum after oral immunisation alone, but these could be stimulated by combined oral and parenteral immunisation with OVA ISCOMS (Personal Communication A.M. Donachie). Later studies showed that repeated oral immunisation with OVA ISCOMS resulted in both Th1 and Th2 dependent immune responses, with OVA-specific proliferative responses and the production of IL-2, γIFN and IL-5 in the MLN and spleen [Maloy et al., 1995]. Oral OVA ISCOMS also primed for both IgG1 and IgG2a serum antibody production after challenge with OVA parenterally [Maloy et al., 1995]. Thus, orally administered ISCOMS are strong inducers of both local and systemic immunity, prime both MHC class I and MHC class II restricted responses, induce cellular and humoral responses and do not bias towards either the Th1 or Th2 cells. Subsequent work has shown that the oral immunogenicity of ISCOMS is not confined to the model antigen OVA. Local and systemic immune responses which protected against challenge were seen after oral administration of ISCOMS containing subunit antigens derived from influenza virus [Ghazi et al., 1995, Scheepers and Becht, 1994], and surface sporozoite antigens from Eimeria falciformis [Kazanji et al., 1994].

These studies also have important practical implications for the use of ISCOMS as vaccine vectors. Firstly, the toxicity often found due to the Quil A component of ISCOMS given by other routes is reduced when given orally [Phillips et al., 1979]. Secondly, oral immunisation with OVA ISCOMS does not induce susceptibility to immunopathology in the intestine upon subsequent oral exposure to antigen [Mowat et al., 1993], as is found in other circumstances when oral tolerance is broken. Together these results suggest that ISCOMS will be safe and effective when given as an oral or nasal vaccine.

There have been few studies of the immunogenicity of ISCOMS given by other mucosal routes. However it has been shown that local antigen-specific antibody responses
can be generated when ISCOMS containing antigens from sheep erythrocytes are administered into the vagina or the upper reproductive tracts of female mice. [Thapar et al., 1991].

Thus, especially after the encouraging start to human trials of an intramuscular ISCOMS based influenza vaccine, the development of oral human ISCOMS based vaccines is a second priority.

4.5 Mechanisms for ISCOMS Adjuvanticity

Little is known currently of how ISCOMS act. However, previous work in our laboratory had suggested that Quil A and the particulate nature of ISCOMS played an important role [Maloy, 1996]. Quil A itself is capable of inducing similar antigen-specific immune responses by both parenteral and oral routes, with the same range of CD4+ and CD8+ T cell responses, as well as local and systemic antibody production [Campbell and Peerbaye, 1992]. However, much larger amounts of both Quil A and antigen are required to generate immune responses equivalent to those induced by ISCOMS themselves [Maloy, 1996]. Thus it seems that delivery of the Quil A adjuvant in the particulate form of the ISCOMS is central to their adjuvant effects. Other work has suggested that ISCOMS may influence the innate immune response, with reports of increased recruitment of neutrophils [Watson et al., 1989] and the production of IL-1 [Villacres-Eriksson et al., 1993] IL-6 [Behboudi et al., 1997] and IL-12 [Villacres-Eriksson et al., 1997] after parenteral administration. In addition recent evidence has indicated that ISCOMS induce an upregulation of the expression of B7.2 [Sambhara et al., 1998]. However, these properties have not been studied in detail, nor is it known if they are essential for the adjuvant effects of ISCOMS on specific immune responses. Finally no studies have been undertaken in the mucosa. These were the aims of the current work.
5.0 Specific Aims of Study

In the first part of this thesis, I assessed the innate responses induced by a single administration of ISCOMS. To do this, I studied the effects of injecting ISCOMS into the peritoneum, as this provided an easily accessible and discrete compartment from which inflammatory cells could be removed. I monitored the number and phenotypic populations of cells that were recruited and determined their functional activity by measuring the production of inflammatory cytokines and mediators. Having obtained data from this site, I then performed equivalent studies on the innate immune responses induced in the secondary lymphoid tissues of the small intestine following a single oral dose of ISCOMS. The results of these studies are described in Chapter 3.

As these experiments showed that ISCOMS stimulated a large range of innate immune responses, I then went on to determine how some of these factors influenced the induction of antigen-specific immune responses to ISCOMS using gene-targeted knock out mice. The results of this work are described in Chapter 4.

As these studies indicated that only certain components of the innate immune response were required for the immunogenicity of ISCOMS, finally, I examined how defects in these factors correlated with differences in the early inflammatory responses induced by ISCOMS. These results are presented in Chapter 5.
Figure 1.1 Ultrastructural appearance of OVA ISCOMS.

A transmission electron micrograph (magnification x73 000) of ISCOMS after negative staining, with 3% phosphotungstic acid, showing the characteristic cage-like structure.
Chapter 2
Materials and Methods

2.1 Animals

Female C57Bl/6 (B6) mice were purchased from Harlan Olac (Bicester, Oxon, UK.) while female BALB/c mice were bred at the University of Glasgow. 129/Sv γIFN-type II-receptor knockout (γIFNRFKO) [Huang et al., 1993] mice and (B6x129) F2 IL-4 knockout (IL-4KO) [Kopf et al., 1993] mice were originally obtained from Dr H. Bluethmann (Hoffmann-La Roche, Basal, CH). p40 IL-12 deficient (IL-12KO) BALB/c and C57BL/6 [Magram et al., 1996] mice were obtained from Dr. J. Magram, Roche Pharmaceuticals, Piscataway, NJ, USA. Inducible nitric oxide synthase deficient (INOSKO) MF1 mice [Wei et al., 1995] and IL-18 deficient (MF1x129) mice were a gift from Prof. F.Y. Liew, Department of Immunology, University of Glasgow. All these mice were bred and maintained at the University of Glasgow under SPF conditions and first used at 6-8 weeks of age.

Female IL-6 deficient (IL-6KO) SV mice [Kopf et al., 1994] were obtained from Prof. J. Alexander, Department of Immunology, University of Strathclyde, Glasgow and were bred and maintained at the University of Strathclyde.

2.2 Anaesthesia

For some procedures, animals were anaesthetised using 5% halothane BP (Rhone Merieux, Harlow, Essex, U.K.)

2.3 Antigens

Ovalbumin (OVA, Grade V) was obtained from Sigma (Poole, Dorset, U.K.) as a lyophilised powder and stored at 4°C until required.
Heat-aggregated OVA (HAO) was prepared by heating a 2% (w/v) solution of OVA in sterile saline (Baxter Healthcare Ltd, Thetford, Norfolk, U.K.) at 70°C for 60 minutes in a waterbath. The precipitated OVA was then centrifuged for 10 minutes at 450g at 4°C and the supernatant removed. The pellet was then resuspended and washed with cold saline and re-centrifuged. The pelleted HAO was resuspended in sterile saline at a concentration of 20mg/ml and stored in aliquots at -20°C until required. For use as an in vivo challenge, HAO was resuspended at a concentration of 2mg/ml in sterile saline and sonicated for 20 minutes until a colloidal suspension was obtained.

2.4 Adjuvants

Quil A (Spikoside) produced by Iscotech AB, Lulea, Sweden, was kindly provided by Dr. K. Lövgren (Department of Veterinary Medical Microbiology, Swedish University of Agricultural Sciences, Uppsala, Sweden.) and whole cholera toxin (CT) derived from *Vibrio cholerae* was purchased from Sigma, resuspended in sterile saline to a concentration of 1mg/ml and stored at 4°C until required.

2.5 Production of OVA ISCOMS

OVA ISCOMS were prepared using a modified protocol of that described previously [Mowat and Reid, 1992]. In order to incorporate the non-hydrophobic OVA protein into the lipophilic ISCOMS matrix, OVA was chemically modified by attachment of hydrophobic palmitic acid groups via a succinimide esterification reaction. Palmitified OVA was then mixed with cholesterol and phosphatidyl choline in the presence of Quil A and the ISCOMS formed spontaneously.

i) Palmitification of OVA

20mg OVA was dissolved in 2.5ml of 0.05M carbonate buffer (pH 9.2) and passed through a Sephadex PD10 column (Pharmacia, Uppsala, Sweden.) to remove low molecular
weight peptides. Whole OVA was eluted from the column with 0.05M carbonate buffer and 200μl fractions collected in a Falcon flexible 96 well assay plate (Becton Dickinson Labware, Oxnard, CA, USA.). Protein content was assessed by the Bradford assay and the protein containing fractions pooled. The concentration of protein was adjusted to 1mg/ml by addition of 0.05M carbonate buffer containing 5% sodium deoxycholate (BDH Ltd, Poole, Dorset, U.K.) and 10% dimethyl sulfoxide (DMSO) (Sigma).

Palmitification of the resulting purified OVA was achieved by dropwise addition of 314μl of a 10mg/ml N-(palmitoyloxy) succinimide (NPS) (Sigma) solution dissolved in DMSO giving a 20:1 molar ratio of palmitic acid to OVA. Both NPS and OVA were prewarmed to 37°C and the reaction performed with constant shaking to prevent precipitation of NPS. The mixture was then incubated overnight at 37°C in a shaking incubator with a stroke rate of 100/minute. The palmitification reaction was stopped by addition of 1ml Tris (hydroxymethyl methylamine (TrisHCl, pH 8.5), followed by a further incubation for 30 minutes at 37°C. Excess TrisHCl prevents palmitification by providing free amino groups.

Free palmitic acid was separated from palmitified OVA by ultracentrifugation. A 40% (w/v) solution of sucrose (BDH) was prepared in phosphate buffered saline (PBS) and 8ml pipetted into six Ultraclear tubes (Beckman Ltd, High Wycombe, Bucks, U.K.). 1g sucrose was added to the protein/NPS mixture so as to give a 5% w/v solution, and 4ml of this was overlaid on to the 40% sucrose layer in each tube. 1ml of a 2% (w/v) solution of decanoyl N-methylglucamide (Mega-10) (Sigma) in PBS was added carefully to the top of each tube, which were then centrifuged at 40,000 rpm for 4 hours at 4°C using a SW41.14 rotor (Sorvall (UK) Ltd, Stevenage, Herts, U.K.) in an ultracentrifuge (Sorvall). Following ultracentrifugation, the top layer of PBS containing the free palmitic acid was discarded and the palmitified OVA harvested from the 5% sucrose layer.

ii) Preparation of OVA ISCOMS

A mixture of cholesterol and phosphatidyl choline (both Sigma) was prepared by adding 50mg of each to 1ml chloroform (Aldrich Chemical Co., Poole, Dorset, U.K.) and adding this to 5 ml of distilled H2O containing 20% (w/v) Mega-10. The chloroform was
evaporated under a stream of nitrogen until the mixture was completely clear, leaving a solution containing 10mg/ml of each lipid. The lipid mixture was dispensed in 1ml aliquots and stored at -20°C until required.

To prepare OVA ISCOMS, 1ml of the lipid mixture (giving a final concentration of 0.5mg/ml) and 50mg Quil A (giving a final concentration of 0.1% (w/v)) was added to the palmitified OVA solution. The solution was sonicated for 20 minutes, transferred into dialysis tubing (Visking, Medicell International Ltd, London, U.K.) and dialysed for 4-5 days at 20°C against 4 litres of 50mM Tris-HCl or PBS which was changed every 12 hours. The formation of ISCOMS was observed by a cloudiness of the dialysate.

The ISCOMS were separated from free reaction products by ultracentrifugation over a discontinuous sucrose gradient prepared in Ultraclear tubes. The sucrose gradient was produced by pipetting 4mls of 40% sucrose (w/v) solution in PBS into Ultraclear tubes (Beckman) and overlaying 4mls of 10% sucrose (w/v) solution in PBS. 5mls of the ISCOMS mixture was carefully layered on to the top of each tube and these were then centrifuged at 40,000 rpm for 16 hours at 4°C using the SW41.14 rotor (Sorvall) and a Sorvall ultracentrifuge. The ISCOMS were visualised as a white band at the interface between the 10% and 40% sucrose layers and were harvested and dialysed for 24 hours against 4 litres of PBS to remove excess sucrose.

ISCOMS were then sterilised by filtration through a 0.2µm filter (Acrodisc, Gelman Sciences, Ann Arbor, MI, U.S.A.), aliquoted and stored at -20°C until required. The formation of intact ISCOMS was confirmed by negatively staining with 3% phosphotungstic acid (pH 6.6) and analysis on a Philips CM10 transmission electron microscope (TEM) at a final magnification of 73000x (Mrs Jane Hare, Department of Pathology, Western Infirmary, Glasgow).

iii) Quantification of OVA ISCOMS Protein Content

The concentration of OVA in samples of purified protein and in OVA ISCOMS was measured using Bradford's Assay. Briefly, 20µl of test sample were added to 180µl of a 20% (v/v) solution of Bradford's reagent (Coomassie Blue Dye in 55% phosphoric acid with 15%
methanol) (Bio-Rad, Hemel Hempstead, Bucks, U.K.) in dH2O. After an incubation for 20 minutes at room temperature, the O.D. 570nm of the samples was read using a MR5000 automatic plate reader (Dynatech Laboratories Ltd., Billingshurst, West Sussex, U.K.) and the concentration of OVA calculated by comparison with a standard curve generated from dilutions of OVA in PBS.

iv) Quantification of Endotoxin Content in OVA ISCOMS

The content of lipopolysaccharide (LPS) in OVA ISCOMS was quantified using the Limulus lysate assay (Sigma) and was found to be very low (<0.5μg/ml), equivalent to 0.5ng/dose of ISCOMS.

2.6 Administration of OVA ISCOMS in vivo

ISCOMS were administered parenterally either as a subcutaneous (s.c.) injection in a volume of 50μl sterile saline into the hind footpad under light halothane anaesthesia or as an (i.p.) injection in a total volume of 200μl sterile saline.

Oral immunisation of ISCOMS was performed by feeding 200μl volumes using a rigid steel gavage needle placed in the oesophagus. Control mice were injected with saline and killed after 3.5 hours.

2.7 Isolation of Peritoneal Exudate Cells

Peritoneal exudate cells (PEC) were removed by lavage. Mice were injected i.p. with 6mls of RPMI 1640 (Gibco BRL, Paisley, U.K.), the abdomen gently massaged and fluid withdrawn using a 19 gauge needle. The cells were washed by centrifuging in RPMI 1640 at 450g for 5 minutes, resuspended in fresh RPMI 1640 and viable cell counts performed in a Neubauer haemocytometer (Weber Scientific, Middlesex, U.K.) using a phase contrast microscope at x400 magnification (Nikon Labophot, UK). The cells were then centrifuged again at 450g and the pellet resuspended at a concentration of 1x10^7 PEC/ml in the appropriate medium and stored on ice until required.
2.8 **Histological Analysis of PEC by Cytospin**

Aliquots of $5 \times 10^5$ cells were spun onto glass microscope slides at 200 rpm for 5 minutes using a cyto-centrifuge (Shandon, Runcorn, UK) and fixed in a 50:50 methanol in acetone solution for 2 minutes. The slides were allowed to air dry and washed in PBS before being immersed in Geimsa stain (Sigma) for 30 minutes. The slides were rinsed in distilled water, allowed to air dry and then mounted in Histamount (Sigma) under glass.

The cells were then assessed histologically at x400 magnification using a Nikon Labophot microscope. To perform qualitative analysis of cell numbers, 10 fields/cytospin were assessed and the average calculated.

2.9 **Isolation of Lymphoid Cells**

Popliteal lymph nodes (PLN), spleens (SP), Peyer’s patches (PP) and mesenteric lymph nodes (MLN) were removed after sacrifice and cleaned of any surrounding tissue. The lymphoid organs were then gently crushed using a sterile 2ml syringe plunger (Plastipak, Becton Dickinson, Mountain View, CA, USA) in a Petri dish (Costar, Northumbria Biologicals, Cramlington, U.K.) containing RPMI 1640 medium. The cells were then pipetted several times through a sterile glass pipette to obtain a single cell suspension which was then passed through sterile nylon mesh (Nitex, Cadich and Sons Ltd. London, U.K.) to remove debris. The cells were washed by centrifuging at 450g for 5 minutes, resuspended in fresh RPMI 1640, counted, resuspended at an appropriate concentration and stored on ice until use.

2.10 **Flow Cytometry**

Lymphoid cells and PEC were analysed phenotypically by flow cytometry using the surface markers listed in Table I. Aliquots of $10^6$ cells were washed twice in FACS Buffer (PBS containing 2% FCS (Gibco BRL) and 0.02% sodium azide) and all staining reactions
performed for 45 minutes on ice in a total volume of 50µl FACS Buffer containing antibodies at 1:25 dilutions. Between staining steps, cells were washed twice in cold FACS Buffer and finally resuspended in 500µl of FACSflow (Becton Dickinson). For analysis, a Becton Dickinson FACScan® flow cytometer (Becton Dickinson) was used which consisted of a single argon laser of 488nm wavelength. Data from 10,000 cells were acquired and analysed using Lysis II software.

2.11 Stimulation of Cytokine Production in vitro

For the assessment of cytokine production, 4×10^6 cells were cultured in vitro in 24 well plates (Costar) in 1ml of RPMI 1640 containing 10% heat inactivated FCS, 100U/ml penicillin, 100µg/ml streptomycin, 50µg/ml Fungizone (all Gibco BRL) and 0.05µM 2-mercaptoethanol (Sigmaa) (culture medium) in the presence or absence of 10µg/ml LPS (S. enteritidis, Sigma) plus 20ng/ml recombinant murine γIFN (Pharmingen) or with 10µg/ml concanavalin A (Con A). For the measurement of antigen-specific cytokine secretion, similar aliquots of 4×10^6 cells were cultured with or without 10µg/ml Con A or 1mg/ml OVA. After culture at 37°C in 5% CO₂ in air, the supernatants were removed and centrifuged for 5 minutes at 13000g before being frozen at -20°C until required.

2.12 Removal of Adherent Cells in vitro

Adherent cells were removed from PEC populations by adding 4×10^6 PEC in 1ml culture medium to 24 well plates (Costar) and incubating at 37°C in a humidified incubator containing 5% CO₂ in air for 3 hours. Non-adherent cells were then gently aspirated using a sterile glass pipette and transferred into fresh wells.
2.13 Measurement of Reactive Oxygen Intermediate Production

Reactive oxygen intermediates (ROI) released during the respiratory burst were measured by a chemiluminescence assay [Easmon et al., 1980]. Briefly, cells were washed in Hank's Balanced Salts Solution (HBSS) (Gibco BRL) without phenol red, and warmed to 37°C in a water bath. 100µl of 0.1mM 5-amino-2,3-dihydro-1,4-phthalazinedione solution (Luminol) (Sigma) was added to 2x10⁶ cells in 400µl of the warmed HBSS and these were then stimulated by addition of 1µg/ml phorbol 12-myristate 13-acetate (PMA) (Sigma). The suspensions were mixed at 37°C and the chemiluminescence measured using a 1250 Luminometer (LKB Wallac, Turku, Finland) every 10 seconds for a total of 10 minutes. All measurements were expressed as mV and the background chemiluminescence was assessed by incubating cells in the absence of PMA.

2.14 Measurement of Nitric Oxide Production

The concentration of nitric oxide (NO) present in culture supernatants was determined by detection of nitrite, a stable metabolite of NO, using the Griess reaction. Briefly, the Griess reagent was made by mixing equal volumes of 5% orthophosphoric acid containing 1% sulphanilamide (Sigma) and 0.1% naphthylethylenediamine (Sigma) and kept at 4°C until required. 50µl culture supernatant or standard dilutions of sodium nitrite in RPMI 1640 containing 10% FCS were added to 96 well Immulon 4 microtitre plates (Dynatech) in triplicate and 50µl of the Griess reagent was then added. The colour generated by the reaction was measured spectrophotometrically at 570nm using a MR5000 microtitre plate reader (Dynatech).

2.15 Measurement of Systemic Delayed Type Hypersensitivity (DTH) Responses

Systemic OVA-specific DTH responses were assessed 7 days after immunisation with OVA ISCOMS by measuring the increment in footpad thickness 24 hours after a
subcutaneous challenge with 100μg HAO, using callipers (Kroplin Ltd, Kingston-upon-Thames, Surrey, U.K.) . Background responses were determined by challenging naive mice with HAO and were subtracted to obtain antigen-specific DTH levels.

2.16 Measurement of OVA-Specific Antibodies in Serum

Blood was obtained from the retro-orbital plexus using heparinised capillary tubes (Hawksley & Sons Ltd, Lancing, Sussex, U.K.) under light halothane anaesthesia and the serum was separated by centrifugation at 500g for 10 minutes. Samples were stored at -20°C until required and the levels of serum antibody were then analysed by ELISA, [Garside et al., 1995].

i) Quantification of Total IgG Antibodies

Immulon 4 ELISA plates (Dynatech) were coated overnight at 4°C with 50μl of a 10μg/ml solution of OVA in 50mM carbonate buffer. The plates were then washed three times with PBS containing 0.05% polyoxyethylene sorbitan monolaurate (Tween 20) (Sigma) (PBST). 100μl of samples diluted 1:400 in PBST were added to the plate in triplicate and incubated for 2.5 hours at room temperature in a humid environment. The plates were then washed three times with PBST and 100μl of a 1:1000 dilution of alkaline phosphatase conjugated goat-anti-mouse IgG (Sigma) was added and the plates left for a further 3 hours at room temperature in a humid environment. Plates were then washed three times with PBST and 100μl of a 1mg/ml solution of phosphatase substrate (p-nitrophenyl phosphate) (Sigma) dissolved in dH2O containing 10% diethanolamine (DEA) (Aldrich) was added to each well. The O.D. 450nm of the samples was read using an MR5000 automatic microplate reader (Dynatech) after an incubation for 10-30 minutes at room temperature. The results from individual mice were expressed either as an O.D. 450nm, or as the dilution that gave an equivalent O.D. 450nm of a 5% concentration of an hyperimmune standard of ammonium sulphate-purified anti-OVA IgG which had been obtained from mice immunised twice with 100μg OVA in CFA.
ii) Quantitation of OVA-Specific Serum IgG Antibody Isotypes

Immulon 4 plates were coated overnight at 4°C with 50µl of a 10µg/ml OVA solution, then washed three times with PBST. The plates were blocked with 3% (w/v) bovine serum albumin (BSA) (Sigma) in PBST for 1 hour at room temperature and then washed again three times with PBST. A 1:400 dilution of hyperimmune OVA-specific serum as standard or serum samples were diluted either 1:400 in PBST for IgG1 or 1:20 in PBST for IgG2a and added to the plates in a volume of 50µl and then serially diluted 1:1 in PBST. The plates were incubated for 2.5 hours at room temperature and then washed three times with PBST. IgG1 was detected by adding 50µl of a 1:16,000 dilution of biotinylated rat-anti-mouse IgG1 antibody (Serotec) in PBST and IgG2a by the addition of 50µl of a 1:500 dilution of biotinylated rat-anti-mouse IgG2a (Serotec) in PBST. The plates were then incubated at room temperature for 1 hour and then washed three times with PBST. 100µl of a 1:1000 dilution of extravidin peroxidase (Sigma) in PBST was added to each well and incubated for 1 hour at room temperature. The plates were washed several times with PBST and 100µl of the chromophore 3, 3', 5, 5'-tetramethylbenzidine (TMB) and H2O2 (Dynatech) added to each well. After an incubation of 10 minutes at room temperature the plates were read at 630nm on a MR5000 microtitre plate reader (Dynatech). The level of IgG isotypes present in test wells was calculated the dilution that gave an equivalent O.D. 450nm ≥ 5% of the hyperimmune standard.

2.17 Measurement of Intestinal Secretory IgA Antibodies

Intestinal secretions were collected using a lavage technique modified from that published previously [Elson et al., 1984]. Mice were given four feeds of 200µl 16% polyethylene glycol (PEG) (Sigma) solution in PBS within an hour. The small intestine and caecum were then removed and rinsed through with 6ml of ice cold PBS containing 0.1mg/ml soyabean trypsin inhibitor and 50mM ethylendiaminetetraacetic acid (EDTA) (both Sigma). The fluid was clarified by centrifugation at 1500g for 10 minutes and 3ml of the
supernatant was removed. Then 30μl of 100mM phenylmethylsulfonyl (PMSF) (Sigma) in 95% ethanol (Aldrich) was added to each aliquot, which were then centrifuged in Eppendorf tubes at 27000g for 15 minutes at 4°C. 10μl of PMSF solution, 10μl of a 1% (w/v) solution of sodium azide (Sigma) in PBS and 50μl of FCS were then added to 1ml of the resulting supernatants which were then stored at -20°C until required.

OVA-specific intestinal IgA responses were also assessed by ELISA. Immulon 4 ELISA plates (Dynatech) were coated overnight at 4°C with 50μl of a 10μg/ml solution of OVA in 50mM carbonate buffer. The plates were then washed thoroughly with PBST and 100μl of undiluted sample added in triplicate, incubated for 2.5 hours at room temperature in a humid environment and then washed three times with PBST. 100μl of a 1:1000 dilution of alkaline phosphotase conjugated goat-anti-mouse IgA (Sigma) was added and the plates left for a further 3 hours at room temperature in a humid environment. The plates were then washed three times with PBST and 100μl of a 1mg/ml solution of phosphotase substrate (Sigma) dissolved in dH2O containing 10% DEA (Aldrich) was added to each well. The O.D. 450nm of the samples was read using an MR5000 automatic microplate reader (Dynatech) after an incubation of 10-30 minutes at room temperature. The results from individual mice were expressed as an O.D. 450nm.

2.18 Measurement of OVA-Specific Proliferative Responses

Single cell suspensions from spleen or popliteal lymph node (PLN) were cultured in flat bottomed 96 well microtitre plates (Costar) in quadruplicate. Cells were cultured at a concentration of 2.5×10^5/well in culture medium with or without 1μg/ml OVA or 10μg/ml Con A at 37°C in 5% CO2 and humidified air. Eighteen hours prior to harvesting, the cells were pulsed with 1μCi 3H-thymidine (West of Scotland Radionucleotide Dispensary, Western Infirmary, Glasgow) and harvested onto glass fibre filter mats using a Betaplate 96 well harvester (LKB Wallac, Turku, Finland). DNA bound 3H-thymidine was then counted using a Betaplate scintillation counter (LKB Wallac).
2.19 **Measurement of Cytokines by ELISA**

Culture supernatants were assayed for cytokine levels by sandwich ELISAs, already established in the laboratory [Garside et al., 1995]. Immulon 4 plates (Dynatech) were coated with an appropriate concentration of rat-anti-cytokine antibody (See Table II) diluted in 0.1M carbonate buffer and incubated overnight at 4°C. The plates were then washed three times with PBST and blocked for 1 hour with 200μl of 10% FCS in PBS. The plates were then washed twice with PBST and 50μl of samples, or serial dilutions of recombinant murine cytokines as standards, added in triplicate to the plate (See Table III). The plates were then incubated at 37°C for three hours before being washed three times with PBST. 50μl of the appropriate biotinylated-detection antibody was added to the plate and incubated for 1 hour at 37°C (See Table IV). The plates were then washed three times with PBST before 100μl of a 1:1000 dilution of extravidin peroxidase (Sigma) in PBS + 10% FCS was added to each well and incubated for 1 hour at 37°C. The plates were washed several times with PBST and 100μl of the chromophore TMB and H2O2 (Dynatech) added to each well. After an incubation of 10 minutes at room temperature, the plates were read at 630nm on a MR5000 microtitre plate reader (Dynatech). The level of cytokine present in test wells was calculated from the standard curve.

2.20 **Measurement of OVA-Specific Cytotoxic T Cell Responses**

OVA-specific CTL activity was measured in spleens of mice 7 days after i.p. immunisation or 7 days after the final feed of OVA ISCOMS as described previously [Mowat et al., 1991b]. 3x10^7 spleen cells from immunised animals were restimulated in vitro with 1.5x10^6 OVA transfected EG7.0VA cells which had been treated for 60 minutes at 37°C with 50μg of mitomycin c per 1x10^7 cells in a volume of 1 ml of culture medium containing 5% NCTC-135 medium (Gibco) (CTL medium). The cells were co-cultured in 25cm^2 culture flasks (Costar) for 5 days at 37°C in 5% CO2 and humidified air. After culture, the effector cells were washed three times and assayed for CTL activity using EG7.0VA cells that had
been labelled with $^{51}\text{Cr}$ by incubating $2.5 \times 10^6$ EG7.OVA cells in 1ml of RPMI 1640 containing 5\% newborn calf serum (NCS) (Gibco) and 2MBq Na$_2^{51}$CrO$_4$ (West of Scotland Radionucleotide Dispensary) for 60 minutes at 37\°C in 5\% CO$_2$ and humidified air. The target cells were then washed five times to remove excess Na$_2^{51}$CrO$_4$ by centrifugation at 450g for 5 minutes and added to V-bottomed 96 well microtitre plates (Costar) in RPMI 1640+5\% NCS at a concentration of $2 \times 10^4$ cells/well. Effector cells were added to target cells in quadruplicate at various concentrations so as to give effector:target (E:T) ratios of 100:1, 50:1 and 25:1 in a total volume of 200\pl. The cultures were then incubated at 37\°C in 5\% CO$_2$ for 4 hours before 100\pl of supernatant was removed from the top of each well and $^{51}$Cr release counted on a Compugamma counter (LKB Wallac). The percentage of OVA-specific CTL lysis of target EG7 cells was calculated by using the following formula:

$$\text{% Cytotoxicity} = \frac{(\text{Experimental Release} - \text{Spontaneous Release})}{(\text{Total Release} - \text{Spontaneous Release})} \times 100\%$$

In all experiments, 10\% Triton X (BDH Laboratory Supplies, Poole, UK) was used to obtain the maximum release and medium or naive spleen cells restimulated with EG7.OVA cells was used to obtain the spontaneous release. $^{51}$Cr-labelled EL4 cells were used as non-OVA expressing negative control target cells.

### 2.2.1 Statistics

Unless otherwise stated, all results are expressed as means ± 1 standard deviation (1SD) and were compared using Student's $t$-test.
## Table I. Phenotypic marker antibodies used for flow cytometry

<table>
<thead>
<tr>
<th>MARKER</th>
<th>CLONE</th>
<th>ISOTYPE</th>
<th>HOST</th>
<th>CONJUGATE</th>
<th>DILUTION</th>
<th>COMPANY</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4</td>
<td>RM4-5</td>
<td>IgG2αK</td>
<td>Rat</td>
<td>PE</td>
<td>1:25</td>
<td>Pharmingen</td>
</tr>
<tr>
<td>CD8</td>
<td>53-6.7</td>
<td>IgG2αK</td>
<td>Rat</td>
<td>FITC</td>
<td>1:25</td>
<td>Pharmingen</td>
</tr>
<tr>
<td>Whole Neutrophils</td>
<td>5120-</td>
<td>IgG2α</td>
<td>Rat</td>
<td>Biotin</td>
<td>1:10</td>
<td>Serotec</td>
</tr>
<tr>
<td>F4/80</td>
<td>C1;A3-1</td>
<td>IgG2b</td>
<td>Rat</td>
<td>Biotin</td>
<td>1:10</td>
<td>Serotec</td>
</tr>
<tr>
<td>CD11c</td>
<td>HL3</td>
<td>IgG1</td>
<td>Hamster</td>
<td>PE</td>
<td>1:25</td>
<td>Pharmingen</td>
</tr>
<tr>
<td>I-Abd</td>
<td>25.9-17</td>
<td>IgG2αK</td>
<td>Mouse</td>
<td>FITC</td>
<td>1:25</td>
<td>Pharmingen</td>
</tr>
<tr>
<td>CD25</td>
<td>7D4</td>
<td>IgMκ</td>
<td>Rat</td>
<td>FITC</td>
<td>1:25</td>
<td>Pharmingen</td>
</tr>
<tr>
<td>CD16/</td>
<td>2.4G2</td>
<td>IgG2βκ</td>
<td>Rat</td>
<td>-</td>
<td>1:25</td>
<td>Pharmingen</td>
</tr>
<tr>
<td>CD32</td>
<td></td>
<td></td>
<td></td>
<td>PE</td>
<td>1:10</td>
<td>Vector</td>
</tr>
</tbody>
</table>

42
Table II. Capture antibodies used for sandwich ELISA

<table>
<thead>
<tr>
<th>CYTOKINE</th>
<th>CLONE</th>
<th>ISOTYPE</th>
<th>HOST</th>
<th>CONCENTRATION (ng/ml)</th>
<th>COMPANY</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-1α</td>
<td>ALF161.1</td>
<td>IgG</td>
<td>Hamster</td>
<td>10μg/ml</td>
<td>Genzyme</td>
</tr>
<tr>
<td>IL-5</td>
<td>TRFK5</td>
<td>IgG1</td>
<td>Rat</td>
<td>4μg/ml</td>
<td>Pharmingen</td>
</tr>
<tr>
<td>IL-6</td>
<td>MP5-20F3</td>
<td>IgG1</td>
<td>Rat</td>
<td>1μg/ml</td>
<td>Pharmingen</td>
</tr>
<tr>
<td>IL-12</td>
<td>C17.15</td>
<td>IgG2a</td>
<td>Rat</td>
<td>5μg/ml</td>
<td>Genzyme</td>
</tr>
<tr>
<td>γIFN</td>
<td>XMG1.2</td>
<td>IgG1</td>
<td>Rat</td>
<td>2μg/ml</td>
<td>Pharmingen</td>
</tr>
</tbody>
</table>

Table III. Recombinant cytokine used in sandwich ELISA

<table>
<thead>
<tr>
<th>CYTOKINE</th>
<th>TOP STANDARD</th>
<th>BOTTOM STANDARD</th>
<th>COMPANY</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-1α</td>
<td>20,000 ng/ml</td>
<td>31.250 pg/ml</td>
<td>Genzyme</td>
</tr>
<tr>
<td>IL-5</td>
<td>200,000 U/ml</td>
<td>0.313 U/ml</td>
<td>Genzyme</td>
</tr>
<tr>
<td>IL-6</td>
<td>10,000 ng/ml</td>
<td>15.625 pg/ml</td>
<td>Genzyme</td>
</tr>
<tr>
<td>IL-12</td>
<td>10,000 ng/ml</td>
<td>15.625 pg/ml</td>
<td>Genzyme</td>
</tr>
<tr>
<td>γIFN</td>
<td>40,000 ng/ml</td>
<td>62,500 ng/ml</td>
<td>Genzyme</td>
</tr>
<tr>
<td>CYTOKINE</td>
<td>CLONE</td>
<td>ISOTYPE</td>
<td>CONJUGATE</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>IL-1α</td>
<td>Polyclonal</td>
<td>-</td>
<td>Biotin</td>
</tr>
<tr>
<td>IL-5</td>
<td>TRFK4</td>
<td>IgG2a</td>
<td>Biotin</td>
</tr>
<tr>
<td>IL-6</td>
<td>MP5-32C11</td>
<td>IgG2a</td>
<td>Biotin</td>
</tr>
<tr>
<td>IL-12</td>
<td>Polyclonal</td>
<td>-</td>
<td>Biotin</td>
</tr>
<tr>
<td>γIFN</td>
<td>XMG1.2</td>
<td>IgG1</td>
<td>Biotin</td>
</tr>
</tbody>
</table>
Chapter 3
Parenteral and Oral Administration of ISCOMS induces an Inflammatory Cascade in vivo.

Introduction

Although ISCOMS are well known to induce a wide range of antigen-specific immune responses in vivo by both parenteral and mucosal routes, the basis for their adjuvant properties has not been studied in any detail. As it is now clear that an ability to stimulate the innate immune response exerts a powerful influence over the type of acquired immunity generated to an antigen [Medzhitov and Janeway Jr, 1997a, Fearon and Locksley, 1996], it seemed appropriate to explore the effects of ISCOMS on the early non-specific immune response. Therefore, in the experiments described in this chapter, I investigated if ISCOMS were capable of inducing an innate response after parenteral or oral administration.

Experimental Protocol

In the first experiments, mice were injected i.p. with 5μg OVA ISCOMS in saline. The peritoneum was chosen as it provided a discrete, relatively localised compartment for sampling, that was also easily accessible. In addition, previous studies in our laboratory had shown that ISCOMS were immunogenic by this route [Mowat et al., 1991a, Maloy et al., 1995]. At various times after injection, PEC were removed by lavage, counted and examined by cytospins and flow cytometry. The release of ROI was determined by PMA induced chemiluminescence of Luminol and the production of nitric oxide was measured by the Greiss reaction after in vitro culture in the presence or absence of γIFN+LPS. Inflammatory cytokines were assessed by ELISA analysis of supernatants in response to γIFN+LPS. After studying the responses to i.p. ISCOMS, I went on to perform similar experiments using Peyer’s patches and mesenteric lymph nodes taken from mice fed 200μg OVA ISCOMS. In all experiments, control mice received saline alone.
Results

3.1 Recruitment of Local Inflammatory Cells after Intraperitoneal Administration of ISCOMS.

Intraperitoneal administration of ISCOMS induced recruitment of an inflammatory infiltrate as determined by the total number of PEC obtained in peritoneal lavage. This was preceded by an early reduction in the number of PEC, with a 50% decrease in the total number of PEC being observed at 3.5 hours after administration of ISCOMS as compared with saline injected controls. The numbers of PEC remained depressed until 48 hours after ISCOMS injection, by which time there was a marked and significant increase in the number of PEC to levels three times that of control mice. The number of PEC was still significantly elevated at 72 hours (Figure 3.1).

3.2 Histological Examination of PEC after i.p. ISCOMS

I next explored the nature of the inflammatory infiltrate by histological analysis of cytospins prepared of PEC isolates. PEC from control mice consisted mostly of small resting lymphocytes and macrophages, together with a small number of mast cells which were identified by the presence of multiple dense granules (Figure 3.2a). The decrease in total PEC early after injection of ISCOMS was accompanied by an increase in the absolute number of polymorphonuclear leukocytes at 3.5 hours (Figure 3.2b) and 7 hours (Figure 3.2c). Polymorphonuclear cells were still present at 24 hours, although in much lower numbers, (Figure 3.2d), and by 48 and 72 hours, polymorphonuclear cell numbers had returned to control levels (Figures 3.2e and f). Mast cell numbers also increased soon after injection of ISCOMS and showed evidence of degranulation. This was seen as early as 3.5 hours (Figure 3.2b), when a substantial number of these cells had degranulated. There was a second rise in mast cell numbers at 48 hours, although no degranulation was seen at this time (Figure 3.3).
Mast cell numbers then returned to control levels at 72 Hours (Figure 3.3). There was no change in the numbers of macrophages from PEC isolated at early timepoints after injecting ISCOMS, but at 48 hours, there was an influx of large mononuclear cells, many with a foamy appearance consistent with activated macrophages (Figure 3.2e). In parallel, there was a steady increase in the numbers of lymphoid cells from control levels to a peak at 48 hours, when many were lymphoblastoid in appearance (Figure 3.2e). At 72 hours after ISCOMS injection, lymphocyte morphology was returning to that observed in control cytospins (Figure 3.2f).

3.3 Phenotypic Analysis of PEC Recruited by Parenteral Administration of ISCOMS.

To analyse the inflammatory infiltrate in more detail, I used flow cytometry to assess the expression of cell surface markers specific for neutrophils, macrophages, dendritic cells and T and B lymphocytes. In addition, I determined the activation status of these cells by assessing the levels of MHC class II on macrophages and dendritic cells and the IL-2Rα chain (CD25) on CD4+ and CD8+ T cells. Unfortunately, no statistical analysis of these results were feasible as I had to pool the PEC cells from injected mice.

Consistent with the histological appearances I had observed previously, the decrease in PEC numbers early after injection of ISCOMS was accompanied by a large increase in the absolute numbers and proportions of neutrophils which peaked at 3.5 hours and declined rapidly thereafter. The number of F4/80 expressing macrophages began to increase by 7 hours, reached a peak at 48 hours and then declined (Figure 3.4a), again confirming the microscopic analysis of cytospins.

The numbers of dendritic cells, as determined by expression of the CD11c surface marker, were low in control PEC but, after a further drop at early timepoints, these increased to a peak at 72 hours. These CD11c+ cells were observed to be virtually all MHC class II+, consistent with them being mature dendritic cells (Figure 3.4d).

The numbers of CD4+ and CD8+ T cells declined rapidly over the first 7 hours after ISCOMS injection (Figure 3.4b). Thereafter, the numbers of CD4+ T cells returned toward
control levels, whereas CD8+ T cells remained low until 72 hours, before rising to a level that was twice that of control mice (Figure 3.4b). The numbers of B220+ B cells followed a similar pattern, with a rapid early decrease followed by recovery to levels which were eventually double that of control values at 48 hours after administration of ISCOMS (Figure 3.4c).

I next determined the activation status of the inflammatory infiltrate by examining the expression of CD25 and MHC class II antigens and their co-expression on T cells and macrophages respectively. MHC class II+ F4/80+ macrophages were not found in control PEC, but their numbers increased dramatically from 7 hours until 48 hours, when 25% of macrophages were MHC class II+. By 72 hours, few MHC class II+ macrophages remained (Figure 3.4c). There were also virtually no CD4+ T cells coexpressing CD25 in control PEC. Although the rise in the absolute numbers of CD4+ T cells was not dramatic after injection of ISCOMS, these CD4+ T cells were clearly becoming activated, as evidenced by their expression of CD25, with 26% of CD4+ T cells being CD25+ by 48 hours (Figure 3.4c). As the numbers were much smaller, I was unable to assess the level of CD25+ CD8+ T cells.

Thus i.p. injection of ISCOMS induced a rapid, local recruitment of inflammatory cells, consisting initially of neutrophils and mast cells, followed by macrophages and DC and later by both T and B lymphocytes. Once recruited, many of these cells became activated as indicated by their increased expression of MHC class II and CD25.

3.4 Parenteral Administration of ISCOMS Induces Production of Local Inflammatory Cytokines and Mediators

I next assessed the functional consequences of the cellular recruitment observed after an i.p. injection of ISCOMS by measuring IL-1, TNFα, IL-6 and IL-12 as products of activated macrophages and dendritic cells and γIFN as a lymphocyte product.
i) IL-1α

PEC from control mice showed very low levels of spontaneous production of IL-1α, but spontaneous IL-1α production was significantly enhanced 48 hours after ISCOMS injection, when PEC produced more than 20 times that of controls, before decreasing to undetectable levels (Figure 3.5a). An almost identical pattern of increased IL-1α production by ISCOMS induced PEC, following stimulation in vitro with γIFN+LPS was found (Figure 3.5a).

ii) IL-6

PEC from control animals produced moderate levels of IL-6 both spontaneously and after stimulation with γIFN+LPS in vitro (Figure 3.5b). Immediately after i.p. injection of ISCOMS both the spontaneous and γIFN+LPS induced production of IL-6 fell to undetectable levels, before increasing again after 24 hours, to levels more than double those of controls at 48 and 72 hours (Figure 3.5b).

iii) Immunoreactive IL-12

Control PEC cultures did not produce IL-12 spontaneously and only small amounts of γIFN+LPS induced IL-12 (Figure 3.5c). Spontaneous IL-12 production rose gradually from 24 hours after administration of ISCOMS, plateauing after 48 hours at levels significantly above those of control PEC. The γIFN+LPS stimulated production of IL-12 declined to approximately 20% that of controls within 3.5 hours, but rose sharply to a peak at 72 hours, when levels were twice that of controls (Figure 3.5c).
iv) γIFN

There was no spontaneous production of γIFN from control PEC, but low levels were detected after stimulation with Con A. Significant levels of spontaneous γIFN production were detected 24 hours after injection of ISCOMS but not thereafter. Con A stimulated PEC showed a small, but significant increase in γIFN production 3.5 hours after injection with ISCOMS. This fell back to control levels at 7 hours, but increased again to peak at 24 hours, when γIFN production was twice that of control PEC (Figure 3.5d).

v) TNFα

No TNFα production was found in the supernatants from any PEC preparation either spontaneously or after stimulation with γIFN+LPS (data not shown).

Thus, the local infiltration by macrophages, dendritic cells and T cells with activated phenotypes following injection of ISCOMS is accompanied by the production of inflammatory cytokines, indicating that recruited cells are not only phenotypically but also functionally activated by exposure to ISCOMS.

3.5 Stimulation of Nitric Oxide and Reactive Oxygen Intermediate Production After Parenteral Administration of ISCOMS

In view of the marked recruitment of activated phagocytic cells such as macrophages and neutrophils, I next examined the production of two other characteristic mediators of such cells, nitric oxide and reactive oxygen intermediates. The concentration of NO in PEC culture supernatants was determined from the concentration of its stable breakdown product nitrite, as assessed by the Griess Reaction. There was very little spontaneous NO production by
control PEC, but this was increased by stimulation with γIFN+LPS (Figure 3.6). Spontaneous production of NO was detectable by 24 hours after injection of ISCOMS and substantial amounts were still present at 48 hours (Figure 3.6). Immediately after injection with ISCOMS, γIFN+LPS stimulated production of NO fell, but recovered from 7 hours onwards, reaching a peak at 48 hours which was significantly above control levels (Figure 3.6).

PMA stimulated production of ROI was measured by chemiluminescence of Luminol. Control PEC produced little or no ROI, but within 6 hours after injection of ISCOMS, ROI production was greatly increased (Figure 3.7). PEC taken 24 hours after ISCOMS produced even more ROI, with levels more than twenty times that of control cells. Thereafter, there was a decline in ROI production and by 72 hours after injection of ISCOMS, ROI production had returned to control levels (Figure 3.7).

Thus the recruitment of neutrophils and macrophages by ISCOMS is accompanied by increased production of ROI and NO respectively, underlining the possibility that these cells are activated following administration of ISCOMS.

3.6 Secretion of Inflammatory Mediators by ISCOMS Induced PEC is Dependent on the Presence of Adherent Cells

I next investigated the role of adherent cells in the production of inflammatory cytokines and nitric oxide, by depleting these cells from populations of PEC removed 48 hours after administration of ISCOMS. As before, ISCOMS stimulated PEC produced small amounts of spontaneous IL-12, NO and IL-1α at this time, which were all increased by stimulation with γIFN+LPS (Figures 3.8a, b and c). There was no spontaneous production of IL-6 in this experiment, but marked amounts occurred after stimulation in vitro with γIFN+LPS (Figures 3.8d). In all cases, both the spontaneous and stimulated production of these mediators was reduced virtually to background levels when adherent cells were depleted (Figures 3.8a, b, c, d). Removal of adherent cells also abolished the spontaneous production of γIFN and significantly reduced the Con A stimulated production of γIFN by the same cells (Figure 3.8e). These results are consistent with the critical role of adherent cells,
perhaps macrophages, in the production of inflammatory mediators after injection of ISCOMS.

3.7 Oral Administration of ISCOMS Induces Cellular Recruitment in the Gut Associated Lymphoid Tissues.

As one of the important features of ISCOMS is that they are active via mucosal routes, I went on to investigate whether oral administration of ISCOMS induced inflammatory responses in intestinal lymphoid tissues similar to those found in the peritoneum. Therefore I performed phenotypic and functional studies on PP and MLN cells at various times after a single feed of 200µg OVA ISCOMS. I was again unable to perform statistical analysis on these data, because I pooled the cells from each group of animals.

Oral administration of ISCOMS induced cellular recruitment in both PP and MLN as evidenced by total cell numbers in these tissues (Figures 3.9a and b). This was less marked in PP than in the MLN and was less pronounced compared with that found following an i.p. injection of ISCOMS (Figure 3.1). Nevertheless, a small increase in cell yield was found in both MLN and PP early after feeding ISCOMS, at 3.5 and 7 hours respectively, and after a subsequent fall, the numbers of MLN cells began to rise steadily, so that by 48 hours they were 2.5 times that of controls (Figure 3.9a). The total number of PP cells also increased from 48 hours onwards, but when this peaked at 72 hours, it was only 50% above that of controls (Figure 3.9b).
3.8 Phenotypic Analysis of GALT Cells After Oral Administration of ISCOMS.

In order to assess the nature of the inflammatory infiltrate induced by ISCOMS, I analysed cell-specific surface markers and the expression of cellular activation molecules in PP and MLN cells.

i) Mesenteric Lymph Nodes

In contrast to the peritoneal cavity, there was no change in the numbers of neutrophils found in MLN at any time after oral administration of ISCOMS (Figure 3.10a). However, the numbers of F4/80+ macrophages increased steadily to a maximum 48 hours after feeding ISCOMS, at which time the numbers of F4/80+ macrophages were six times that of controls (Figure 3.10a). The numbers of F4/80 cells then began to decline towards control levels by 72 hours. An early increase in the numbers of MLN derived CD11c+ dendritic cells occurred 3.5 hours after feeding ISCOMS, but this was transient and the numbers quickly decreased to 50% of controls by 24 hours after feeding ISCOMS. However, the numbers of dendritic cells then increased again, reaching a maximum by 48 hours after ISCOMS, at which time numbers were 2.5 times those in control mice, before returning to background levels by 72 hours (Figure 3.9d). The majority of these CD11c+ cells were also MHC class II+, indicating that these cells were fully differentiated dendritic cells (Figure 3.10b).

The numbers of CD4+ T cells in MLN rose transiently immediately after feeding ISCOMS, fell thereafter and then increased steadily to a maximum at 48 hours, by which time numbers had increased to three times that of control animals (Figure 3.10c). An identical pattern was observed for CD8+ T cells (Figure 3.10c). The numbers of both CD4+ and CD8+ T cells returned towards background levels by 72 hours. A similar trend was noted for the numbers of B lymphocytes, with a small spike in the numbers of B220+ cells occurring 3.5 hours after feeding ISCOMS, followed by a more sustained recruitment after 24 hours, with peak numbers of B220+ B cells being noted at 48 hours, before decreasing towards control levels by 72 hours (Figure 3.10d).
I used the coexpression of MHC class II on macrophages and CD25 on CD4 lymphocytes to determine the degree of activation of these cells after oral administration of ISCOMS. After a small increase in the numbers of MHC class II\(^+\) F4/80 macrophages at 7 hours, however these numbers fell at 24 hours after feeding ISCOMS, when they were 50\% that of control mice. This was despite the increase in total macrophages numbers at this time. However, the numbers of activated macrophages then quickly rose to a peak at 48 hours, by which time they were 3.5 times greater than controls (Figure 3.10e). There was a more gradual, but sustained, increase in the numbers of activated CD4 lymphocytes, as measured by coexpression of the CD25. These reached a maximum level at 72 hours after feeding ISCOMS, by which time the numbers of CD4\(^+\) CD25\(^+\) cells were twice that of controls (Figure 3.10e). It was not possible to measure the numbers of CD8\(^+\) CD25\(^+\) lymphocytes derived from the MLN, as the numbers were so low as to make accurate quantitation impossible.

ii) Peyer’s Patch

As in MLN, there was no increase in the numbers of neutrophils recovered from the PP at any time after feeding ISCOMS (Figure 3.11a). The numbers of F4/80\(^+\) macrophages, increased markedly at 3.5 and 7 hours, to levels nearly four times that of controls, but had returned to control levels by 24 hours (Figure 3.11a). The numbers of CD11c\(^+\) dendritic cells in PP changed very little throughout the experiment, and although there was some evidence of a transient increase at 3.5 hours, only 50\% of these cells expressed MHC II in contrast to the dendritic cells in other tissues I examined (Figure 3.11b).

A small and transient increase in the numbers of CD4\(^+\) T cells was noted at 3.5 hours but this then declined before rising gradually to a peak at 72 hours when there was a 50\% increase in the numbers of CD4\(^+\) lymphocytes compared with controls (Figure 3.11c). There were no differences in CD8\(^+\) T cell numbers at any time after feeding ISCOMS (Figure 3.11c). There was a small increase in the numbers of B220\(^+\) B cells early after feeding
ISCOMS, but by 24 hours B cell numbers had returned to control levels before rising again to reach a plateau from 48 hours onwards, when their numbers were increased by 45% above control levels (Figure 3.11d).

The numbers of activated MHC class II+ macrophages paralleled those of total F4/80+ cells, with an early increase up to 7 hours, followed by a return to control levels by 24 hours and thereafter (Figure 3.11e). There was no alteration in the numbers of CD25+ CD4+ lymphocytes at any time after feeding ISCOMS (Figure 3.10e).

Therefore, although oral administration of ISCOMS induces an inflammatory response in intestinal lymphoid tissues, this is less intense and more restricted in scope than that found after intraperitoneal injection. In addition, an inability to perform statistical analysis means that caution is required when interpreting the results.

3.9 Effects of Oral Administration of ISCOMS on the Production of Inflammatory Mediators by GALT Cells

After observing that there was some recruitment of inflammatory cells into the GALT, I went on to determine if these cells were functionally activated as I had found with PEC. Therefore, I isolated MLN and PP cells at different times after a single feed of ISCOMS and cultured them in vitro in the presence or absence of γIFN+LPS to examine for production of inflammatory mediators.

i) Mesenteric Lymph Node

Control MLN produced a relatively large level of IL-6 spontaneously and this was only slightly elevated after stimulation in vitro with γIFN+LPS (Figure 3.12a). Spontaneous production of IL-6 was completely ablated after a single feed of ISCOMS and did not recover to control levels at any point thereafter (Figure 3.12a). The γIFN+LPS induced production of IL-6 from MLN was also severely reduced within 3.5 hours of feeding ISCOMS and never
recovered to that of controls, despite a small rise after 24 hours (Figure 3.12a). Control MLN produced some IL-12 spontaneously and this was more than doubled in the presence of γIFN+LPS (Figure 3.12b). Spontaneous IL-12 production was decreased within 3.5 hours of feeding ISCOMS to 40% of control levels and did not rise thereafter. γIFN+LPS induced IL-12 production was reduced by 50% immediately after a feed of ISCOMS and continued lower than normal throughout the time course (Figure 3.12b). Spontaneous production of γIFN by control MLN cells was very low, but after restimulation with Con A, γIFN secretion was more than 10 times greater (Figure 3.12c). Spontaneous production of γIFN did not vary from control levels at any time after feeding ISCOMS (Figure 3.12c). However within 7 hours, the Con A induced γIFN levels were reduced by 90%, before steadily returning to control levels by 72 hours (Figure 3.12c). No IL-1α or NO production from MLN cells was found at any time after feeding ISCOMS (Data not shown).

Thus despite the fact that ISCOMS induced recruitment of inflammatory cells into the MLN, these cells fail to produce inflammatory cytokines in this environment.

ii) Peyer's Patch

Control PP produced measurable levels of IL-12 which were not significantly elevated after stimulation in vitro with γIFN+LPS (Figure 3.13a). There was a decrease in the production of spontaneous IL-12 seven hours after feeding ISCOMS, but this was not maintained and levels returned to that of controls within 24 hours (Figure 3.13a). After feeding ISCOMS, a slow decrease in γIFN+LPS induced IL-12 production culminated in a 60% reduction by 24 hours (Figure 3.12a). However, IL-12 levels then began to rise, and by 48 hours, a very small but significant increase above controls was noted, before levels fell to that of controls once more (Figure 3.13a). Spontaneous production of γIFN was not detectable in control PP, but Con A induced γIFN could be measured (Figure 3.13b). There was a small increase in the level of spontaneous γIFN production early after feeding ISCOMS, but this returned to control levels by 24 and 48 hours, before evidence of a further increase by 72 hours (Figure 3.13b). In contrast, the Con A induced production of γIFN was significantly reduced below control levels immediately after feeding ISCOMS and remained
so for the duration of the experiment (Figure 3.12b). There was no spontaneous or stimulated production of NO, IL-1α or IL-6 detectable in the PP cells at any time after feeding ISCOMS (Data not shown). These data reflected the small changes in PP cell populations as determined by flow cytometry. However, a small increase in activated F4/80 macrophages was noted at 7 hours and this may be responsible for the small increase in IL-12 secretion at later times. This cytokine production observed in the PP of ISCOMS fed mice was similar to that of the MLN, in that the majority of factors were either undetectable or unchanged after the administration of ISCOMS.

Summary and Conclusions

The results presented in this chapter indicate that ISCOMS induce intense local activation of the innate immune system with the recruitment of a wide variety of inflammatory cells including neutrophils, mast cells, dendritic cells, macrophages and lymphocytes. This inflammatory cascade is most evident when ISCOMS are administered parenterally, where many of the recruited cells were activated, as evidenced by expression of surface activation markers and the production of cytokines and other mediators. Oral administration of ISCOMS also induced an inflammatory cascade in the GALT, with recruitment of activated macrophages, dendritic cells, activated CD4+, CD8+ T cells and B cells. However there was no neutrophilia and although these recruited cells showed signs of phenotypic activation, very little or no increase in the production of inflammatory cytokines and mediators was measured after oral administration of ISCOMS.

In the next chapter, I will describe experiments conducted to determine which if any of the inflammatory mediators induced by ISCOMS were important in the induction of antigen-specific immunity.
Figure 3.1 ISCOMS Recruit Inflammatory Cells Following Local Injection.

The graph shows PEC recruitment following an i.p. injection of 5μg OVA ISCOMS. PEC were removed by lavage and cell counts of PEC from the individual mice performed. The results shown are mean PEC numbers for three mice ± 1 SD (p<0.005 * versus saline injected mice).
Figure 3.2  Histological Examination of PEC after ISCOMS Injection

Cytospin appearances of pooled PEC removed from (a) saline injected mice or (b) 3.5 hours, (c) 7 hours after i.p. injection of 5μg OVA ISCOMS. Giemsa staine cytopsins were examined by microscopy at x400 magnification. (Key: RL - resting lymphocyte, MC - mast cell, Mϕ - macrophage, Nϕ - neutrophil, DMC - degranulating mast cell.)
Figure 3.2 Histological Examination of PEC after ISCOMS Injection

Cytospin appearances of pooled PEC removed from (d) 24 hours, (e) 48 hours and (f) 72 hours after i.p. injection of 5μg OVA ISCOMS. Giemsa stained cytospins were examined by microscopy at x400 magnification. (Key: RBC - red blood cell, AL - activated lymphocyte, MC - mast cell, Nφ - neutrophil, AMφ - activated macrophage, RL - resting lymphocyte and Eφ - eosinophil).
Figure 3.3 Induction of Mast Cell Recruitment and Degranulation by ISCOMS

Mast cells were counted on cytopsins of PEC removed at various times after i.p. injection of 5μg OVA ISCOMS. The results shown are the mean numbers of mast cells and degranulating mast cells in ten microscope fields at x400 magnification ± 1 SD (* p<0.01 versus saline injected mice).
Figure 3.4 Phenotypic Analysis of ISCOMS Recruited PEC.

PEC were removed by lavage after an i.p. injection of 5μg OVA ISCOMS and analysed by flow cytometry. The results shown are the numbers of (a) neutrophils and F4/80+ macrophages, (b) CD4 and CD8 T cells, (c) B220+ B cells, (d) CD11c+ dendritic cells, (e) MHC class II+ F4/80 macrophages and CD25+ CD4 T cells. The results are expressed as the number of cells per mouse which were calculated from the percentage of cells positive for each marker in the PEC pooled from 5 animals per group. Control mice received saline alone.
**Figure 3.5** ISCOMS Induce Local Secretion of Inflammatory Cytokines by PEC.

Production of (a) IL-1α, (b) IL-6, (c) immunoreactive IL-12 and (d) γIFN by PEC pooled from 5 mice given an i.p. injection of 5µg ISCOMS 3.5-72 hours before. Control mice received saline alone. The results shown are the mean concentration of cytokines measured in triplicate after 48 hours stimulation in the presence or absence of γIFN+LPS (a-e) or the presence or absence of Con A (d) ± 1 SD (* p<0.05 versus saline injected mice; ** p<0.005 versus saline injected mice).
Figure 3.6  ISCOMS Induced Nitric Oxide Production from PEC

Production of nitric oxide from PEC pooled from 5 mice after injection of 5μg ISCOMS or saline. The results shown are the mean concentration of nitrite measured in triplicate after culture for 48 hours in the presence or absence of γIFN+LPS ± 1 SD (* p<0.01 versus saline injected mice).
Figure 3.7 ISCOMS Induced Production of Reactive Oxygen Intermediates

Production of reactive oxygen intermediates from PEC pooled from 5 animals after injection with 5μg ISCOMS or saline. The results show the release of ROI from $1 \times 10^6$ PEC as measured by the PMA stimulated chemiluminescence of Luminol and are expressed in mV.
Figure 3.8 Adherent Cells are Required for the Production of ISCOMS Induced Inflammatory Mediators

Production of (a) IL-12, (b) NO, (c) IL-1α, (d) IL-6 and (e) γIFN by PEC pooled from 5 mice given an i.p. injection of 5μg ISCOMS 48 hours earlier. The results shown are the mean concentration of cytokines from supernatants of either whole PEC cultures or of PEC depleted of adherent cells after 48 hours stimulation in the presence or absence of γIFN+LPS (a-d) or the presence or absence of Con A (e) ± 1 SD (* p<0.05 versus whole PEC cultures; ** p<0.005 versus whole PEC cultures.)
Figure 3.9 Recruitment of Inflammatory Cells by a Single Feed of ISCOMS

The graph shows recruitment of (a) MLN and (b) PP cells after a single feed of 200μg OVA ISCOMS. MLN and PP tissues were removed from five mice at various times after oral ISCOMS and cell counts performed. The results shown are the mean cell numbers per MLN or PP, calculated from pooled samples. Control mice received saline alone.
Figure 3.10 Phenotypic Examination of MLN Cells Induced by Oral Administration of ISCOMS

MLN were removed at various times after a single feed of 200μg OVA ISCOMS, pooled and analyzed by flow cytometry. The results shown are the numbers of (a) neutrophils and F4/80+ macrophages, (b) CD4 and CD8 T cells, (c) B220+ B cells, (d) CD11c+ dendritic cells and MHC class II+ CD11c+ dendritic cells, (e) MHC class II+ F4/80 macrophages and CD25+ CD4 T cells. The results are expressed as the number of cells per MLN, calculated from the percentage of cells positive for each marker. Control mice received saline alone.
Figure 3.11 Phenotypic Examination of PP Cells Induced by Oral Administration of ISCOMS

PP were removed at various times after a single feed of 200μg OVA ISCOMS, pooled and analysed by flow cytometry. The results shown are the numbers of (a) neutrophils and F4/80+ macrophages, (b) CD4 and CD8 T cells, (c) B220+ B cells, (d) CD11c+ dendritic cells and MHC class II+ CD11c+ dendritic cells, (e) MHC class II+ F4/80 macrophages and CD25+ CD4+ T cells. The results are expressed as the number of cells per MLN, calculated from the percentage of cells positive for each marker. Control mice received saline alone.
Figure 3.12 Secretion of Inflammatory Cytokines by MLN After Oral Administration of ISCOMS

Production of (a) IL-6, (b) IL-12 and (c) γIFN by MLN pooled from 5 mice given an i.p. injection of 5 μg ISCOMS 3.5-72 hours before. Control mice received saline alone. The results shown are the mean concentration of cytokines measured in triplicate after 48 hours stimulation in the presence or absence of γIFN+LPS (a, b) or the presence or absence of Con A (c) ± 1 SD (* p<0.05 versus saline injected mice; ** p<0.005 versus saline injected mice; *** p<0.001 versus saline injected mice).
Figure 3.13 Secretion of Inflammatory Cytokines by PP After Oral Administration of ISCOMS

Production of (a) IL-12 and (b) γIFN by PP pooled from 5 mice after a single feed of 200μg ISCOMS 3.5-72 hours before. Control mice received saline alone. The results shown are the mean concentration of cytokines measured in triplicate after 48 hours stimulation in the presence or absence of γIFN+LPS (a) or the presence or absence of Con A (b) ± 1 SD (* p<0.05 versus saline injected mice; ** p<0.01 versus saline injected mice).
Chapter 4
The Importance of ISCOMS Induced Inflammatory Mediators for the Generation of Antigen-Specific Immunity

Introduction

It is currently believed that adjuvants act principally by stimulating different components of the innate immune system, with consequent upregulation of costimulatory molecules and production of accessory cytokines [Khortus and Jenkins, 1996]. In the previous chapter, I showed that ISCOMS are no exception to this theory, being capable of inducing a rapid and diverse range of inflammatory effects after parenteral or oral administration. In particular, there was a notable increase in the production of a number of proinflammatory mediators including γIFN, IL-6, IL-12 and NO after an i.p. injection or feeding of ISCOMS. I felt that it was essential to determine if any of these mediators played a role in the generation of antigen-specific immune responses to ISCOMS associated antigen.

We had demonstrated previously that oral or parenteral immunisation with OVA-ISCOMS induced a wide range of antigen-specific responses, as measured by a number of in vitro and in vivo parameters, including delayed type hypersensitivity (DTH), MHC class I restricted cytotoxic T cells, as well as antigen-specific proliferation, cytokine and antibody production [Maloy et al., 1995, Mowat et al., 1993, Mowat et al., 1991b]. Therefore, in the experiments described in this chapter, I monitored these antigen-specific responses in genetargeted knockout animals deficient in IL-6, γIFN, IL-12, iNOS, IL-18 and IL-4.

Experimental Protocol

Female KO mice and appropriate wild type mice all of 6-8 weeks of age, were immunised subcutaneously (s.c.) in the rear footpad with 5μg of OVA ISCOMS in a volume of 50μl saline, intraperitoneally (i.p.) with 5μg of OVA ISCOMS in a volume of 200μl saline, or orally with six consecutive feeds of 100μg OVA ISCOMS in 200μl saline on days
1, 2, 3, 8, 9, and 10. Control mice were immunised with saline alone. OVA-specific DTH was measured in mice 24 hours after subcutaneous challenge of 100µg heat aggregated OVA (HAO) given in the footpad, seven days after s.c. immunisation or the final feed of OVA ISCOMS. Antigen-specific proliferation and cytokine production in response to in vitro restimulation with OVA was measured in popliteal lymph nodes removed from animals 14 days after s.c. immunisation or spleens taken at the same time after the final feed of OVA ISCOMS. OVA-specific CTL activity was measured in spleens of mice 7 days after i.p. immunisation or 14 days after oral administration of ISCOMS. Antigen-specific antibody production was assessed in serum taken 7 days after challenge with HAO. Antigen-specific secretory IgA production was measured in intestinal secretions collected 7 days after the final feed of ISCOMS.

Results

4.1 Immune Responses to ISCOMS in Interleukin 12 Deficient Mice

I have described earlier that production of IL-12 by ISCOMS recruited PEC was greatly enhanced immediately after injection with ISCOMS. IL-12 triggers the production of γIFN from NK cells [Trinchieri, 1995] and is responsible for driving the development of γIFN producing Th1 CD4+ T cells, as well as the differentiation and activation of CTL [Abdi and Herrmann, 1997]. IL-12 also regulates the expression of the IL-2Rα and β subunits [Robertson et al., 1992, Nuame et al., 1993] on the surface of lymphocytes, meaning that it could potentially control T cell proliferation to an immune signal. IL-12 has also been implicated in the induction of cell surface IL-8 [Nuame et al., 1993] and so could also be involved in initiating the chemotactic compartments of an inflammatory cascade. For these reasons I was interested to investigate how IL-12 might regulate ISCOMS induced antigen-specific immune responses. To do this, IL-12KO mice on the BALB/c background were used for the assessment of antigen-specific DTH, antibody, proliferation and cytokine production.
and IL-12KO mice on the C57BL/6 background were used to measure antigen-specific CTL activity.

### 4.1.1 Antigen-Specific DTH Responses

As anticipated, wild type BALB/c mice showed a good level of OVA-specific DTH following s.c. immunisation with OVA ISCOMS (Figure 4.1a) and there was an even better response in orally immunised mice (Figure 4.1b). IL-12KO mice had dramatically decreased DTH responses after s.c. immunisation (Figure 4.1a) and these were also reduced by 50% in orally immunised IL-12KO mice (Figure 4.1b).

### 4.1.2 OVA-Specific Proliferative Responses

Lymph node cells from wild type BALB/c mice immunised with OVA ISCOMS s.c. or orally generated good proliferative responses on restimulation with OVA in vitro. These were reduced by 40-60% in IL-12KO mice (Figure 4.2a and b).

### 4.1.3 Antigen-Specific Cytokine Production

OVA ISCOMS induced antigen specific production of γIFN from wild type BALB/c PLN after s.c. immunisation (Figure 4.3a), and from the spleen after oral immunisation (Figure 4.3b). Wild type mice also produced OVA-specific IL-5 after s.c. (Figure 4.3c) and oral immunisation (Figure 4.3d). As expected, IL-12KO mice produced virtually no OVA-specific γIFN in response to s.c. or oral immunisation (Figure 4.3a and b), but interestingly, these animals also had a 40% reduction in antigen-specific IL-5 production after s.c. immunisation (Figure 4.3c). However, orally immunised IL-12KO animals showed significantly increased levels of IL-5, which were twice that of wild types (Figure 4.3d).
4.1.4 OVA-Specific CTL Activity

Wild type C57Bl/6 mice generated good OVA-specific CTL responses after i.p. immunisation (Figure 4.4a). In IL-12KO animals, OVA-specific CTL activity was significantly reduced compared to that in wild type mice, with responses in the order of 50-60% that of normal animals (Figure 4.6.4a). There was no lysis of non OVA-expressing EL4 cells by any cell population. Orally immunised wild type animals produced strong OVA-specific CTL responses (Figure 4.4b), with IL-12KO mice showing a slight reduction in the CTL activity at high effector : target cell ratios compared with wild type mice, but when less effector cells were used, this difference was not so obvious (Figure 4.4b).

4.1.5 Serum IgG Isotypes

Wild type BALB/c animals produced large amounts of OVA-specific IgG2a and IgG1 antibodies after s.c. immunisation with ISCOMs (Figure 4.5a and b). IgG2a levels were significantly decreased in IL-12KO mice but the mice had normal production of IgG1 antibodies, (Figure 4.5a and b). Orally immunised wild type animals produced OVA-specific IgG1 antibodies in serum and these responses were significantly increased in IL-12KO animals (Figure 4.5e). Neither wild type nor IL-12KO mice produced any IgG2a antibodies after oral immunisation in this experiment.

4.1.6 Secretory Intestinal IgA Antibody Production

Wild type BALB/c and IL-12KO BALB/c mice produced equivalent amounts of secretory IgA antibodies in gut washes after oral immunisation (Figure 4.6).
4.1.7 Summary

IL-12KO mice have a severely impaired antigen-specific immune response to OVA ISCOMS compared with wild type controls. The defect in OVA-specific immunity is more dramatic after s.c. immunisation, where IL-12KO mice generally produced less than half the level of immunity of their wild type counterparts for all the parameters measured in vivo and in vitro, including both Th1 and Th2 type responses. A similar defect was seen in orally immunised IL-12KO mice, but in this case immune responses were generally only reduced by approximately 30-40%. In addition some responses, such as OVA-specific IgA, IL-5 and IgG1 production, were either equivalent to, or increased compared with wild type controls after oral immunisation. Thus IL-12 plays an important role in the generation of ISCOMS induced OVA-specific immunity, but this is partly dependent on the route of immunisation used, apparently being important when ISCOMS are given subcutaneously than orally. The residual responses present in IL-12KO mice show that IL-12 is clearly not the sole factor required for the generation of antigen-specific immunity and so I went on to investigate other factors induced during an ISCOMS induced inflammatory cascade, which might replace or synergise with IL-12.

4.2 Immune Responses to ISCOMS in IL-18 Deficient Mice

IL-18 is a recently described cytokine which is part of the IL-1 family of proteins. It is secreted early in inflammation by a wide variety of cells including APC, keratinocytes and epithelial cells [Kohno and Kurimoto, 1998]. It is known to induce the activation of γIFN from NK cells and T cells, thus having similar properties to IL-12 [Okamura et al., 1998a, Okamura et al., 1995]. I had not been able to measure the presence of IL-18 after ISCOMS injection, because of the absence of a suitable ELISA, but the fact that IL-12KO mice had persistent responses to ISCOMS suggested that it would be useful to investigate whether IL-18 played a role. Mice deficient in IL-18 (IL-18KO) had been recently generated in this department by Dr. X-Q. Wei and I therefore performed a preliminary examination of antigen-
specific immune responses to ISCOMS in wild type MFl, heterozygous (IL-18+/-) and IL-18KO animals.

4.2.1 Antigen-Specific DTH Responses

A single s.c. immunisation of OVA ISCOMS in the footpad induced a large DTH response in wild type MFl animals, but homozygous IL-18KO animals showed almost complete ablation of the OVA-specific DTH response and IL-18+/- heterozygous mice also had significantly reduced DTH responses compared with wild types (Figure 4.7a). Six feeds of OVA ISCOMS also induced a strong DTH response in wild type animals, but in contrast to s.c. immunised animals, orally immunised homozygous IL-18KO and IL-18+/- heterozygous mice had normal DTH responses (Figure 4.7b).

4.2.2 Antigen-Specific Proliferative Responses

Wild type mice immunised with s.c. OVA ISCOMS produced a good level of antigen-specific proliferation on restimulation with OVA in vitro and identical responses were obtained in homozygous and heterozygous IL-18KO mice (Figure 4.8). Unfortunately, I obtained no results from the proliferation assays set up from spleen cells taken from orally immunised mice.

4.2.3. Antigen-Specific Cytokine Production

Wild type animals immunised s.c. with OVA ISCOMS produced large amounts of γIFN when restimulated with OVA in vitro, as did heterozygous and homozygous IL-18KO mice (Figure 4.9a). Subcutaneously immunised wild type mice also produced a large amount of OVA-specific IL-5 and again there was no difference in the heterozygous or homozygous IL-18KO mice (Figure 4.9b). Wild type animals immunised orally with ISCOMS produced a large amount of γIFN, but neither heterozygous nor homozygous IL-18KO mice produced
significant levels of γIFN (Figure 4.9c). Wild type mice also produced OVA-specific IL-5 and this was elevated to nearly three times that of wild type levels in both heterozygous and homozygous IL-18KO mice (Figure 4.9d).

4.2.4. Antigen-Specific CTL Activity

Wild type animals were primed for good antigen specific CTL activity after six feeds of OVA ISCOMS (Figure 4.10). There was no difference in the degree of cytotoxicity between either homozygous or heterozygous IL-18KO animals and wild types (Figure 4.10). Unfortunately there was not enough mice at this time to perform parallel experiments in parenterally immunised IL-18KO mice.

4.2.5. Serum IgG Antibody Production

Wild type animals were primed for IgG1 and IgG2a antibody production after s.c. immunisation with OVA ISCOMS and equivalent secondary responses occurred in heterozygous and homozygous IL-18KO mice (Figures 4.11a and b). Wild type mice given six feeds of OVA ISCOMS were also primed for IgG1 and IgG2a antibody production, as were heterozygous and homozygous IL-18KO mice (Figures 4.11c and d).

4.2.6 Summary

Thus IL-18KO mice appear to have some defect in immune responses to ISCOMS. However, no consistent pattern was observed for either route of administration, or for individual components of the immune response, even those which IL-18 is thought to be important, such as γIFN production. Unfortunately, no further mice were available for these experiments to be repeated during the course of my project, but in view of the defects of IL-12KO mice and possibly IL-18KO mice, I went on to investigate the role of mediators downstream of these cytokines, beginning with γIFN, using γIFNRKO mice.
4.3. Immune Responses to ISCOMS in γIFN-Receptor-Deficient Mice

γIFN is essential for many aspects of effector immune responses, being central to the maintenance of the Th1 polarised response [Maggi et al., 1992] and assisting the generation of class I MHC-restricted CTL [Scott and Kaufman, 1991]. As a result, it is often difficult to induce such responses or protective immunity to intracellular pathogens, in mice lacking γIFN or its receptor [Buchmeier and Schreiber, 1985, Scott, 1991, Schijns et al., 1994]. ISCOMS are potent inducers of Th1 dependent responses in vivo, as well as CTL activity [Maloy et al., 1995, Mowat et al., 1991b, Mowat et al., 1993] and I showed in Chapter 3 that γIFN production was one of the components of early inflammatory response to ISCOMS. Therefore it seemed important to determine if γIFN was required for the induction of local and systemic immune responses by ISCOMS. To do this I used γIFNKO mice which lack functional γIFN.

4.3.1 OVA-Specific DTH Responses

Subcutaneously immunised wild type mice produced low but significant antigen-specific DTH responses upon challenge with HAO and unexpectedly, s.c immunised γIFNKO mice had a significantly increased DTH response compared with wild type mice which was four times greater than wild type mice (Figure 4.12a). Wild type animals fed OVA ISCOMS produced good DTH responses and there was no significant difference in the DTH responses in orally immunised γIFNKO mice as compared to wild type mice (Figures 4.12b).

4.3.2 OVA-Specific Proliferative Responses

Wild type mice immunised with OVA ISCOMS generated strong proliferative responses on restimulation with OVA in vitro after both subcutaneous or oral immunisation
(Figure 4.13a and b). Proliferative responses were significantly enhanced in s.c. immunised γIFN−/− mice (Figure 4.13a), but these were significantly decreased in orally immunised γIFN−/− animals (Figure 4.13b).

4.3.3 OVA-Specific Cytokine Production

Subcutaneous immunisation with OVA ISCOMS induced a low but significant level of antigen specific γIFN from wild type mice and this was significantly enhanced in γIFN−/− mice (Figure 4.14a). Subcutaneous immunisation with OVA ISCOMS also primed antigen-specific IL-5 production in wild type mice and this was nearly twice as high in γIFN−/− mice (Figure 4.14b). In general, the antigen-specific cytokine production was much less in orally immunised mice than following s.c. immunisation with ISCOMS. Oral immunisation with OVA ISCOMS induced a low level of antigen-specific γIFN production from wild type mice and this was increased in γIFN−/− mice to three times that of wild type animals (Figure 4.14c). Six consecutive feeds of OVA ISCOMS also primed low levels of antigen-specific IL-5 production in wild type mice and γIFN−/− mice produced IL-5 responses that were approximately 6 times greater than wild type animals (Figure 4.14d).

4.3.4. OVA-Specific CTL Responses

Wild type mice generated good OVA-specific CTL responses after i.p. immunisation, as did γIFN−/− mice, which showed normal levels of OVA-specific CTL activity (Figures 4.15a). Wild type animals also produced good OVA-specific CTL responses after feeding OVA ISCOMS and these were somewhat elevated in γIFN−/− mice fed ISCOMS (Figure 4.15b).
4.3.5 Antigen-Specific Serum IgG Production

OVA ISCOMS primed for good secondary humoral immune responses in wild type mice when administered orally or as a s.c. immunisation. As expected, γIFNRKO mice showed increased production of IgG1 and reduced IgG2a antibodies when ISCOMS were given subcutaneously (Figure 4.16a and b).

4.3.6 OVA-Specific Intestinal IgA Production

Wild type mice had significant induction of IgA antibodies in gut washes following six consecutive feeds of OVA ISCOMS and these were greatly increased in the absence of functional γIFN (Figure 4.17).

4.3.7 Summary

Thus, immune responses to either oral or parenteral immunisation with OVA ISCOMS are essentially normal, or even increased, in the absence of functional γIFN. Despite the high level of inflammatory γIFN released immediately after exposure to ISCOMS, as well as some evidence for the role of the γIFN inducing cytokines IL-12 and IL-18, it appeared that γIFN did not directly promote the generation of the antigenic immunity induced by OVA ISCOMS. Therefore I carried out further investigations into the involvement of other cytokines that are known to direct the immune response.

4.4 Immune Responses to ISCOMS in Interleukin 6 Deficient Mice

In Chapter 3, I showed that ISCOMS induced a large non-specific increase in secretion of IL-6 after a parenteral injection. This is consistent with the role of this cytokine in the early acute inflammatory response [Baumann and Gauldie, 1994, Kopf et al., 1994] and also with reports that IL-6 is involved with the generation of protective antigen-specific
immune responses in vivo against Candida albicans [Romani et al., 1996], Listeria monocytogenes [Kopf et al., 1994] and Mycobacterium avium [Appelberg et al., 1994]. In addition, it has been suggested that IL-6 acts as an early inducer of Th2 responses [Rincon et al., 1997] and there has been disputed evidence that mucosal IgA responses in IL-6KO mice may be defective [Ramsay et al., 1994] [Ramsay et al., 1994, Bromander et al., 1996]. Thus I investigated if IL-6 played any part in the development of acquired immune responses to OVA ISCOMS using IL-6 deficient (IL-6KO) mice. In these studies, I first performed preliminary experiments using the subcutaneous route and, in view of the results obtained and the difficulty in obtaining access to the mice, I carried out very few oral immunisation studies.

4.4.1 Antigen-Specific DTH Responses

Wild type 129/Sv animals produced good antigen-specific DTH responses seven days after a s.c. immunisation of OVA ISCOMS and there was no significant difference in the DTH response in IL-6KO mice (Figure 4.18).

4.4.2 Antigen-Specific Proliferative Responses

Wild type mice immunised with OVA ISCOMS subcutaneously generated good proliferative responses on restimulation with OVA in vitro and identical results were obtained in IL-6KO mice (Figure 4.19).

4.4.3 Antigen-Specific Cytokine Production

Subcutaneous immunisation with OVA ISCOMS primed very low antigen-specific γIFN (Figure 4.20a) and IL-5 (Figure 4.20b) production in wild type mice. Normal γIFN production was measured after s.c. immunisation in IL-6KO mice (Figure 4.20a), but OVA-specific IL-5 in IL-6KO mice was twice that of the wild type animals (Figure 4.20b).
4.4.4 Antigen-Specific CTL Activity

Wild type SVJ mice generated good OVA-specific CTL responses after i.p. immunisation with OVA ISCOMS and identical responses were found with IL-6KO mice (Figure 4.21). There was no killing of the non-antigen expressing EL4 cells.

4.4.5 Antigen-Specific Serum IgG Antibody Production

Wild type mice produced OVA-specific IgG1 and IgG2a when immunised subcutaneously with OVA ISCOMS (Figure 4.22a and b). There was no difference in the levels of either IgG isotype obtained in IL-6KO mice (Figure 4.22a and b).

4.4.6 Summary

Thus the absence of IL-6 does not impair the generation of antigen-specific immune responses after immunisation with OVA ISCOMS. In light of this information I went on to investigate the influence of another of the Th2 cytokines, IL-4.

4.5. Antigen-Specific Responses to ISCOMS in Interleukin 4 Deficient Mice

Previous results had shown that ISCOMS primed a number of Th2 responses, including antigen-specific cytokines as well as serum IgG1 antibodies [Maloy et al., 1995] and recently, the oral adjuvant properties of cholera toxin (CT), another potent mucosal vaccine vector, were found to be entirely dependent on the presence of IL-4 in vivo [Vajdy et al., 1995]. Therefore it was important to investigate the role of this cytokine in ISCOMS induced immunogenicity.
4.5.1. Antigen-Specific DTH Responses

As expected, wild type mice had significant DTH responses when challenged 7 days after subcutaneous immunisation with OVA ISCOMS. These were significantly greater in IL-4KO mice (Figure 4.23a). Wild type animals fed OVA ISCOMS also produced strong DTH responses when challenged with HAO seven days after the final feed, but there was no significant difference in the DTH results obtained in orally immunised IL-4KO mice (Figures 4.23b).

4.5.2. Antigen-Specific Proliferative Responses

Wild type mice immunised with OVA ISCOMS subcutaneously generated good proliferative responses from PLN cells after restimulation with OVA in vitro and these were significantly enhanced in IL-4KO mice to 5 times of those in wild type animals (Figure 4.24a). A similar pattern was observed in the spleens of orally immunised wild type mice and IL-4KO mice (Figure 4.24b).

4.5.3. Antigen-Specific Cytokine Production

Subcutaneous immunisation with OVA ISCOMS primed good antigen-specific production of γIFN from wild type splenocytes and, as expected, IL-4KO mice showed a dramatic increase in the level of antigen-specific γIFN production (Figure 4.25a). OVA-specific IL-5 production was also induced in wild type mice, and as expected, this was significantly reduced in IL-4KO mice (Figure 4.25b). Six feeds of OVA ISCOMS primed only low levels of antigen-specific γIFN production in wild type mice (Figure 4.25c) and no OVA-specific IL-5 production (Figure 4.25d). As before, orally immunised IL-4KO mice had significantly increased production of γIFN (Figure 4.25c), but unexpectedly, also showed some residual production of IL-5, although this was very low in comparison to that obtained in s.c. immunised animals (Figure 4.25d).
4.5.4. Antigen-Specific CTL Activity

Wild type mice generated good OVA-specific CTL responses after i.p. immunisation with OVA ISCOMS (Figure 4.26a) and also significant CTL activity after oral immunisation (Figure 4.26b). IL-4KO mice were primed for identical levels of OVA-specific CTL activity after i.p. immunisation (Figure 4.26a), and also had CTL activity after oral immunisation, although the levels that were approximately 30% less than those in wild type animals (Figure 4.26b). There was no killing of the non-OVA expressing EL4 cell line.

4.5.5 Antigen-Specific Serum IgG Antibody Production

Wild type animals produced antigen-specific IgG1 and IgG2a antibodies after both subcutaneous and (Figures 4.27a, b). As expected, IL-4KO mice had decreased levels of IgG1 and elevated IgG2a antibody in serum after either subcutaneous or oral immunisation with OVA ISCOMS (Figures 4.27a, b).

4.5.6. Increased Production of Intestinal Secretory IgA in IL-4KO Mice

Fourteen days after the last of six feeds of OVA ISCOMS, wild type mice had good OVA-specific secretory IgA production as measured in gut washes. This was significantly increased in orally immunised IL-4KO mice (Figure 4.28).

4.5.7 Summary

Thus, apart from the expected defects in Th2 activity, IL-4KO mice generate normal immune responses to either oral or parenteral immunisation with ISCOMS. I therefore went on to examine the last of the inflammatory mediators induced by injection of ISCOMS, namely NO.
4.6 Immune Responses to ISCOMS in Inducible Nitric Oxide Synthase Deficient Mice

In the previous chapter, I showed that NO levels increased dramatically after an injection of ISCOMS into the peritoneum. During inflammation, NO is produced mainly via the action of inducible nitric oxide synthase (iNOS) and it plays an important part in regulating several aspects of inflammation, including blood supply [Moncada et al., 1991], macrophage microbicidal activity [Nathan and Hibbs, 1991] and IL-12 production [Huang et al., 1998]. There has recently been evidence that iNOS deficient mice are unable to control *L. major* infection [Wei et al., 1995]. Therefore I investigated the role of inflammatory NO in the development of antigen-specific immune responses to OVA ISCOMS using iNOS deficient mice (iNOSKO). The experiments shown, only examined the responses to subcutaneous immunisation, as these mice were being bred onto an inbred background whilst my project was being concluded and before I could perform studies of oral immunisation.

4.6.1 Antigen-Specific DTH Responses

Wild type animals given a s.c. immunisation of OVA ISCOMS produced a good OVA-specific DTH response when challenged with HA one week later and there was no significant difference in the DTH response obtained in iNOSKO mice (Figure 4.29).

4.6.2 Antigen-Specific Proliferative Responses

Wild type MFl mice immunised with OVA ISCOMS subcutaneously generated good proliferative responses upon restimulation with OVA *in vitro* (Figure 4.30). Although, there was a slightly reduced proliferative response in iNOSKO mice, this was not statistically significant (Figure 4.30).
4.6.3 Antigen-Specific Cytokine Production

Subcutaneous immunisation with OVA ISCOMS induced antigen-specific production of γIFN from wild type mice and this was significantly reduced in iNOSKO mice (Figure 4.31a). Subcutaneous immunisation also primed antigen-specific IL-5 production in wild type mice, although this was low compared with that found in other experiments. iNOSKO mice showed reduced levels of OVA-specific IL-5 production which were four times lower than those in wild type animals (Figure 4.31b).

4.6.4 Antigen-Specific Serum IgG Antibody Production

Wild type and iNOSKO mice produced low, but similar levels of both IgG1 and IgG2a antibodies after challenge with HAO (Figure 4.32a and b).

4.6.5 Summary

The absence of functional iNOS and thus a reduction in the production of inflammatory NO did not affect many of the antigen-specific immune responses generated by subcutaneous immunisation with OVA ISCOMS. The only alteration in OVA-specific immunity in iNOS mice was the reduction in cytokine production which affected IL-5 and γIFN equally. Therefore, there is a possible defect in these mice but, given that these were preliminary experiments, it is a priority to repeat studies with the iNOSKO mice with measurement of a full range of immune parameters after both parenteral and oral immunisation.

Summary and Conclusions

The results presented in this chapter show that even though ISCOMS induce a wide range of non-specific inflammatory mediators in vivo, their mucosal and systemic adjuvant
effects are expressed normally in mice lacking the function of most of these factors, including IL-4, IL-6 and γIFN. Systemic DTH, class I MHC-restricted CTL responses and humoral immunity in vivo, as well as antigen-specific proliferation and cytokine production in vitro, together with intestinal secretory antibody responses where measured, were induced normally after either oral or parenteral immunisation of mice deficient in these factors.

However, the adaptive immune response to ISCOMS was at least partly dependent on the presence of IL-12, as mice deficient in IL-12 appeared to have significantly decreased immune responses when immunised with OVA ISCOMS parenterally. The majority of responses were also significantly reduced in orally immunised IL-12KO mice, but the reduction under these circumstances was not as dramatic as with s.c. immunised animals and some responses such as intestinal IgA secretion were entirely normal. Preliminary studies in IL-18KO mice suggested that some immune responses may also have been dependent on the complimentary cytokine IL-18, although the pattern was less clear and the experiments need repeated and extended. The study in iNOSKO mice also suggests that some aspects of the OVA-specific response may be altered in these animals, but these experiments were also preliminary and need to be repeated and extended.

Together, these findings emphasise that the scope of action of ISCOMS may not be limited by the absence of many individual regulatory cytokines, perhaps because they have an ability to exploit redundant cytokines. To try and explore in more detail how these inflammatory mediators help to regulate the induction adaptive immune responses to ISCOMS, in the next chapter I will describe the innate immune responses which were induced in the different knockout mice and will indicate how these correlate with antigen-specific immunity in the same animals.
Figure 4.1 Antigen-Specific DTH in OVA ISCOMS Immunised IL-12 KO mice.

The graph shows OVA specific DTH responses measured 24 hours after subcutaneous challenge into the footpad with 100μg HAo. Mice were immunised with either (a) 5μg OVA ISCOMS in 50μl saline subcutaneously into the rear footpad or (b) six feeds of 100μg OVA ISCOMS in 200μl saline. The results shown are the mean specific increments in footpad thickness of 5 animals per group ± 1 SD, measured 7 days after the last immunisation (*p<0.005, *p<0.05 verses wild type BALB/c mice). The background footpad increment obtained in unimmunised animals has been subtracted.
Figure 4.2 Antigen-Specific in vitro Proliferation in OVA-ISCOMS Immunised IL-12KO Mice.

OVA specific proliferative responses were measured in PLN removed (a) 14 days after a single subcutaneous immunisation in the rear footpad with 5µg OVA ISCOMS in 50µl saline or (b) 14 days after the last of 6 feeds of 100µg OVA ISCOMS in 200µl saline. The graph shows the mean OVA-specific proliferation following a 96 hour culture with 1µg/ml OVA as determined by incorporation of [3H]thymidine into DNA after 16 hours incubation. Results are shown as mean counts of quadruplicate cultures of cells pooled from 5 animals ± 1 SD (*p<0.05 verses wild type BALB/c mice). Background proliferation from control animals has been subtracted.
Figure 4.3  Antigen-Specific T Cell Cytokine Production in OVA ISCOMS Immunised IL-12KO Mice.

OVA-specific γIFN (a) and IL-5 (b) production after s.c. immunisation with 5μg OVA ISCOMS. OVA-specific γIFN (c) and IL-5 (d) production following six feeds of 100μg OVA ISCOMS. The results are shown as means ± 1 SD of triplicate cultures using cells pooled from 5 mice per group, 14 days after the last immunisation. Background cytokine production from control animals has been subtracted. (*p<0.05, **p<0.001 versus wild type BALB/c mice).
Figure 4.4 Antigen-Specific MHC Class I-Restricted CTL Activity in OVA ISCOMS immunised IL-12KO Mice.

OVA-specific CTL activity in spleens of IL-12KO or C57Bl/6 wild type mice, seven days after the last immunisation with either (a) a single i.p. immunisation of 5µg OVA ISCOMS in 200µl saline or (b) 14 days after the final of 6 feeds of 100µg OVA ISCOMS in 200µl saline. Spleens from 5 animals were pooled and 3 x 10^7 cells restimulated with 1.5 x 10^5 mitomycin c treated OVA expressing EG7.OVA cells. The results show the % cytotoxicity calculated from quadruplicate samples. Antigen-specificity was determined by the degree of lysis of non-OVA expressing EL4 cells.
Figure 4.5 Antigen-Specific Serum IgG Isotype in OVA-ISCOMS Immunised IL-12KO Mice.

OVA-specific IgG1 (a and c) and IgG2a (b) antibody levels in serum, 7 days after s.c. challenge of HAO in mice immunised s.c. (a and b) or orally (c) with OVA ISCOMS. The results show the reciprocal dilutions of serum from individual mice which produced the equivalent O.D. 630nm to a 5% dilution of a standard anti-OVA serum (*p<0.05 verses wild type mice). The control levels are from mice that received HAO only.
Figure 4.6 Antigen-Specific Intestinal IgA Production in OVA ISCOMS Immunised IL-12KO Mice.

IgA secretion from the small intestine was assessed in gut washes by ELISA seven days after the last six feeds of 100μg OVA ISCOMS. The results shown are the mean OD 405nm of triplicate samples from 5 mice ± 1SD.

Background IgA production from control animals has been subtracted.
Figure 4.7 Antigen-Specific DTH in OVA ISCOMS Immunised IL-18KO mice.

The graph shows OVA specific DTH responses measured 24 hours after subcutaneous challenge into the footpad with 100μg HAO. Heterozygous (IL-18KO{+/−}), homozygous (IL-18KO{−/−}) or wild type mice were immunised with either (a) 5μg OVA ISCOMS in 50μl saline subcutaneously into the rear footpad or (b) six feeds of 100μg OVA ISCOMS in 200μl saline. The results shown are the mean specific increments in footpad thickness of 5 animals per group ± 1 SD, measured 7 days after the last immunisation (***p<0.001, * p<0.01 versus wild type mice). The background footpad increment obtained in unimmunised animals has been subtracted.
Figure 4.8 Antigen-Specific in vitro Proliferation in OVA-ISCOMS Immunised IL-18KO Mice.

OVA specific proliferative responses were measured in PLN removed from heterozygous (IL-18KO+/−), homozygous (IL-18KO−/−) or wild type mice 14 days after s.c. immunisation with 5μg OVA ISCOMS in 50μl saline. The graph shows the mean OVA-specific proliferation following a 96 hour culture with 1mg/ml OVA as determined by incorporation of [3H]thymidine into DNA after 16 hours incubation. Results are shown as mean counts of quadruplicate cultures of cells pooled from 5 animals ± 1 SD (*p<0.05 versus wild type mice). Background proliferation from control animals has been subtracted.
Figure 4.9 Antigen-Specific T Cell Cytokine Production in OVA ISCOMS Immunised IL-18KO Mice.

OVA-specific γIFN (a) and IL-5 (b) production after s.c. immunisation with 5μg OVA ISCOMS. OVA-specific γIFN (c) and IL-5 (d) production following six feeds of 100μg OVA ISCOMS. The results are shown as means ± 1 SD of triplicate cultures using cells pooled from 5 mice per group, 14 days after the last immunisation. Background cytokine production from control animals has been subtracted. (*p<0.05, **p<0.001 verses wild type mice).
Figure 4.10 Antigen-Specific MHC Class I-Restricted CTL Activity in OVA ISCOMS immunised IL-18KO Mice.

OVA-specific CTL activity in spleens 14 days after the final of 6 feeds of 100μg OVA ISCOMS in 200μl saline. Spleens from 5 animals were pooled and 3 x 10^7 cells restimulated with 1.5 x 10^6 mitomycin c treated OVA expressing EG7.OVA cells. The results show the % cytotoxicity calculated from quadruplicate samples.
Figure 4.11 Antigen-Specific Serum IgG Isotype in OVA-ISCOMS Immunised IL-18KO Mice.

OVA-specific IgG1 (a and c) and IgG2a (b and d) antibody levels in serum, 7 days after s.c. challenge of HAO in mice immunised s.c. (a and b) or orally (c and d) with OVA ISCOMS. The results show the reciprocal dilutions of serum from individual mice which produced the equivalent O.D. 630nm to a 5% dilution of a standard anti-OVA serum. The control levels are from mice that received HAO only.
Figure 4.12 Antigen-Specific DTH in OVA ISCOMS Immunised yIFNKO mice.

The graph shows OVA specific DTH responses measured 24 hours after subcutaneous challenge into the footpad with 100μg HAO. Mice were immunised with either (a) 5μg OVA ISCOMS in 50μl saline subcutaneously into the rear footpad or (b) six feeds of 100μg OVA ISCOMS in 200μl saline. The results shown are the mean specific increments in footpad thickness of 5 animals per group ± 1 SD, measured 7 days after the last immunisation (*p<0.01 versus wild type C57Bl/6 mice). The background footpad increment obtained in unimmunised animals has been subtracted.
Figure 4.13 Antigen-Specific *in vitro* Proliferation in OVA-ISCOMS Immunised γIFNRKO Mice.

OVA specific proliferative responses were measured in PLN removed (a) 14 days after a single subcutaneous immunisation in the rear footpad with 5μg OVA ISCOMS in 50μl saline or (b) 14 days after the last of 6 feeds of 100μg OVA ISCOMS in 200μl saline. The graph shows the mean OVA-specific proliferation following a 96 hour culture with 1μg/ml OVA as determined by incorporation of [*H]thymidine into DNA after 16 hours incubation. Results are shown as mean counts of quadruplicate cultures of cells pooled from 5 animals ± 1 SD ("p<0.05, *p<0.001 versus wild type C57Bl/6 mice). Background proliferation from control animals has been subtracted.
Figure 4.14 Antigen-Specific T Cell Cytokine Production in OVA ISCOMS Immunised γIFNKO Mice.

OVA-specific γIFN (a) and IL-5 (b) production from PLN after s.c. immunisation with 5μg OVA ISCOMS, and OVA-specific γIFN (c) and IL-5 (d) production from spleen following six feeds of 100μg OVA ISCOMS. The results are shown as means ± 1 SD of triplicate cultures using cells pooled from 5 mice per group, 14 days after the last immunisation. Background cytokine production from control animals has been subtracted. (*p<0.05, **p<0.005 versus wild type C57Bl/6 mice).
Figure 4.15 Antigen-Specific MHC Class I-Restricted CTL Activity in OVA ISCOMS immunised γIFNKO Mice.

OVA-specific CTL activity in spleens seven days after the last immunisation with either (a) a single i.p. immunisation of 5μg OVA ISCOMS in 200μl saline or (b) 14 days after the final of 6 feeds of 100μg OVA ISCOMS in 200μl saline. Spleens from 5 animals were pooled and 3 x 10⁶ cells restimulated with 1.5 x 10⁶ mitomycin c treated OVA expressing EG7.OVA cells. The results show the % cytotoxicity calculated from quadruplicate samples. Antigen-specificity was determined by the degree of lysis of non-OVA expressing EL4 cells.
Figure 4.16 Antigen-Specific Serum IgG Isotype in OVA-ISCOMS Immunised γIFNKO Mice.

OVA-specific IgG1 (a) and IgG2a (b) antibody levels in serum, 7 days after s.c. challenge of HAO in mice immunised s.c with OVA ISCOMS. The results show the reciprocal dilutions of serum from individual mice which produced the equivalent O.D. 630nm to a 5% dilution of a standard anti-OVA serum (p<0.005 versus wild type mice). The control levels are from mice that received HAO only.
**Figure 4.17** Antigen-Specific Intestinal IgA Production in OVA ISCOMS Immunised γIFNRKO Mice.

IgA secretion from the small intestine was assessed in gut washes by ELISA seven days after the last six feeds of 100μg OVA ISCOMS. The results shown are the mean OD 405nm of triplicate samples from 5 mice ± 1SD (*p<0.01 versus wild type C57Bl/6 mice). Background IgA production from control animals has been subtracted.
Figure 4.18 Antigen-Specific DTH in OVA ISCOMS Immunised IL-6KO mice.

The graph shows OVA specific DTH responses measured 24 hours after subcutaneous challenge into the footpad with 100μg HAO. Mice were immunised with 5μg OVA ISCOMS in 50μl saline subcutaneously into the rear footpad. The results shown are the mean specific increments in footpad thickness of 5 animals per group ± 1 SD, measured 7 days after the last immunisation. The background footpad increment obtained in uninmunised animals has been subtracted.
Figure 4.19 Antigen-Specific *in vitro* Proliferation in OVA-ISCOMS Immunised IL-6KO Mice.

OVA specific proliferative responses were measured in PLN removed 14 days after a single subcutaneous immunisation in the rear footpad with 5μg OVA ISCOMS in 50μl saline. The graph shows the mean OVA-specific proliferation following a 96 hour culture with 1mg/ml OVA as determined by incorporation of $[^3H]$thymidine into DNA after 16 hours incubation. Results are shown as mean counts of quadruplicate cultures of cells pooled from 5 animals ± 1 SD. Background proliferation from control animals has been subtracted.
Figure 4.20  Antigen-Specific T Cell Cytokine Production in OVA ISCOMS Immunised IL-6KO Mice.

OVA-specific γIFN (a) and IL-5 (b) production after s.c. immunisation with 5μg OVA ISCOMS. The results are shown as means ± 1 SD of triplicate cultures using cells pooled from 5 mice per group, 14 days after the last immunisation. Background cytokine production from control animals has been subtracted. (*p<0.05 verses wild type 129/Sv mice).
Figure 4.21  Antigen-Specific MHC Class I-Restricted CTL Activity in OVA ISCOMS immunised IL-6KO Mice.

OVA-specific CTL activity in spleens of IL-12KO or C57Bl/6 wild type mice, seven days after the last immunisation with a single i.p. immunisation of 5μg OVA ISCOMS in 200μl saline. Spleens from 5 animals were pooled and 3 x 10^7 cells restimulated with 1.5 x 10^6 mitomycin c treated OVA expressing EG7.0VA cells. The results show the % cytotoxicity calculated from quadruplicate samples. Antigen-specificity was determined by the degree of lysis of non-OVA expressing EL4 cells.
Figure 4.22 Antigen-Specific Serum IgG Isotype in OVA-ISCOMS Immunised IL-6KO Mice.

OVA-specific IgG1 (a) and IgG2a (b) antibody levels in serum, 7 days after s.c. challenge of HAO in mice immunised s.c. with OVA ISCOMS. The results show the reciprocal dilutions of serum from individual mice which produced the equivalent O.D. 630nm to a 5% dilution of a standard anti-OVA serum. The control levels are from mice that received HAO only.
Figure 4.23 Antigen-Specific DTH in OVA ISCOMS Immunised IL-4KO mice.

The graph shows OVA specific DTH responses measured 24 hours after subcutaneous challenge into the footpad with 100μg HAO. Mice were immunised with either (a) 5μg OVA ISCOMS in 50μl saline subcutaneously into the rear footpad or (b) six feeds of 100μg OVA ISCOMS in 200μl saline. The results shown are the mean specific increments in footpad thickness of 5 animals per group ± 1 SD, measured 7 days after the last immunisation (*p<0.05 versus wild type C57BL/6 mice). The background footpad increment obtained in unimmunised animals has been subtracted.
Figure 4.24 Antigen-Specific in vitro Proliferation in OVA-ISCOMS Immunised IL-4KO Mice.

OVA specific proliferative responses were measured in PLN removed (a) 14 days after a single subcutaneous immunisation in the rear footpad with 5µg OVA ISCOMS in 50µl saline or (b) 14 days after the last of 6 feeds of 100µg OVA ISCOMS in 200µl saline. The graph shows the mean OVA-specific proliferation following a 96 hour culture with 1µg/ml OVA as determined by incorporation of [3H]thymidine into DNA after 16 hours incubation. Results are shown as mean counts of quadruplicate cultures of cells pooled from 5 animals ± 1 SD (*p<0.005 verses wild type C57Bl/6 mice). Background proliferation from control animals has been subtracted.
Figure 4.25 Antigen-Specific T Cell Cytokine Production in OVA ISCOMS Immunised IL-4KO Mice.

OVA-specific γIFN (a) and IL-5 (b) production after s.c. immunisation with 5μg OVA ISCOMS. OVA-specific γIFN (c) and IL-5 (d) production following six feeds of 100μg OVA ISCOMS. The results are shown as means ± 1 SD of triplicate cultures using cells pooled from 5 mice per group, 14 days after the last immunisation. Background cytokine production from control animals has been subtracted. (*p<0.05, **p<0.005 versus wild type C57Bl/6 mice).
Figure 4.26 Antigen-Specific MHC Class I-Restricted CTL Activity in OVA ISCOMS immunised IL-4KO Mice.

OVA-specific CTL activity in spleens of IL-14KO or C57Bl/6 wild type mice, seven days after the last immunisation with either (a) a single i.p. immunisation of 5μg OVA ISCOMS in 200μl saline or (b) 14 days after the final of 6 feeds of 100μg OVA ISCOMS in 200μl saline. Spleens from 5 animals were pooled and 3 x 10^7 cells restimulated with 1.5 x 10^6 mitomycin c treated OVA expressing EG7.OVA cells. The results show the % cytotoxicity calculated from quadruplicate samples. Antigen-specificity was determined by the degree of lysis of non-OVA expressing IL-4 cells.
Figure 4.27 Antigen-Specific Serum IgG Isotype in OVA-ISCOMS Immunised IL-4KO Mice.

OVA-specific IgG1 (a) and IgG2a (b) antibody levels in serum, 7 days after s.c. challenge of HAO in mice immunised s.c. with OVA ISCOMS. The results show the reciprocal dilutions of serum from individual mice which produced the equivalent O.D. 630nm to a 5% dilution of a standard anti-OVA serum (\( ^{\text{*}}p<0.05 \) versus wild type mice). The control levels are from mice that received HAO only.
Figure 4.28 Antigen-Specific Intestinal IgA Production in OVA ISCOMS Immunised IL-4KO Mice.

IgA secretion from the small intestine was assessed in gut washes by ELISA seven days after the last six feeds of 100μg OVA ISCOMS. The results shown are the mean OD 405nm of triplicate samples from 5 mice ± 1SD (*p<0.01 versus C57Bl/6 wild type mice). Background IgA production from control animals has been subtracted.
Figure 4.29 Antigen-Specific DTH in OVA ISCOMS Immunised iNOSKO mice.

The graph shows OVA specific DTH responses measured 24 hours after subcutaneous challenge into the footpad with 100μg HAO. Mice were immunised with 5μg OVA ISCOMS in 50μl saline subcutaneously into the rear footpad. The results shown are the mean specific increments in footpad thickness of 5 animals per group ± 1 SD, measured 7 days after the last immunisation. The background footpad increment obtained in unimmunised animals has been subtracted.
Figure 4.30 Antigen-Specific *in vitro* Proliferation in OVA-ISCOMS Immunised iNOSKO Mice.

OVA specific proliferative responses were measured in PLN removed 14 days after a single subcutaneous immunisation in the rear footpad with 5μg OVA ISCOMS in 50μl saline. The graph shows the mean OVA-specific proliferation following a 96 hour culture with 1μg/ml OVA as determined by incorporation of [3H]thymidine into DNA after 16 hours incubation. Results are shown as mean counts of quadruplicate cultures of cells pooled from 5 animals ± 1 SD. Background proliferation from control animals has been subtracted.
Figure 4.31 Antigen-Specific T Cell Cytokine Production in OVA ISCOMS Immunised INOSKO Mice.

OVA-specific γIFN (a) and IL-5 (b) production after s.c. immunisation with 5μg OVA ISCOMS. The results are shown as means ± 1 SD of triplicate cultures using cells pooled from 5 mice per group, 14 days after the last immunisation. Background cytokine production from control animals has been subtracted. (*p<0.005 versus wild type MFl mice).
Figure 4.32 Antigen-Specific Serum IgG Isotype in OVA-ISCOMS Immunised iNOSKO Mice.

OVA-specific IgG1 (a) and IgG2a (b) antibody levels in serum, 7 days after s.c. challenge of HAO in mice immunised s.c. with OVA ISCOMS. The results show the reciprocal dilutions of serum from individual mice which produced the equivalent O.D. 630nm to a 5% dilution of a standard anti-OVA serum. The control levels are from mice that received HAO only.
Chapter 5
Role of Inflammatory Mediators Induced by ISCOMS in Regulating Innate Immune Responses.

Introduction

As I have already described in Chapter 3, parenteral or oral administration of ISCOMS induces a wide range of innate immune responses, including the recruitment and activation of inflammatory cells and the production of several inflammatory mediators. In Chapter 4 I determined, by utilising gene-targeted knockout mice, which of these mediators were important for the generation of an antigen-specific immune response to OVA ISCOMS. I found that although most of these factors were not essential for antigen-specific immunity to OVA ISCOMS, mice lacking functional IL-12 had abnormal immune responses when immunised with OVA ISCOMS. It is now generally accepted that the development of an acquired response is influenced by the initiation of innate cascades, and so in this chapter I have attempted to investigate if these defects in adaptive immunity were related to abnormalities in the activation of the different components of the early inflammatory response. To do this, I explored the inflammatory responses induced in cytokine deficient mice, using the model of PEC recruitment I described in Chapter 3.

Experimental Protocol

Gene targeted IL-12KO, IL-18KO, γIFNKO, IL-6KO and IL-4KO mice, together with wild type controls, were injected i.p. with a single dose of 5μg OVA ISCOMS in 200μl saline. At various times after injection of ISCOMS, PEC were removed from the animals by peritoneal lavage, and examined phenotypically by FACS. The production of cytokines and nitric oxide was measured after 48 hour culture in vitro in the presence or absence of various stimuli. In all experiments control mice were injected with saline.
Results

5.1 Innate Responses to ISCOMS in Interleukin 12 Deficient Mice

In Chapters 3 and 4, I have shown that IL-12 was not only induced as part of the inflammatory cascade, but was also vital for the generation of antigen-specific immunity to OVA-ISCOMS. As IL-12 is an early inflammatory factor which has been linked to the initiation of cellular recruitment through its regulation of the chemokine IL-8 [Nuamé et al., 1993], I was interested to examine if the absence of this cytokine affected the innate inflammatory cascade, and if so, whether this could account for the importance of IL-12 in the generation of antigen-specific immunity.

5.1.1. ISCOMS Induced Inflammatory Infiltrate.

Wild type B6 mice produced the usual pattern of PEC recruitment following i.p. injection of ISCOMS. Initially, PEC numbers were reduced, with the minimum occurring at 7 hours after administration of ISCOMS. However PEC numbers then began to increase to a peak at 48 hours by which time they were 1.5 times greater than in uninjected mice. PEC numbers were beginning to return to background levels by 72 hours (Figure 5.4.1). In contrast, IL-12KO mice showed an early spike in the numbers of PEC after administration of ISCOMS, which then rapidly declined below that of the control saline injected animals and remained so until 72 hours, when PEC numbers returned to normal (Figure 5.1).

5.1.2. Phenotypic Analysis of PEC

As I found in earlier experiments, the number of neutrophils in PEC increased dramatically in wild type B6 mice soon after injection of ISCOMS, with peak levels being seen at 3.5 hours. Neutrophil numbers then returned to control levels (Figure 5.2a). IL-12KO mice also showed an immediate increase in the numbers of neutrophils after injection of
ISCOMS, but the increase was only 20% of that in wild type mice and the peak numbers were recorded later, at 7 hours. At all other times, no neutrophils could be found in IL-12KO mice (Figure 5.2a).

The number of F4/80+ macrophages also increased after an injection of ISCOMS into wild type mice, with maximal levels being seen at 48 hours, returning towards control levels by 72 hours (Figure 5.2b). In contrast, IL-12KO mice had higher baseline numbers of F4/80+ macrophages before injection and these cells were almost completely lost within 3.5 hours of administration of ISCOMS. Thereafter, the levels of F4/80+ cells remained very much lower than in control mice for the duration of the experiment (Figure 5.2b).

Wild type animals showed a steady increase in the numbers of activated F4/80+ macrophages from a baseline of zero, as indicated by the expression of the MHC class II molecule. Peak levels of activated macrophages were observed at 48 hours, when 25% of all macrophages were MHC class II+ (Figure 5.2c). In addition to the failure to recruit macrophages, IL-12KO mice also did not show this pattern of activation. Class II MHC+ macrophages were present in uninjected mice, but there was a marked drop in their numbers with no recovery thereafter (Figure 5.2c).

The numbers of dendritic cells in wild type B6 mice as determined by expression of CD11c, were low in control PEC, but after a further drop at early timepoints after injection of ISCOMS, these made a gradual return to baseline levels by 72 hours (Figure 5.2d). IL-12KO mice had a much higher level of baseline CD11c+ dendritic cells compared with wild type mice and these increased numbers were present throughout the experiment. However, the numbers of CD11c+ dendritic cells from IL-12KO mice fell dramatically within 3.5 hours after injection of ISCOMS and although their numbers began to increase at 48 hours, they were still below baseline numbers and even fell again slightly at 72 hours (Figure 5.2d).

Wild type mice showed an immediate reduction in the number of CD4+ lymphocytes in PEC after injection of ISCOMS, before returning towards control levels by 48 hours. IL-12KO mice had slightly higher numbers of CD4+ T cells before injection of ISCOMS, but these fell rapidly after injection of ISCOMS and there was no subsequent recovery in their numbers at later times (Figure 5.3a).
Although there was no dramatic increase in CD4+ T cells in wild type B6 mice after injection of ISCOMS, these cells were becoming activated as shown by their expression of CD25 and by 48 hours, 26% of CD4+ T cells were CD25+ (Figure 5.3b). In contrast, IL-12KO mice did not show any increase in the expression of this activation marker and in fact, the levels of CD25+ CD4 cells were lower than those in the uninjected controls throughout the experiment (Figure 5.3b).

A small decrease in the number of CD8+ lymphocytes was also noted immediately after administration of ISCOMS to wild type animals, but these began to recover rapidly and by 72 hours, CD8 cell numbers were more than twice those of uninjected controls (Figure 5.3c). IL-12KO mice showed the same immediate loss of CD8+ cell numbers, but these did not recover above baseline levels during the experiment (Figure 5.3c). It was not possible to determine the activation state of these cells, as numbers were so low.

The numbers of B220+ B cells in wild type B6 mice showed a rapid early decrease, followed by recovery to levels which were eventually double that of control values at 48 hours after administration of ISCOMS (Figure 5.3d). Although IL-12 KO mice had baseline numbers of B cells that were greater than those in wild type mice, these fell constantly after injection of ISCOMS and remained suppressed below that of the control animals throughout the experiment (Figure 5.3d).

### 5.1.3. Inflammatory Cytokine Production

In parallel with the numbers of activated macrophages, PEC from saline injected wild type mice produced little or no γIFN+LPS stimulated IL-1α and this remained the case until 48 hours after administration of ISCOMS, when IL-1α secretion was nearly eight times greater than baseline levels, before falling back to zero (Figure 5.4a). Consistent with the presence of class II MHC+ macrophages, IL-12KO mice had a slightly higher basal level of IL-1α production, but this was quickly reduced to below control levels after injection of ISCOMS and remained so until 72 hours (Figure 5.4a).
There was some basal γIFN+LPS stimulated IL-6 production by PEC removed from saline injected wild type mice. However, this was reduced almost to zero within 3.5 hours of injection of ISCOMS, remaining very low until 48 hours, when IL-6 production was nearly double that of control mice and then returned towards normal levels by 72 hours (Figure 5.4b). PEC from IL-12KO mice produced nearly double the background IL-6 levels compared with wild type PEC, but this too was reduced to extremely low levels within 3.5 hours of injection of ISCOMS. Unlike wild type mice, this low level of IL-6 production then persisted throughout the experiment (Figure 5.4b).

PEC from wild type B6 mice injected with ISCOMS produced two peaks of γIFN production when restimulated with Con A in vitro, both of which were approximately 6 times greater than that in uninjected mice. The first peak was at 3.5 hours and the second at 48 hours, but γIFN production had returned to control levels by 72 hours (Figure 5.4c). PEC taken from IL-12KO mice and cultured in vitro with Con A showed a similar level of basal γIFN production, but immediately after administration of ISCOMS, this was reduced by half, before returning to control levels by 24 hours. γIFN production then remained at this level until 72 hours (Figure 5.4c).

As anticipated, no IL-12 was measurable in IL-12KO mice, although wild type B6 mice showed the characteristic early decrease followed by an increase to a peak in IL-12 production by 72 hours (data not shown).

5.1.4. Secretion of Nitric Oxide

PEC from saline injected wild type mice secreted high levels of NO after stimulation in vitro with γIFN+LPS. This was reduced by 80% within 3.5 hours of injection of ISCOMS. The depressed level of NO production was maintained until 48 hours, when levels rose to 1.5 times of those in control mice, before returning to normal by 72 hours (Figure 5.5). PEC from IL-12KO mice produced a similar level of baseline NO production as wild types. This also decreased soon after administration of ISCOMS, but this suppressed level persisted for most of the experiment, only returning to normal levels by 72 hours (Figure 5.5).
5.1.5. Summary

Thus, the absence of IL-12 severely inhibits the generation of the inflammatory cascade induced by injection of ISCOMS. Apart from some neutrophilia and a higher than normal level of macrophages present before injection of ISCOMS, IL-12KO mice were unable to recruit inflammatory cells into the peritoneum and the production of inflammatory mediators was also abolished.

5.2 Innate Responses to ISCOMS in γInterferon-Receptor Deficient Mice

γIFN is another of the inflammatory cytokines that I showed in Chapter 3 to be upregulated after injection of ISCOMS. However, I showed in Chapter 4 that unlike IL-12, γIFN appeared not to be required for the generation of antigen-specific immunity to OVA-ISCOMS. Therefore I decided to explore the innate cascade induced by ISCOMS in γIFNKO mice to determine if this might shed light on the different patterns of antigen-specific immune responses to ISCOMS found in these two strains.

5.2.1 ISCOMS Induced Inflammatory Infiltrate.

Wild type B6 mice showed the characteristic profile of cellular recruitment after i.p. injection of ISCOMS, with an early decrease in PEC numbers, followed by an increase at later times, peaking at 48 hours when numbers had increased by approximately two fold (Figure 5.6). Control γIFNKO mice had similar numbers of PEC and showed the same early loss of PEC numbers after injection of ISCOMS. However, PEC remained low in these animals and did not return to control levels throughout the timecourse of the experiment (Figure 5.6).
5.2.2. Phenotypic Analysis PEC

The detailed phenotypic analysis of the inflammatory infiltrates induced by ISCOMS in γdef mice was performed at the same time as that in IL-12KO mice, using the same group of wild type B6 mice as controls. These data are shown again for comparison in the relevant figures. γdef mice showed the early neutrophilia soon after injection of ISCOMS, but the numbers were much reduced compared with those in controls and they peaked later than in wild type mice (Figure 5.7a).

Saline injected γdef mice had a larger baseline number of F4/80+ macrophages than wild type mice, but this decreased rapidly to very low levels within 3.5 hours of an injection of ISCOMS and remained low for the duration of the experiment (Figure 5.7b). In parallel with the failure to recruit macrophages to the same extent as in wild type mice, F4/80+ macrophages in ISCOMS injected γdef mice did not express MHC class II at any time during the experiment (Figure 5.7c).

γdef mice showed a similar reduction of dendritic cell numbers seen in the first 7 hours after injection of ISCOMS as that seen in wild type mice. However some CD11c+ cells remained and the numbers were actually greater than baseline by 24 hours, before decreasing again at later times, when numbers were steadily increasing in wild type animals (Figure 5.7d).

Despite the numbers of CD4+ PEC in saline injected γdef mice being much lower than in wild types, γdef CD4 numbers began a steady increase immediately after administration of ISCOMS, peaking after 48 hours, when there was over twice the number of CD4+ cells than in control animals and then began to decline back to control levels by 72 hours (Figure 5.8a). Although the numbers of CD4+ T cells were much lower, this recruitment was different to that seen in wild types, as no increase in CD4+ T cell numbers was observed.

Whereas wild type mice injected with ISCOMS showed a dramatic increase in the level of activated CD4+ T cells expressing the IL-2Rα chain CD25, the level of CD25 expression on CD4+ T cells removed from γdef mice remained at baseline levels
throughout the experiment (Figure 5.8b). CD8⁺ lymphocytes in γIFNRKO mice increased steadily from very low levels in control mice to a maximum by 48 hours when their numbers were nearly 6 times greater than baseline. However these numbers were still much reduced compared with those in injected wild type mice (Figure 5.8c).

The numbers of B cells in control γIFNRKO mice were approximately 50% lower than in wild type mice and fell further immediately after injection of ISCOMS, remaining below the baseline level for a further 24 hours and then returning to normal levels by 48 hours. However, unlike the subsequent recruitment seen in wild type mice, there was no increase in B cell numbers above baseline levels in γIFNRKO mice at any time and the numbers were always lower than those in wild type animals (Figure 5.8d).

5.2.3. Inflammatory Cytokine Production

As described earlier in Chapter 3, PEC from uninjected wild type mice produced a low but significant level of IL-1α in response to stimulation with γIFN+LPS, and this was increased to more than 5 times greater than uninjected levels at 48 hours after injection of ISCOMS, before decreasing quickly to baseline levels (Figure 5.9a). γIFNRKO mice did not produce any IL-1α at any time before or after administration of ISCOMS (Figure 5.9a).

PEC from saline injected wild type mice produced a large amount of IL-6 after stimulation with γIFN+LPS, which was reduced by 75% within 3.5 hours of injection with ISCOMS (Figure 5.9b). IL-6 production then returned to normal and, in this experiment, continued at control levels for the remainder of the study. PEC from saline injected γIFNRKO mice produced significantly higher levels of IL-6 compared with PEC from wild type mice, but IL-6 levels then fell rapidly to 50% of baseline within 3.5 hours and continued at low levels thereafter (Figure 5.9b).

PEC from saline injected wild type mice produced IL-12 after stimulation in vitro with γIFN+LPS and this declined soon after injection of ISCOMS, so that by 7 hours, it was half that of unimmunised mice. However, the levels of IL-12 production began to rise at later times and by 72 hours, ISCOMS stimulated PEC produced more than twice the amount of IL-
12 compared with uninjected animals (Figure 5.9c). PEC from saline injected γIFNKO mice secreted very small amounts of IL-12 and although this increased slightly by 3.5 hours after injection of ISCOMS, the levels of IL-12 from γIFNKO mice did not change thereafter and remained significantly lower than those of wild type mice until the duration of the experiment (Figure 5.9c).

As I found in Chapter 3, PEC from saline injected wild type mice produced two peaks of Con A stimulated γIFN production, both of which were approximately 6 times greater than those of uninjected control mice. The first peak was at 3.5 hours, and the second peak occurred at 48 hours (Figure 5.9d). γIFNKO mice on the other hand, did not produce any γIFN in response to Con A at any time either before or after injection of ISCOMS (Figure 5.9d).

5.2.4 Nitric Oxide Release

As I observed in Chapter 3, PEC from saline injected wild type animals produced substantial amounts of NO in response to γIFN+LPS stimulation in vitro before injection of ISCOMS and this was reduced to zero immediately after administration of ISCOMS. NO production returned to control levels by 24 hours and by 48 hours was increased significantly by approximately 20% above baseline levels, before declining to below control levels by 72 hours (Figure 5.10). There was no measurable production of NO from γIFNKO PEC either before or after administration of ISCOMS (Figure 5.10).

5.2.5 Summary

Thus γIFNKO mice showed a major defect in the inflammatory response induced by ISCOMS. There was a dramatic yet selective failure to recruit cells into the peritoneum after injection of ISCOMS, as seen by reduced numbers of neutrophils, macrophages and activation of CD4+ T cells and macrophages. However, normal levels of B cells, CD4+ T cells and dendritic cells were observed in PEC from γIFNKO mice. However, a major
defect in inflammatory mediator production from ISCOMS injected γIFNRCO PEC was noted as cells were not activated nor secreting inflammatory mediators.

5.3 Innate Responses to ISCOMS in Interleukin 18 Deficient Mice

As I showed in Chapter 4, antigen-specific immune responses were not completely defective after immunisation of IL-12KO mice with OVA ISCOMS and some antigen-specific responses were also defective in mice lacking the functionally related cytokine IL-18. Therefore I thought that it was important to determine if IL-18KO mice shared the defective innate immune response seen in IL-12KO mice. Only a small number of IL-18KO mice were available for these studies and no wild type or heterozygous littermate animals at all were available. However, in view of the potential importance of the cytokine and because I had found relatively consistent inflammatory responses to ISCOMS in the wild type animals used in other experiments, I decided to proceed with a preliminary experiment.

5.3.1. ISCOMS Induced Inflammatory Infiltates

Immediately after injection of ISCOMS into IL-18KO mice, the number of PEC fell by half and remained below baseline levels until 72 hours, by which time the numbers returned to baseline levels (Figure 5.11). However, the numbers did not rise above the background, in contrast to what I had observed earlier in wild type mice.

5.3.2. Phenotypic Analysis of PEC

The numbers of neutrophils decreased to zero immediately after injection of ISCOMS into IL-18KO mice and these reduced levels of neutrophils continued until 72 hours, when neutrophil numbers had returned to normal (Figure 5.12a). The numbers of F4/80+ macrophages also dropped to zero within 3.5 hours after injection of ISCOMS and remained so for the duration of the experiment (Figure 5.12b). This contrasts with the increase in
neutrophils I had observed previously using wild type mice injected with ISCOMS. In addition, there was also no evidence of the usual macrophage activation in IL-18KO mice (Figure 5.12c).

The numbers of CD11c+ dendritic cells were also reduced to background numbers in IL-18KO mice immediately after injection with ISCOMS and this suppressed level was maintained until 72 hours (Figure 5.12d), in contrast to the increased recruitment of CD11c+ dendritic cells I observed previously in wild type animals.

The numbers of CD4+ lymphocytes in IL-18KO PEC also decreased soon after administration of ISCOMS and failed to recover at any time thereafter and ISCOMS also failed to activate these T cells in IL-18KO mice as identified by expression of CD25 (Figure 5.13a). The numbers of CD8+ T lymphocytes followed the same pattern as CD4+ T lymphocytes, with an immediate decrease which was sustained until the end of the experiment (Figure 5.13b). Such a pattern contrasts with the profile of CD4 and CD8 recruitment I had found in wild type mice injected with ISCOMS.

The numbers of B cells from IL-18KO mice dropped by 50% immediately after injection of ISCOMS, but as previously observed in wild type mice, this then returned to normal before increasing to five times the baseline numbers at 72 hours (Figure 5.13d).

5.3.3. Inflammatory Cytokine Production

PEC from saline injected IL-18KO mice did not produce any IL-1α after in vitro stimulation with γIFN+LPS and this was the case until 72 hours after injection of ISCOMS, when IL-1α production was significantly increased above background levels (Figure 5.14a).

Saline injected IL-18KO PEC secreted significant amounts of IL-6 after in vitro stimulation with γIFN+LPS, but in contrast to what I had found previously with wild type mice, there was no significant change in the production of IL-6 from PEC removed from ISCOMS injected IL-18KO mice at any time during the experiment (Figure 5.14b).

Saline injected IL-18KO PEC produced very little IL-12 when stimulated in vitro with γIFN+LPS, but within 6 hours of administration of ISCOMS, IL-12 production was
significantly increased. By 24 hours, levels were more than twenty times greater than in uninjected mice and continued to a peak at 72 hours, when IL-12 production was 25 times greater than background (Figure 5.14c). Although the early increase contrasts with the normal decrease in IL-12 after injection of ISCOMS in wild type animals, maximal production of IL-12 from IL-18KO PEC coincided with that normally seen with wild type animals.

PEC from saline injected IL-18KO mice produced a small amount of γIFN after in vitro stimulation with Con A, and within 6 hours of administration of ISCOMS, γIFN production more than doubled, reaching a peak at 24 hours when γIFN levels were nearly five times greater than control animals and remained high until 72 hours (Figure 5.14d). This pattern of sustained increase in γIFN production is in contrast to the biphasic pattern normally seen in wild type animals.

5.3.4 Summary

Thus, in the absence of IL-18, no recruitment of PEC occurred in response to ISCOMS, but there appeared to be normal or even increased production of γIFN and IL-12 as well as an abnormal pattern of IL-1α secretion, with the only defective cytokine measured being IL-6 as the levels were unchanged after injection with ISCOMS.

5.4. Innate Responses to ISCOMS in Interleukin 4 Deficient Mice

As I had observed normal antigen-specific immune responses in IL-4KO mice immunised with OVA-ISCOMS, I wished to see if innate immune responses were also normal in these mice and if correlating these responses in the different mice would provide information on how the innate response regulates adaptive immunity. Again, because I found that these mice retained normal antigen-specific responses to ISCOMS, I decided to use representative timepoints only.
5.4.1. Recruitment of PEC

PEC numbers from wild type B6 mice were normal 24 hours after injection of ISCOMS in this study. Thereafter PEC numbers increased by approximately two fold at 72 hours and remained at an elevated level at 168 hours (Figure 5.15). An identical pattern of PEC recruitment was seen in IL-4KO mice at all times after injection of ISCOMS (Figure 5.15).

As there were no gross differences in the pattern of ISCOMS recruited PEC in IL-4KO mice and their antigen-specific responses were entirely normal, phenotypic studies were not performed on PEC in this study and only selected functional studies were undertaken.

5.4.2. Inflammatory Cytokine Production

No detectable levels of IL-1α were measured in ISCOMS injected wild type or IL-4KO mice, but this was not unexpected, given that this timecourse did not include the times when I found IL-1α to be maximal (data not shown).

As with other wild type mice, PEC from saline injected animals produced detectable IL-6 production in response to γIFN+LPS and this fell markedly by 24 hours after injection of ISCOMS, remaining depressed throughout the remainder of the experiment. (Figure 5.16a). Again this may be because the usual peak of IL-6 production was missed. PEC from IL-4KO mice show a decrease in γIFN+LPS stimulated IL-6 production at 24 hours, but in these mice, there was an increase in IL-6 production at 72 hours, when levels were significantly greater than in wild type animals. IL-6 levels then decreased below background levels by 168 hours (Figure 5.16a).

As before, wild type B6 mice produced low levels of IL-12 which initially decreased at early timepoints, but then increased markedly to a peak at 72 hours after injection of ISCOMS, when levels of IL-12 secretion were 20 times greater than the saline injected controls. IL-12 production then returned to background levels by 168 hours (Figure 5.16b). IL-4KO mice showed a similar pattern of γIFN+LPS stimulated IL-12 secretion, which also
peaked by 72 hours, when it was significantly greater than that in wild type mice, before returning to control levels by 168 hours (Figure 5.16b).

PEC from saline injected wild type B6 mice produced a significant amount of Con A stimulated \( \gamma \)IFN and after an initial decrease in \( \gamma \)IFN secretion 24 hours after injection of ISCOMS, this increased steadily to a peak at 72 hours at a level more than twice that of controls (Figure 5.16c). IL-4KO mice showed an identical pattern of \( \gamma \)IFN production, with an early decrease compared with background levels, followed by a peak at 72 hours which returned to control levels by 168 hours. There were no significant differences between Con A induced \( \gamma \)IFN production from IL-4KO and wild type mice at any time (Figure 5.16c).

5.4.3. Secretion of Nitric Oxide

NO production in wild type mice fell soon after injection of ISCOMS to zero, before levels returned to those of saline injected control mice by 72 hours. (Figure 5.20). An identical pattern was found in ISCOMS injected IL-4KO mice, although a significant decrease was noted at 168 hours compared with wild types (Figure 5.20).

5.4.4 Summary

Together these results indicate that the absence of IL-4 has no effect on the ability of ISCOMS to induce an inflammatory cascade.

5.5 Innate Responses to ISCOMS in Interleukin 6 Deficient Mice

I had shown in Chapters 3 and 4 that large amounts of IL-6 were induced by an injection of ISCOMS, but IL-6 was not important for the induction of antigen-specific immune responses to ISCOMS. As I found discrepancies between the innate and adaptive immune responses induced by ISCOMS in \( \gamma \)IFNRKO mice, I was interested to see if a similar dichotomy occurred in IL-6KO mice. In these experiments I only assessed two representative
timepoints, 24 hours and 72 hours, as well as an extended timepoint at 168 hours in order to assess if there might be a more delayed response in these animals.

5.5.1 Recruitment of PEC

The recruitment of PEC in wild type 129/Sv mice after injection of ISCOMS induced a steady increase in cell numbers which reached a peak at 72 hours when PEC numbers had nearly doubled before returning towards control levels by 168 hours. The recruitment of PEC in IL-6KO mice followed an almost identical pattern to that found in wild type mice (Figure 5.18). Because of this and because I found that the IL-6KO mice had normal antigen-specific responses, I did not conduct further experiments to assess individual populations of PEC phenotypically.

5.5.2 Inflammatory Cytokine Production

There was no measurable production of γIFN+LPS stimulated IL-1α in either 129/Sv or IL-6KO mice, but this is not unexpected given the lack of a 48 hour timepoint when IL-1α has been shown previously to be maximal (Data not shown). No γIFN+LPS stimulated IL-6 production was measured in IL-6KO mice, although SV/129 wild types produced a normal profile of IL-6 with decreased levels detected at 24 hours which then returned to control levels by 72 and 168 hours (Data not shown).

Wild type 129/Sv mice produced increased levels of γIFN+LPS stimulated IL-12 at 24 hours after injection of ISCOMS, which were approximately 4 times greater than in saline injected control 129/Sv mice. However as in my previous experiments, the maximal production of IL-12 occurred at 72 hours, by which time IL-12 production was 5 times that of control levels (Figure 5.19a). IL-12 production was also increased in ISCOMS injected IL-6KO mice, but this peaked at the earlier time of 24 hours and remained high at 72 hours. The peak of IL-12 production in IL-6KO mice was twice that in wild type mice. At later times,
IL-12 production from both 129/Sv and IL-6KO mice returned to control levels (Figure 5.19a).

In these experiments, uninjected wild type 129/Sv mice had high baseline levels of Con A stimulated γIFN production, but this decreased rapidly after injection of ISCOMS and remained depressed until 168 hours (Figure 5.19b). Saline injected IL-6KO mice produced very low amounts of γIFN and this was not increased after injection of ISCOMS. (Figure 5.19b).

5.5.3 Secretion of Nitric Oxide

PEC from wild type 129/Sv mice stimulated with γIFN+LPS produced a large amount of NO before injection with ISCOMS and this decreased rapidly by 90% within 24 hours of administration of ISCOMS. NO production then gradually returned to background levels by 168 hours (Figure 5.20). IL-6KO mice had significantly lower levels of NO production than wild type controls and these remained very low until 168 hours, when there was a dramatic increase in NO production which was now significantly greater than wild types (Figure 5.20).

5.5.4 Summary

IL-6KO mice did not show any defect in cellular recruitment after injection of ISCOMS and were capable of sustaining inflammatory responses after an injection of ISCOMS, but there were some differences in the ability to produce inflammatory mediators in particular γIFN.

Summary and Conclusions

The experiments in this chapter were designed to investigate how the absence of individual inflammatory mediators influenced the induction of innate immune responses by...
ISCOMS and to explore how these correlated with the generation of antigen-specific immunity in these mice.

My previous results had shown that antigen-specific immune responses to ISCOMS were dependent on the presence of IL-12 and here I found that IL-12KO mice had severely crippled innate responses to ISCOMS, lacking recruitment or activation of an inflammatory infiltrate and with little or no inflammatory mediator production. Thus, this cytokine plays a crucial role in the initiation of the inflammatory cascade by ISCOMS.

γIFNKO mice proved to be the most interesting of the knockout animals. Although I had previously found that these mice had intact antigen-specific immune responses to OVA ISCOMS, the innate immune response was unexpectedly and severely deficient in γIFNKO mice. The most dramatic abnormality in these mice was the complete absence of cellular recruitment or activation especially of macrophages or CD4+ lymphocytes, but numbers of B cells and dendritic cells were unaltered. However, these mice had severely defective inflammatory mediator production following injection with ISCOMS.

In Chapter 4 I found that certain antigen-specific responses to ISCOMS were defective in IL-18KO mice and in this chapter, I found that IL-18KO mice also appeared to have defective cellular recruitment into the peritoneum, with B cells being the only cell type which seemed to be recruited in the same way as in wild type mice. However, IL-18KO mice actually retained the ability to produce high levels of IL-12, γIFN and IL-1α, occasionally at levels somewhat higher than I had found previously with wild type animals. However, IL-1 responses were delayed and there was no induction of IL-6. The interpretation of these experiments was limited by the unavailability of appropriate controls.

IL-6 is a member of the inflammatory cascade and was increased after administration of ISCOMS in wild type animals. However IL-6 was shown not to be involved in the generation of OVA-specific immunity to ISCOMS and in this chapter I found that this cytokine is not important for the innate immune response, as IL-6KO mice had normal cellular recruitment and there was no gross defect in the inflammatory mediator production. A similar pattern was seen in IL-4KO mice which had normal antigen-specific immune responses to OVA ISCOMS and an intact inflammatory response. One problem with these
experiments was that they were conducted before I had determined the optimal time courses for the induction of inflammatory cytokine production and therefore some of the responses I observed were variable or suboptimal. Nevertheless, as there was no gross defect in the inflammatory cascade and because specific immune responses were normal for both IL-4KO and IL-6KO, I decided that it was inappropriate to perform further work in these animals.

In conclusion, individual components of the immune system showed different patterns of involvement in antigen-specific and innate immunity. Whereas IL-4 and IL-6 appear not to be required for either aspect of the immune response, IL-12 is important for both. In contrast, the absence of γIFN had dramatic effects on the induction of innate inflammatory cascade, but was not required for antigen-specific immunity, whereas IL-18 appeared to have variable effects on both aspects of the immune response. Therefore, these experiments show that the links between the innate and adaptive immune system are regulated by a highly complex and delicately balanced system.
Figure 5.1 ISCOMS Induced Recruitment of PEC in IL-12KO Mice.

The graph shows PEC recruitment following an i.p. injection of 5μg OVA ISCOMS. PEC were removed from five mice by lavage, pooled and cell counts performed. The results shown are mean PEC numbers for wild type mice (closed squares) and IL-12KO mice (open squares). Saline injected mice from each strain were used as controls.
Figure 5.2 Phenotypic Analysis of ISCOMS Recruited PEC from IL-12KO Mice.

PEC were removed by lavage after an i.p. injection of 5μg OVA ISCOMS and analysed by flow cytometry. The results shown are the numbers of (a) neutrophils, (b) F4/80+ macrophages, (c) MHC class II+ F4/80 macrophages and (d) CD11c+ dendritic cells. The results are expressed as the number of cells per peritoneum which were calculated from the percentage of cells positive for each marker in the PEC pooled from 5 animals per group for wild type mice (closed squares) and IL-12KO mice (open squares). Saline injected animals of each strain were controls.
Figure 5.3 Phenotypic Analysis of ISCOMS Recruited PEC from IL-12KO Mice.

PEC were removed by lavage after an i.p. injection of 5μg OVA ISCOMS and analysed by flow cytometry. The results shown are the numbers of (a) CD4⁺ lymphocytes, (b) CD4⁺ cells, (c) CD8⁺ lymphocytes and (d) B220⁺ B cells. The results are expressed as the number of cells per peritoneum which were calculated from the percentage of cells positive for each marker in the PEC pooled from 5 animals per group for wild type mice (closed squares) and IL-12KO mice (open squares). Control mice were saline injected animals of each strain.
Figure 5.4 ISCOMS Induced Inflammatory Cytokine Production by PEC from IL-12KO Mice

Production of (a) IL-1α, (b) IL-6, (c) γIFN by PEC pooled from 5 mice given an i.p. injection of 5μg ISCOMS 3.5-72 hours before. The results shown are the mean concentration of cytokines from wild type mice (closed squares) or IL-12KO mice (open squares), measured in triplicate after 48 hours stimulation in the presence or absence of γIFN+LPS (a and b) or the presence or absence of Con A (c) ± 1 SD (*p<0.05 versus wild type mice; **p<0.01; ***p<0.001 versus wild type mice). Control mice were uninjected animals of each strain.
Figure 5.5 ISCOMS Induced Nitric Oxide Production from IL-12KO PEC

Production of nitric oxide from PEC pooled from 5 mice following injection of 5μg ISCOMS. The results shown are the mean concentration of nitrite measured in triplicate from wild type mice (closed squares) or IL-12KO mice (open squares), after culture for 48 hours in the presence or absence of γIFN+LPS ± 1 SD (* p<0.05 versus wild type mice; ** p<0.005 versus wild type mice). Control mice were uninjected animals of each strain.
Figure 5.6 ISCOMS Induced Recruitment of PEC in γIFNKO Mice.

The graph shows PEC recruitment following an i.p. injection of 5μg OVA ISCOMS. PEC were removed from five mice by lavage, pooled and cell counts performed. The results shown are mean PEC numbers for wild type mice (closed squares) and IFNKO mice (open squares). Saline injected mice from each strain were used as controls.
Figure 5.7 Phenotypic Analysis of PEC from γIFNKO mice after Injection of ISCOMS.

PEC were removed by lavage after an i.p. injection of 5μg OVA ISCOMS and analysed by flow cytometry. The results shown are the numbers of (a) neutrophils, (b) F4/80+ macrophages, (c) MHC class II+ F4/80 macrophages and (d) CD11c+ dendritic cells. The results are expressed as the number of cells per peritoneum which were calculated from the percentage of cells positive for each marker in the PEC pooled from 5 animals per group for wild type mice (closed squares) and γIFNKO mice (open squares). Control mice were uninjected.
Figure 5.8 Phenotypic Analysis of ISCOMS Recruited PEC from γIFNKO Mice.

PEC were removed by lavage after an i.p. injection of 5μg OVA ISCOMS and analysed by flow cytometry. The results shown are the numbers of (a) CD4⁺ lymphocytes, (b) CD25⁺ CD4⁺ lymphocytes, (c) CD8⁺ lymphocytes and (d) B220⁺ B cells. The results are expressed as the number of cells per peritoneum which were calculated from the percentage of cells positive for each marker in the PEC pooled from 5 animals per group for wild type mice (closed squares) and γIFNKO mice (open squares). Control mice were injected with saline.
Figure 5.9 ISCOMS Induced Inflammatory Cytokine Production by PEC from γIFNRKO Mice.

Production of (a) IL-1α, (b) IL-6, (c) immunoreactive IL-12 and (d) γIFN by PEC pooled from 5 mice given an i.p. injection of 5μg ISCOMS 3.5-72 hours before. The results shown are the mean concentration of cytokines from wild type mice (closed squares) or γIFNRKO mice (open squares), measured in triplicate after 48 hours stimulation in the presence or absence of γIFN+LPS (a-c) or the presence or absence of Con A (d) ± 1 SD (*p<0.001 versus wild type mice; **p<0.05 versus wild type mice). Control mice were saline injected animals of each strain.
Figure 5.10 ISCOMS Induced Nitric Oxide Production by PEC from γIFNRKO Mice.

Production of nitric oxide from PEC pooled from 5 mice following injection of 5μg ISCOMS. The results shown are the mean concentration of nitrite measured in triplicate from wild type mice (closed squares) or γIFNRKO mice (open squares), after culture for 48 hours in the presence or absence of γIFN+LPS ± 1 SD. Control mice were saline injected animals of each strain.
Figure 5.11  ISCOMS Induced Recruitment of PEC from IL-18KO Mice.

The graph shows PEC recruitment following an i.p. injection of 5µg OVA ISCOMS. PEC were removed from five mice by lavage, pooled and cell counts performed. The results shown are mean PEC numbers for IL-18KO mice (open squares). Saline injected mice were used as controls.
Figure 5.12 Phenotypic Analysis of ISCOMS Recruited PEC from IL-18KO Mice.

PEC were removed by lavage after an i.p. injection of 5μg OVA ISCOMS and analysed by flow cytometry. The results shown are the numbers of (a) neutrophils, (b) F4/80+ macrophages, (c) MHC class II+ F4/80 macrophages and (d) CD11c+ dendritic cells. The results are expressed as the number of cells per peritoneum which were calculated from the percentage of cells positive for each marker in the PEC pooled from 5 animals per group for IL-18KO mice (open squares). Control mice were saline injected animals.
Figure S.13  Phenotypic Analysis of ISCOMS Recruited PEC from IL-18KO Mice.

PEC were removed by lavage after an i.p. injection of 5µg OVA ISCOMS and analysed by flow cytometry. The results shown are the numbers of (a) CD4+ lymphocytes, (b) CD25+ CD4 lymphocytes, (c) CD8+ lymphocytes and (d) B220+ B cells. The results are expressed as the number of cells per peritoneum which were calculated from the percentage of cells positive for each marker in the PEC pooled from 5 animals per group for IL-18KO mice (open squares). Control mice were saline injected animals.
Figure 5.14 ISCOMS Induced Inflammatory Cytokine Production by PEC from IL-18KOMice.

Production of (a) IL-1α, (b) IL-6, (c) immunoreactive IL-12 and (d) γIFN by PEC pooled from 5 mice given an i.p. injection of 5μg ISCOMS 3.5-72 hours before. The results shown are the mean concentration of cytokines from IL-18KO mice, measured in triplicate after 48 hours stimulation in the presence or absence of γIFN+LPS (a-c) or the presence or absence of Con A (d); 1 SD(* p<0.05 versus wild type mice; ** p<0.001 versus wild type mice). Control mice were saline injected animals of each strain.
Figure 5.15 ISCOMS Induced Recruitment of PEC in IL-4KO Mice.

The graph shows PEC recruitment following an i.p. injection of 5μg OVA ISCOMS. PEC were removed from five mice by lavage, pooled and cell counts performed. The results shown are mean PEC numbers for wild type mice (closed squares) and IL-4KO mice (open squares). Saline injected mice from each strain were used as controls.
Figure 5.16  ISCOMS Induced Inflammatory Cytokine Production by PEC from IL-4KO Mice.

Production of (a) IL-6, (b) immunoreactive IL-12 and (c) γIFN by PEC pooled from 5 mice given an i.p. injection of 5 μg ISCOMS. The results shown are the mean concentration of cytokines from wild type mice (closed squares) or IL-4KO mice (open squares), measured in triplicate after 48 hours stimulation in the presence or absence of γIFN+LPS (a-b) or the presence or absence of Con A (c) ± 1 SD (* p<0.05 versus wild type mice; ** p<0.005 versus wild type mice; *** p<0.001 versus wild type mice). Control mice were saline injected animals of each strain.
**Figure 5.17 ISCOMS Induced Nitric Oxide Production by PEC from IL-4KO Mice**

Production of nitric oxide from PEC pooled from 5 mice following injection of 5μg ISCOMS. The results shown are the mean concentration of nitrite measured in triplicate from wild type mice (closed squares) or IL-4KO mice (open squares), after culture for 48 hours in the presence or absence of γIFN+LPS ± 1 SD (* p<0.01 versus wild type mice). Control mice were saline injected animals of each strain.
**Figure 5.18** ISCOMS Induced Recruitment of PEC from IL-6KO Mice.

The graph shows PEC recruitment following an i.p. injection of 5μg OVA ISCOMS. PEC were removed from five mice by lavage, pooled and cell counts performed. The results shown are mean PEC numbers for wild type mice (closed squares) and IL-6KO mice (open squares). Saline injected mice from each strain were used as controls.
Figure 5.19 ISCOMS Induced Inflammatory Cytokine Production by PEC from IL-6KO Mice.

Production of (a) immunoreactive IL-12 and (b) γIFN by PEC pooled from 5 mice given an i.p. injection of 5 μg ISCOMS 3.5-72 hours before. The results shown are the mean concentration of cytokines from wild type mice (closed squares) or IL-6KO mice (open squares), measured in triplicate after 48 hours stimulation in the presence or absence of γIFN+LPS (a) or the presence or absence of Con A (b) ± 1 SD (* p<0.05 versus wild type mice; * p<0.01 versus wild type mice; **** p<0.001 versus wild type mice). Control mice were saline injected animals of each strain.
Figure 5.20 ISCOMS Induced Nitric Oxide Production by PEC from IL-6KO Mice

Production of nitric oxide from PEC pooled from 5 mice following injection of 5μg ISCOMS. The results shown are the mean concentration of nitrite measured in triplicate from wild type mice (closed squares) or IL-6KO mice (open squares), after culture for 48 hours in the presence or absence of γIFN+LPS ± 1 SD (* p<0.05 versus wild type mice; ** p<0.005 versus wild type mice). Control mice were saline injected animals of each strain.
Chapters 6

Discussion

Although ISCOMS have been used to stimulate antigen-specific immune responses by parenteral and mucosal routes, the mechanisms that underlie these adjuvant effects have not been elucidated. The results presented in this thesis have demonstrated that the adjuvant properties of ISCOMS are associated with an ability to stimulate an innate inflammatory cascade, and that only certain components of this response are essential for the antigen-specific effects of ISCOMS. My work therefore extends previous investigations into the non-specific properties of ISCOMS [Watson et al., 1989, Villacres-Eriksson et al., 1993, Behboudi et al., 1996, Behboudi et al., 1997, Villacres-Eriksson et al., 1997] and showed that IL-12 played a particularly important role in the immunogenicity of ISCOMS. A clearer understanding of how adjuvants like ISCOMS exert their effects may lead to more efficiently designed and effective vaccines that are active parenterally and orally.

My initial experiments examined which, if any, inflammatory effects were induced after an injection of ISCOMS. I decided to focus primarily on following the response after a parenteral injection of ISCOMS into the peritoneum, which provided an easily accessible and discrete site to collect and assess the functional activity of any cellular infiltrate. Once this protocol had been established, I then extended the work to include an assessment of the inflammatory responses occurring at mucosal sites after oral administration of ISCOMS. These experiments showed that ISCOMS induced a cascade of inflammatory events characterised by recruitment and activation of cells to the injection site and release of several inflammatory mediators. To assess the role of these factors in the generation of antigen-specific immune responses to immunisation of ISCOMS, I immunised gene-targeted knockout mice and monitored their specific immune responses as determined by parameters already established in the laboratory. These studies identified IL-12 as the only mediator of all of the factors induced by ISCOMS which was necessary for specific immune responses to ISCOMS. Responses were either completely normal or only partially defective in the absence of the other mediators.
Once this had been established, I then went on to determine how the same inflammatory cytokines influenced the inflammatory cascade induced by ISCOMS. In this case the innate cascade was lacking in both IL-12KO and γIFNRRKO mice, despite the fact that antigen-specific immune responses were lacking only in the IL-12KO animals. This apparent dichotomy indicated that the role of the ISCOMS induced innate immune response in the generation of antigen-specific immunity is as complex as it is important and must be better understood if efficacious and potent vaccines are to be developed.

**ISCOMS Induce an Inflammatory Cascade**

Over the past few years, the view that the innate immune response was merely a retention of an immune mechanism utilised by primitive evolutionary ancestors, has been redefined. As a result, it has been realised that these non-specific inflammatory processes both initiate and co-ordinate the antigen-specific immune responses by recruiting and activating immune cells, as well as providing appropriate cytokines and costimulatory molecules necessary for promoting adaptive immunity. The innate immune response therefore plays a number of crucial roles in the induction and shaping of protective immunity [Medzhitov and Janeway Jr, 1997a, Fearon and Locksley, 1996].

In Chapter 3, I showed that intraperitoneal injection of ISCOMS induced intense local activation of the innate immune response, which consisted of recruitment of a wide variety of inflammatory cells including neutrophils, mast cells, dendritic cells, macrophages and lymphocytes. Many of these cells were activated as evidenced by expression of surface activation markers and the production of cytokines and other mediators.

The first effect of injecting ISCOMS was a pronounced decrease in the numbers of PEC which was retained up to 48 hours after administration of ISCOMS. The saponin derivative Quil A has long been known to have haemolytic properties which are due to its ability to disrupt membranes by binding to cholesterol and inducing pore formation [Kensil, 1996, Ronnberg et al., 1997]. As ISCOMS have some of the haemolytic nature of Quil A [Gupta et al., 1993], the sudden decrease in total PEC cell numbers that occurred immediately
after administration of ISCOMS could be due to cell death because of the toxic effects of Quil A. However I found no evidence of cell death in PEC at any time after injection of ISCOMS as determined by histological examination. As this may have been because I did not examine PEC removed from mice at an early enough time after administration of ISCOMS, it would be important to assess PEC isolated at earlier timepoints. However, at present I did not find any evidence that cell death is responsible for the loss in numbers. An alternative mechanism which may explain this observed phenomenon was that ISCOMS induced some cells to leave the peritoneum and migrate to draining lymph nodes. Experiments to confirm this possibility should be part of any future work and could be performed by labelled PEC prior to injection of ISCOMS and then monitoring where these cells travel to after injection.

In the next 48 hours after injection of ISCOMS there was a large increase in the numbers of cells recovered from the peritoneum. This local inflammatory infiltrate consisted of an initial emigration of neutrophils, followed by macrophages and dendritic cells, and eventually lymphoid cells. Neutrophils are not normally present in the peritoneum, but at 3.5 and 7 hours after administration of ISCOMS, I observed a large increase in the numbers of polymorphonuclear cells. Histological and phenotypic studies identified that these were mostly neutrophils, confirming previous observations that neutrophils are recruited to the site of injection with ISCOMS [Watson et al., 1989, Watson et al., 1992]. In other models of inflammation, neutrophils are recruited by chemokines such as IL-8, neutrophil chemotactic factor (NCF), the C5a fragment of complement, prostaglandin D2 (PGD2) and leukotriene B4 (LTB4) [Baggiolini, 1995]. None of these factors were examined after injection of ISCOMS and this would be an important aspect of future studies.

The neutrophilia was accompanied by the recruitment of mast cells 6 hours after administration of ISCOMS, when there was morphological evidence of mast cell degranulation. A second, larger recruitment of mast cells was observed at 48 hours. It would be important to establish the functional implications of these findings by determining the production of mast cell products such as histamine, or mouse mast cell protease-1 (MCP-1). Together with their ability to produce arachidonic acid metabolites and preformed cytokines such as TNFα, mast cells could play an important role in initiating the early phase of the
inflammatory response. Mast cell products have been implicated as being important for the induction of several cell mediated immune responses \textit{in vivo} such as DTH and contact sensitivity [Church and LeviSchaffer, 1997], and also act as sources of chemotactic agents for other leukocytes. For example TNF\alpha and LTB4 are important for the recruitment of macrophages and monocytes [Wershil et al., 1991]. It is not clear how ISCOMS could recruit and activate mast cells, although mast cells do accumulate early in other forms of acute inflammation, and are known to be recruited by chemotactic signals such as C3 complement fragments [Prodeus et al., 1997]. Although the most usual way that mast cells are activated is by crosslinking of IgE bound to FceR by multivalent antigen [Galli et al., 1999], this could not occur so quickly after administration of ISCOMS. Therefore, an alternative mechanism must be initiating the activation of these cells and one possibility is that a secretory factor produced by neutrophils or another cell type may induce degranulation. This is consistent with other findings that TNF\alpha [Brzezinska-Blaszczyk and Pietrzak, 1997] and stem cell factor (SCF) [Wershil et al., 1992] were able to induce mast cell degranulation and may implicate neutrophils as the cells from which mast cell stimulators are released. However, the role of mast cells in the induction of specific immunity by ISCOMS remains to be clarified, although this could be achieved using mast cell deficient W/W\textsuperscript{v} mice.

Macrophages were next population to appear in the recruited PEC, reaching maximal numbers 48 hours after injection of ISCOMS. Macrophages were identified histologically on cytospins by their characteristic kidney-shaped nuclear morphology, and phenotypically by the expression of the pan metalophilic tissue macrophage marker F4/80. The macrophages may have been recruited to the injection site by neutrophil derived chemotactic factors such as macrophage chemotactic factor-1 (MCP-1) and TNF\alpha. The ISCOMS recruited macrophages were shown to be activated both by their large and foamy morphological appearance and by their increased expression of MHC class II. These observation were consistent with other laboratories' findings of increased MHC class II expression after ISCOMS treatment [Watson et al., 1992, Bergstrom et al., 1990]. Despite this and in contrast to earlier findings of elevated CD86 on APC removed from ISCOMS vaccinated mice [Sambhara et al., 1998], in preliminary studies I found little or no alteration in CD40, CD80

162
or CD86 expression on ISCOMS recruited macrophages. This suggests that these cells may play an inflammatory role, rather than being directly involved in presenting antigen to T cells. This is consistent with evidence from this and other laboratories using silica or the liposomal toxin dichloromethylene diphosphate (Cl2MDP) to block macrophage function, that macrophages are not important for the priming of most specific immune responses by ISCOMS [Maloy, 1996, Claassen et al., 1995]. Nevertheless, ISCOMS appear to be taken up efficiently by macrophages, presumably reflecting their particulate nature [Claassen et al., 1995, Claasen et al., 1995] and it has been shown that eliminating macrophages markedly inhibits the induction of OVA-specific CD8+ CTL responses in vivo [Maloy, 1996] as well as a reduction in viral specific CTL activity in other systems [Wijburg et al., 1997]. Thus the role of macrophages in the uptake and preservation of ISCOMS associated antigen needs to be examined directly.

Increased numbers of dendritic cells, determined as cells expressing CD11c were also observed in the recruited PEC population. Dendritic cells were present in low numbers in control PEC populations and disappeared soon after injection of ISCOMS. The loss of dendritic cells at early timepoints may be a result of cell death, or that dendritic cells are migrating away from the peritoneum after ISCOMS injection, which would be consistent with their proposed immune surveillance role. The number of dendritic cells then increased to a maximum at 72 hours, and these cells were mature as determined by their co-expression of MHC class II [Cella et al., 1997]. It is now considered that dendritic cells are the principle APC that can prime naive T cells, due to their efficient ability to take up and process antigen, as well as their expression of high levels of MHC class II and of costimulatory molecules such as CD40, CD80 and CD86 in conditions of inflammation [Gallucci et al., 1999]. I did perform preliminary experiments to explore the expression of CD80 and CD86 costimulatory molecules on ISCOMS recruited dendritic cells, but I did not detect any expression either before or after administration of ISCOMS at any timepoint. This could reflect that I looked at the wrong time and that the relevant dendritic cells were either recruited at later timepoints or had already left the injection area, and those I examined were recently recruited, immature cells. Recent studies conducted in the laboratory since I left support this latter possibility, as
they show that there is a very early increase in dendritic cell numbers at times before I looked, 1-2 hours after injection of ISCOMS and that PEC contain antigen-loaded APC at this time (Allan Mowat personal communication). In addition, other work using the cytokine Flt3 ligand (FL3L) to recruit dendritic cells, has shown that OVA-specific responses are enhanced in FL3L treated mice immunised with ISCOMS (Allan Mowat personal communication). More work is clearly warranted to investigate fully the role of dendritic cells in the establishment of immune responses to ISCOMS.

At the same time that activated macrophages and dendritic cells were observed in PEC populations, lymphocyte numbers were also increasing. A small number of CD4+ T cells were identified in PEC from control mice, but within a few hours of administration of ISCOMS, this population decreased before steadily returning towards background levels by 48-72 hours. At this time a large percentage of CD4+ T cells were activated, as determined by their co-expression of the IL-2 receptor α chain (CD25). A similar pattern of CD8+ T cell recruitment was also observed, although the low numbers of these cells present, meant that it was not possible to assess their expression of CD25. As ISCOMS are strong inducers of CD8-restricted CTL activity [Mowat et al., 1991a, Heeg et al., 1991, Smith et al., 1998], it would have been useful to have examined this in more detail. The fact that lymphocytes were the last cell types to be recruited into the PEC suggested that these cells might include antigen-specific T cells destined to respond to the OVA incorporated in the ISCOMS. To examine this, I undertook preliminary experiments in which OVA-specific TcR transgenic CD4+ and CD8+ lymphocytes were transferred into syngeneic recipients, before i.p. injection with ISCOMS. These studies indicated that OVA-specific CD4+ and CD8+ T cells were part of the lymphocyte recruitment and that these cells showed signs of activation such as an increase in size (data not shown). More detailed timecourse studies of the appearance and functions of these transgenic T cells would provide information on the relationships between ISCOMS induced inflammation and the priming of specific T cells.

Although ISCOMS can prime antigen-specific antibody responses [Lovgren et al., 1988, Morein, 1991, Sjolander et al., 1996], little is known about how ISCOMS promote these responses. I found that ISCOMS also recruited B cells into the peritoneum, although
whether these cells were activated or producing OVA-specific antibody was not determined. It would also have been interesting to examine if the recruited B cells played any part in the induction of primary immune responses to ISCOMS, but μMT KO mice lacking B cells were not available to examine this.

Oral administration of ISCOMS also induced an inflammatory infiltrate in the lymphoid tissues of the gut. However alterations of the cell populations in these tissues was less marked than in the peritoneum, perhaps indicating tighter regulation of potentially dangerous inflammation in this vulnerable organ, as well as the fact that the gut is not a closed compartment like the peritoneum. A single feed of ISCOMS did not induce the decrease in cell numbers in either PP or MLN that I had observed in PEC. Instead, cell numbers increased steadily in both tissues to peak at 48-72 hours. In addition there was no recruitment of neutrophils in either MLN or PP at any time after feeding ISCOMS, perhaps reflecting the fact that neutrophils are rare in these tissues. It may be important to control rigorously the recruitment of these potent inflammatory cells to such delicate tissues.

Despite the absence of neutrophilia in the gut, recruitment and activation of macrophages was still noted in both MLN and PP. The numbers of F4/80+ macrophages in MLN resembled the pattern of recruitment observed in PEC, with numbers increasing gradually to a peak almost 4 times that of controls at 48 hours. These cells were almost all activated as indicated by their co-expression of MHC class II. The profile of F4/80+ macrophage recruitment in PP was completely different, as it was characterised by an immediate increase at 7 hours and levels above background for the duration of the experiment. Again nearly all these macrophages expressed MHC class II. Thus neutrophils are not essential for the recruitment of macrophages into tissues in response to ISCOMS. MHC class II expressing mature dendritic cell numbers were increased in MLN, with the peak seeming at 48 hours after feeding ISCOMS. However, there was no increase in dendritic cell numbers in the PP and it would be interesting to determine whether this reflected emigration to the MLN by the time I examined the cells. Afferent lymph draining from the gut mucosa and PP contains many dendritic cells [Lui and MacPherson, 1995] which are
known to constantly migrate to the MLN, especially after exposure to inflammatory stimuli [MacPherson et al., 1995]. This could have accounted for the increase in dendritic cells numbers I found in the MLN after feeding ISCOMS.

MLN tissue showed an almost identical pattern of T cell recruitment as that found in PEC. CD8+ lymphocytes increased to a peak at 48 hours and CD4+ lymphocytes also increased gradually until a maximum at 72 hours, and by this time 15% were CD25+. In PP there was no real change in CD8 numbers after feeding ISCOMS, but a small increase in CD4+ T cells was observed at 3.5 hours and again at 72 hours, although these cells did not express CD25. B cell numbers were also increased in MLN after feeding ISCOMS, peaking by 48 hours. This pattern although smaller was also present in PP.

Together these results suggest that there is more recruitment of cells after feeds of ISCOMS in the MLN and they are consistent with the idea that the increased numbers of dendritic cells, lymphocytes and macrophages in MLN are derived from cells emigrating from the PP and the intestinal mucosa. However, this needs to be confirmed in more detailed timecourse studies using OVA-specific TcR transgenic T cells to define where and when ISCOMS first initiates inflammation and then activation of specific T cells. I did undertake preliminary studies to investigate the localisation of orally administered ISCOMS and these suggested that the ISCOMS could be detected rapidly in cells both in the PP and the intestinal LP. This partly which confirms other studies showing localisation of ISCOMS to the PP after feeding [Claasen et al., 1995], but I was unable to establish the identity of the cells involved. It would be of interest to determine the nature of these cells and their subsequent migration pathways in vivo.

Together, these results show that ISCOMS recruit many components of the innate and adaptive immune responses. This recruitment is not restricted to the periphery and although cellular changes are less pronounced in the GALT, the same pattern of recruitment is present at least in the MLN. I then went on to examine the functional significance of this inflammatory infiltrate, by exploring the pattern of inflammatory mediator secretion after administration of ISCOMS.
The Importance of ISCOMS Induced Inflammatory Mediator Production

The cytokines and other inflammatory mediators, produced during the early inflammatory response are critical for initiating and shaping the primary antigen-specific immune response [Fearon and Locksley, 1996b, Medzhitov and Janeway Jr, 1997a]. I therefore examined the pattern of inflammatory cytokine recruitment after administration of ISCOMS and also, how the absence of some of these affected antigen-specific and innate immune responses, using gene-targeted knockout mice.

Although previous studies had demonstrated that in vitro administration of ISCOMS induced IL-1 secretion from spleen cells [Villacres-Eriksson et al., 1993], other reports had suggested that no IL-1 was detected in vivo after administration of ISCOMS [Behboudi et al., 1996]. PEC from control mice did not secrete IL-1α, but 48 hours after injection of ISCOMS, large quantities of IL-1α were present in PEC supernatants. Interestingly, the amount of IL-1 produced by ISCOMS induced PEC was the same irrespective whether the PEC were stimulated with γIFN+LPS or not, suggesting ISCOMS may have primed maximal amounts of IL-1 production. This IL-1 was dependent on the presence of adherent cells, consistent with the source being activated macrophages whose recruitment was also maximal at this time. I was unable to determine the role of IL-1 in ISCOMS mediated antigen-specific immunity, because no viable IL-1 deficient mice or depleting antibodies were available. However, this cytokine is an important component of the acute phase, regulating the recruitment and activation of a number of inflammatory cells, as well as increasing the expression of adhesion molecules on vascular endothelium and assisting in the activation of T cells. Thus a role for IL-1 in the induction of antigen-specific immune responses to ISCOMS cannot be excluded without direct investigation.

IL-6 production was also enhanced in ISCOMS stimulated PEC and again this correlated with maximal numbers of activated macrophages and was dependent on the presence of adherent cells. This observation confirms earlier findings that ISCOMS induced elevated serum IL-6 levels [Behboudi et al., 1997]. IL-6 is an important mediator for effector immune responses, having a role in the promotion of T cell proliferation in synergy with IL-1.
[Houssiau and Van Snick, 1992] and also differentiation to Th2 CD4+ T cells [Rincon et al., 1997], as well as promoting B cell differentiation and antibody responses [Takatsuki et al., 1988]. Therefore I investigated the ability of ISCOMS to induce antigen-specific immune responses in IL-6KO mice. Previous studies in these mice showed them to have defective protective immune responses to intracellular infections such as vaccinia virus [Kopf et al., 1994], *L. major* [Kopf et al., 1994] and *C. albicans* [Romani et al., 1996], as well as defects in mucosal IgA secretion [Ramsay et al., 1994], IgG production and CTL activity [Kopf et al., 1994]. However, I found that IL-6KO mice developed entirely normal antigen-specific immune responses to parenteral immunisation with OVA ISCOMS, as determined by DTH, proliferation, CTL activity, cytokine and antibody profiles. The retention of antigen-specific immune responses in IL-6KO mice is consistent with other studies in these animals which showed normal responses to CT + KLH given orally or nasally and normal IgA responses to an infection of *Helicobacter felis* [Bromander et al., 1996]. I was unable to examine the status of secretory immunity in IL-6KO mice immunised orally with OVA ISCOMS due to the fact that these mice were no longer available to me. However, I can conclude that IL-6 is not required for the majority of responses induced by ISCOMS.

The innate immune cascade induced by ISCOMS was also normal in IL-6KO mice as far as I examined. IL-6KO mice had normal recruitment of total PEC and production of inflammatory mediators. However, in light of the previous reports of the defects in neutrophil recruitment that these mice exhibit [Kopf et al., 1994], it would have been interesting to undertake a phenotypic study of the PEC recruited after injection of ISCOMS, so as to clarify the importance of this cytokine for the recruitment and activation of individual inflammatory cells after injection of ISCOMS.

An i.p. injection of ISCOMS led increased production of γIFN by Con A stimulated PEC. This showed a biphasic pattern, with an early but transient increase first occurring at 3.5 hours. After a subsequent fall, γIFN production rose again to levels four times greater than baseline by 24 hours. As γIFN activates transcription of the genes that encode the enzymes of the NADPH oxidase system [Cassatella et al., 1990], the early spike in γIFN production may have been responsible for the production of H2O2 by neutrophils recruited to the peritoneum.
after injection with ISCOMS. I did not determine the source of the ISCOMS induced γIFN at either timepoint. Although the production of γIFN required the presence of adherent cells, it is unlikely that these cells themselves are producing γIFN. CD4+ T cells, CD8+ T cells and NK cells can all produce γIFN [Heinzel et al., 1994]. However, NK cell derived γIFN requires accessory cell derived cytokines such as IL-12 and TNFα [Tripp et al., 1993], which are both produced by among other cell types, adherent macrophages. CD4+ and CD8+ T cells were rare at the time I found maximal levels of γIFN. Thus it may be that NK cells were involved, an idea that is consistent with evidence from other systems in which NK cells producing γIFN early in the immune response [Billiau, 1995]. One other possibility is the small subset of NK1.1+ CD4+ T cells which recognise lipid antigens derived from microbes in association with non-classical restriction elements such as CD1, and produce large amounts of IL-4 together with other cytokines such as γIFN [Vicari and Zlotnik, 1996]. CD1 is capable of presenting non-peptidic antigens such as lipids and glycolipids [Porcelli et al., 1998], and as ISCOMS contain many lipid elements, it is feasible that these could be capable of binding to CD1. It would be interesting to define the cells producing γIFN early after administration of ISCOMS, for example by intracellular cytokine staining.

γIFN has a number of properties which could influence immune responses and inflammation induced by ISCOMS, including activation of phagocytic activity and increasing MHC class II expression on APC, the development of Th1 responses, the establishment of CTL activity [Roth et al., 1991] and switching to an IgG2a antibody isotype [Finkelman et al., 1988]. I therefore examined the requirement for γIFN in immunity to parenterally and orally administered ISCOMS using γIFNKO mice. Surprisingly, I found that γIFNKO mice had normal or even increased DTH responses after immunisation with OVA ISCOMS. This is in contrast to other observations in the laboratory which had shown that γIFNKO mice had impaired responses to OVA and CFA [Mowat et al., 1999]. As I measured a classical DTH response which peaked at 24-48 hours after challenge, the reasons for this retention of DTH to OVA ISCOMS in the absence of functional γIFN are unclear. However, it could reflect the ability of ISCOMS or Quil A to induce mediators which may compensate for the usual requirement of γIFN. Thus it would be of interest to examine whether the DTH
response in γIFN-RKO mice is identical in all respects to that in normal animals and if it is affected by neutralisation of other cytokines. Overall, there was no evidence for a defect in antigen-specific immunity to OVA ISCOMS in γIFN-RKO mice. Although I found a decrease in OVA-specific proliferative responses after oral immunisation of these mice and others have reported defective mucosal immune responses to orally administered CT [Kjerrulff et al., 1997] and Salmonella in γIFN-RKO mice [Hess et al., 1996], other responses to oral OVA ISCOMS, were normal or increased, including siGf production. In addition, all responses to OVA ISCOMS were normal after parenteral immunisation. Antigen specific proliferative responses were actually increased after subcutaneous immunisation with OVA-ISCOMS, a finding that may be due to the known cytostatic properties of this cytokine [Jeong, 1995, Hansson et al., 1989]. The cytokine profiles of both s.c. and orally immunised γIFN-RKO mice showed a greatly increased level of antigen-specific IL-5 production, consistent with the known ability of γIFN to suppress Th2 dependent responses [Wange et al., 1994]. Similar findings were seen with the IgG1 and IgG2a antibody isotypes, as γIFN-RKO mice had suppressed IgG2a and elevated IgG1 antibodies. I also found that γIFN-RKO mice produced levels of γIFN which were above that of the wild type mice, confirming earlier findings have been reported by others [Dalton et al., 1993]. This indicates that the production of γIFN in vivo does not require γIFN signalling and suggests that γIFN may normally down-regulate its own production. As γIFN has been identified as a potential cofactor for the generation of CD8 restricted CTL activity [Roth et al., 1991], it was somewhat surprising that CTL responses were normal in OVA ISCOMS immunised γIFN-RKO mice, or even increased. These results indicate that other factors must be involved in the generation of OVA-specific CTL by immunisation with ISCOMS.

Despite the mostly normal specific responses in γIFN-RKO mice, the development of a full innate inflammatory cascade was dependent on the presence of functional γIFN, as γIFN-RKO mice failed to generate normal cellular recruitment after injection of ISCOMS. These mice showed reduced recruitment of neutrophils, lowered recruitment of B220+ lymphocytes and CD4+ lymphocytes and no recruitment of macrophages. However, relatively normal CD8 recruitment was noted and an increase in dendritic cell numbers was
also observed. In addition to the defective inflammatory responses seen in γIFNRKO mice, the inflammatory cells that were recruited showed virtually no evidence of activation as assessed by expression of cell surface markers, or the secretion of inflammatory cytokines and mediators. As antigen-specific immune responses to ISCOMS were normal after both parenteral and oral immunisation of IFNRKO mice, the remaining innate responses in these animals may provide enough of an innate trigger to induce adaptive immunity. Alternatively other factors whose activity I did not measure in γIFNRKO mice given ISCOMS, may have been important, such as mast cells. It is possible that a relatively normal range of innate responses did occur in these mice, but that these were delayed beyond the 72 hour timecourse that I examined. Thus a longer time course measuring more innate factors is warranted in these animals to attempt to understand the dichotomy between the innate and adaptive responses to ISCOMS in the absence of functional γIFN.

The cytokine for which I obtained the most conclusive evidence as being involved in the immunogenicity of ISCOMS was IL-12. PEC from ISCOMS injected mice showed elevated IL-12 production at 72 hours, extending recent findings of elevated serum IL-12 levels after injection of ISCOMS [Villacres-Eriksson et al., 1997]. The increased levels of IL-12 in PEC and PP coincided with the appearance of cells such as macrophages, dendritic cells and B cells, all of which can secrete IL-12 [Trinchieri, 1995]. The production of IL-12 in vitro required the presence of adherent cells and recent studies have indicated that ISCOMS can directly stimulate production of IL-12 mRNA from PEC adherent cells [Grdje et al., 1999], suggesting an involvement of macrophages in this process. It would be interesting to determine the source of this IL-12 more directly, for example by observing coexpression of internal IL-12 in phenotypically labelled cells either by flow cytometry or immunohistochemistry in vivo [Reis e Sousa et al., 1997]. Although ISCOMS may indeed induce IL-12 production directly from macrophages, recent studies suggest that a substantial proportion of IL-12 in vivo is derived from dendritic cells, often requiring activation by CD40-CD40 ligand (CD40L) interactions with antigen-specific T cells [Stubber et al., 1996, Kennedy et al., 1996]. This could be explored by a combination of the approaches described above, together with the use of CD40LKO mice.
When I examined the requirement of IL-12 in antigen-specific immune responses to ISCOMS, I found that IL-12KO mice had substantial defects in these responses. This defect was more pronounced in parenterally immunised mice, but was also present after oral immunisation. In contrast to the published evidence that IL-12KO mice have only selective defects in Th1 and CD8 T cell activity [Trinchieri, 1995], I found that virtually all immunological parameters were decreased in IL-12KO mice immunised with OVA ISCOMS. In addition to the expected defects in DTH, γIFN production and CTL activity, I also found that there was a 40% reduction in OVA-specific proliferation in IL-12KO mice. This may reflect the role of IL-12 in inducing the expression of the IL-2Ra and β subunits [Robertson et al., 1992, Nuame et al., 1992], an idea supported by the my observation that IL-12KO mice failed to increase expression of CD25 on peritoneal CD4+ T cells following administration of ISCOMS. More surprisingly, s.c. immunised IL-12KO mice also had defective IL-5 production, supporting further the possibility that IL-12 plays an important role in the priming of all T cells, rather than just Th1 cells. Nevertheless, it should be noted that IL-12KO mice had a selective defect in IgG2a responses, whereas the Th2 dependent IgG1 response was normal or even enhanced. This supports other studies which have revealed that IL-12 regulates the production of IgG isotypes after immunisation [McKnight et al., 1994, German et al., 1995, Buchanan et al., 1995] IL-12KO mice also had a 50% reduction in CTL activity compared with wild types after i.p. immunisation, extending previous studies on the role of IL-12 in the generation of antigen-specific CTL [Abdi and Herrmann, 1997] and the increased susceptibility of these animals to intracellular pathogens such as Leishmania major [Mattner et al., 1996], Mycobacterium tuberculosis [Cooper et al., 1997] and Listeria monocytogenes [Gateley et al., 1998]. Thus IL-12 plays an important and wide ranging role in the induction of systemic immune responses by parenterally administered ISCOMS. However, its influence on the mucosal immune responses seemed less, with entirely normal secretion of intestinal IgA antibodies in IL-12KO mice. This may indicate that the GALT may use alternative mechanisms for generating inflammation, to compensate for the lack of IL-12.
In addition to the defective antigen-specific systemic immune response to ISCOMS in IL-12KO mice, these animals also had a severely impaired innate response to ISCOMS, with low levels of recruitment of neutrophils, macrophages, CD4+ or CD8+ T cells and B cells, being the only changes observed. The macrophages and CD4+ T cells which were recruited also failed to show evidence of activation, such as production of inflammatory mediators and expression of MHC class II or CD25 respectively. Interestingly, the baseline numbers of dendritic cells were increased in these mice, although no additional recruitment of these cells was observed, indicating that IL-12 may in some way regulate proliferation of dendritic cells. The marked lack of an inflammatory cascade in IL-12KO mice could reflect an absence of chemotactic factors such as IL-8 whose production may be dependent on IL-12 [Nuame et al., 1993]. The lack of MHC class II on macrophages presumably reflects the expected absence of γIFN, while the absence of CD25 on T cells supports the suppressed proliferative responses in ISCOMS immunised IL-12KO mice. Despite the severely altered innate immune responses to ISCOMS, it is important to note that antigen-specific responses were not completely lost in IL-12KO mice, indicating that there are other factors which govern the generation of adaptive immunity in the absence of IL-12. These may be factors which I did not measure, such as mast cells and other inflammatory mediators and chemokines, which can replace in part, the function of IL-12. One candidate for this is IL-18, which has many properties that are similar to IL-12, including the generation of NK activity and γIFN secretion [Kohno and Kurimoto, 1998], and is also secreted from activated macrophages [Okamura et al., 1998b].

As a suitable ELISA did not become available until the end of my project and I was unable to establish PCR methods for assessing IL-18 mRNA levels, I could not determine whether ISCOMS stimulated the production of IL-18 in vitro. However, during the course of my work, IL-18KO mice were developed in the department and I was able to perform a preliminary experiment in which specific immune responses were examined in the absence of IL-18. However, conflicting results were obtained. Although, homozygous IL-18−/− mice had dramatically reduced antigen-specific DTH responses after subcutaneous immunisation and a partial decrease was also noted in heterozygous IL-18+/− mice, other responses were normal.
S.c immunised IL-18KO mice had normal OVA-specific IL-5 and more surprisingly, normal γIFN responses, contrasting with earlier findings that IL-18 is closely implicated in the induction of γIFN production [Okamura et al., 1998a, Kohno and Kurimoto, 1998]. Similarly all of the IL-18KO mice also had normal IgG1 and IgG2a antibody responses. When these mice were immunised orally, conflicting data were also obtained. In contrast to s.c. immunised mice, homozygous and heterozygous IL-18KO mice had normal DTH and antigen-specific proliferative responses, but had severely defective OVA-specific γIFN secretion and enhanced IL-5 production. This pattern supports the role of this cytokine in the establishment of Th1 cell activity but contrasts with my earlier observations in s.c. immunised animals. Orally immunised IL-18KO mice also developed normal OVA-specific cytotoxicity, as well as IgG1 and IgG2a antibody responses. These results need confirmation in a larger series of studies in IL-18KO mice.

I also undertook a preliminary experiment to explore the ISCOMS induced inflammatory cascade in IL-18KO animals. Although no wild type animals of the appropriate strain were available at the time I carried out this experiment and the results must be interpreted with caution, but i.p. injection of IL-18KO mice with ISCOMS did not induce the usual pattern of cellular recruitment that I found in previous experiments in wild type mice. There was no increase in total PEC numbers and there was a failure to recruit neutrophils, CD4⁺ T cells and macrophages. There was also no evidence of increased MHC class II expression on macrophages, or of CD25 expression on CD4⁺ T cells. However there were elevated numbers of CD8⁺ T cells, B cells and mature dendritic cells. These features were somewhat similar to those I found in IL-12KO and γIFNKO mice. Nevertheless, PEC from ISCOMS injected IL-18KO mice had some evidence of functional activity, as they produced increased amounts of IL-1α, IL-12 and γIFN, although IL-6 did not increase above control levels. Again it would be important to repeat these studies using more IL-18KO and wild type mice in parallel. However, my preliminary results suggest that the role of IL-18 in the innate and adaptive responses to ISCOMS warrants further study, both by more extensive confirmation of my findings, as well as by determining if IL-18 is induced by ISCOMS as
part of an early innate cascade. It would also be useful to determine if IL-12 and IL-18 play overlapping roles using IL-12 x IL-18 double knockout mice.

IL-4 has potent immunomodulatory properties, including the activation or inhibition of APC activity, as well as promoting the differentiation of Th2 cells [Noble et al., 1993, Nabors and Farrell, 1994]. As my results confirmed, previous work in the laboratory had shown that ISCOMs were capable of inducing antigen-specific Th2 responses [Maloy et al., 1995, Maloy, 1996] and others had shown that mucosal adjuvant properties of CT were dependent on IL-4 [Vajdy et al., 1995]. Therefore I attempted to assess whether IL-4 was important for the induction of immune responses by ISCOMs, first by measuring the secretion of IL-4 immediately after injection of ISCOMs. However, I could not detect any IL-4 protein in supernatants from PEC taken from ISCOMs injected mice by ELISA. Therefore I rested the ability of ISCOMs to induce specific immune responses by oral and parenteral routes in IL-4KO mice.

IL-4KO mice immunised s.c. with OVA ISCOMs produced antigen-specific DTH responses above that of wild type mice, and orally immunised IL-4KO mice retained normal DTH responses. OVA-specific proliferation was increased both in s.c and orally immunised IL-4KO mice, and this normal or enhanced response may be consistent with the ability of IL-4 dependent Th2 cells to suppress Th1 dependent immune responses normally [Maggi et al., 1992]. As expected, both s.c and orally immunised ISCOMs immunised IL-4KO mice had elevated production of OVA-specific γIFN, and s.c. immunised IL-4KO mice produced significantly less IL-5 than wild types. Although orally immunised IL-4KO mice also produced low levels of IL-5, surprisingly these were higher than those in wild type animals. This may be consistent with early reports that IL-5 production could be partially preserved in IL-4KO mice [Kuhn et al., 1991, Kopf et al., 1993]. I found that antigen-specific CTL responses were also retained in IL-4KO mice after both oral and parenteral immunisation at levels similar to or greater than those in the wild type mice, despite evidence that IL-4 may be a growth factor for CTL in vitro [Liang et al., 1992, Horvat et al., 1991]. However, this is the first study to examine antigen-specific CTL induction in IL-4KO animals in vivo and the preserved activity may reflect the ability of other cytokines such as IL-2 [Horvat et al., 1991,
Ley et al., 1991], γIFN [Roth et al., 1991] and IL-15 [Ye et al., 1996] to compensate as CTL growth factors in vivo. Th2 cells and, in particular IL-4, have also been associated with regulating the production of sIgA in the intestine [Murray et al., 1987, Harriman et al., 1988], but I found that the total sIgA antibody production was actually enhanced in IL-4KO mice compared with controls. These results contrast with the defective IgA responses found in IL-4KO mice immunised orally with antigen and cholera toxin (CT) [Vajdy et al., 1995], but similar findings of normal mucosal responses in the absence of IL-4 have been made using Salmonella as a mucosal adjuvant [Okahashi et al., 1996]. The local immune response to CT itself is also intact in IL-4KO mice [Vajdy et al., 1995]. The innate immune responses I measured in IL-4KO mice were also normal after injection of ISCOMS indicating that IL-4 is not essential for either specific or innate immune responses induced by ISCOMS. However, this may be due to the activity of compensatory cytokines such as IL-6, IL-10 or TGFβ [Okahashi et al., 1996]. As described previously, I investigated the role of IL-6 in the generation of antigen-specific immune responses to ISCOMS and found it not to be required. Therefore it would be important to establish the role of IL-10 and TGFβ, in compensating for the absence of IL-4. IL-13 would be a further important molecule to examine shares many of the biological functions of IL-4 [Chomarat and Banchereau, 1998]. Its role could be determined using IL-4 x IL-13 double knockout mice or in IL-4RaKO mice [Mohrs et al., 1999].

An i.p. injection of ISCOMS produced large increases in the respiratory burst, as measured by H2O2 and also increased NO production. The production of oxygen radicals and H2O2 are crucial innate mechanisms for the control of intracellular microbes [Clark, 1999] and are properties of activated macrophages and neutrophils. After injection of ISCOMS, the peak production of ROI coincided with the maximal neutrophilia and occurred at a time when other potential ROI producing cells were virtually absent from the PEC population. In parallel, there was no neutrophil recruitment or ROI production in tissues of the GALT after feeding ISCOMS. These results suggest that neutrophils are the source of ROI after injection of ISCOMS and confirm that these cells are activated.
Although it is unlikely that these ROI could contribute to the induction of specific immunity to ISCOMS, nitric oxide was also increased after injection of ISCOMS. This corresponded with the maximum recruitment of activated macrophages and the production of NO was totally dependent on the presence of adherent cells, supporting other evidence that activated macrophages are the major source of iNOS derived NO [Nathan and Hibbs, 1991]. The peak production of NO also coincided with the maximum secretion of \( \gamma \)-IFN which is a known promoter of iNOS activity [Xie et al., 1992] and its rapid loss may reflect the fact that NO can regulate its own production [Huang et al., 1998]. There was no NO production was observed in the gut after feeding ISCOMS, perhaps because the repeated exposure to low doses of LPS, which occurs in the gut may cause a state of unresponsiveness of iNOS induction which has been demonstrated in macrophages pre-incubated with small concentrations of LPS \textit{in vitro} [Severn et al., 1993]. Mice deficient in iNOS have been shown previously to be susceptible to a range of intracellular and extracellular infections such as \textit{L. major}, herpes simplex virus [McClean et al., 1998], as well as having decreased susceptibility to endotoxic shock [Wei et al., 1995]. In addition to this critical role as a microbicidal factor, other reports have suggested that NO may also influence the outcome of antigen-specific immune responses. First, NO can decrease the expression of MHC class II [Sicher et al., 1994] as well as the proliferation of T lymphocytes [Wei et al., 1995]. In addition, it can down regulate the production of \( \gamma \)-IFN \textit{in vitro} and promote a more Th2 like T cell phenotype [Huang et al., 1998]. Thus I attempted to examine specific immune responses to ISCOMS in a small cohort of iNOSKO mice that had been generated in the department. In these preliminary studies, OVA-specific DTH responses were normal after s.c. immunisation, as was antigen-specific proliferation as well as IgG1 and IgG2a antibody production. However, iNOSKO mice had markedly reduced levels of both OVA-specific \( \gamma \)-IFN and IL-5 production. Thus it appeared that the loss of functional NO may have had some minor effects on the induction of antigen-specific immunity by ISCOMS, but no clear pattern was observed and it would be important to extend these studies when additional mice become available.

When I examined the inflammatory cytokine secretion in GALT after oral administration of ISCOMS a markedly different pattern was observed that compared with that.
seen in PEC cells removed after an i.p. injection of ISCOMS. I was unable to detect IL-1α production in either MLN or PP tissues at any time, IL-6 production was reduced in MLN and absent in PP cells, IL-12 production was reduced in MLN after administration of oral ISCOMS but a small but not significant increase in IL-12 was seen in PP, γIFN production was also reduced in MLN and also PP. Apart from the elevated levels of IL-12 in γIFN+LPS induced PP cells, I did not observe any increase in inflammatory mediator secretion. This is surprising given that there are populations of activated macrophages recruited into both tissues after feeding ISCOMS, although at a lower level that was observed in PEC. The lack of cytokine production may reflect a more tightly regulated inflammatory response in the GALT, or that there are different populations of macrophages secreting different cytokines in different tissues. Therefore, it would be important to assess if feeding ISCOMS induce inflammatory mediator secretion from other GALT tissues such as LP or epithelium, and this could be performed quickly by RT-PCR.

The dichotomy between the specific and innate immune responses induced by ISCOMS in IL-12KO mice and γIFNKO mice may provide some clues to how inflammatory mediators regulate the establishment of antigen-specific immunity. Although the defective antigen-specific immunity to OVA ISCOMS in IL-12KO mice was accompanied by a decrease in innate immunity, γIFNKO mice had normal or even enhanced antigen-specific immune response to OVA ISCOMS, but almost completely absent innate immunity. The only difference in the innate immune responses found in the two strains was that γIFNKO mice retained some recruitment of B cells and an early increase in CD11c+ dendritic cells, suggesting that one of these cell types could be involved in the induction of immunity to ISCOMS. Although both can produce IL-12, this appears to be a function mostly of dendritic cells in vivo [Trinchieri, 1995]. In addition, dendritic cells are generally considered to be the predominant APC able to prime T cells [Gallucci et al., 1999]. Nevertheless, B cells are also capable of acting as APC, under some conditions [Yang and Brunham, 1998, Evans et al., 2000] and it has been shown previously that splenic B cells can present ISCOMS associated antigen to T cells in vitro, almost to the same extent as dendritic
cells [Villacsres-Eriksson, 1995]. As noted earlier, the adjuvant effects of another mucosal adjuvant, CT and its derivatives, appear to be dependent on B cells [Vajdy et al., 1995]. In most cases, no role for B cells in priming T cells has been identified but this needs to be tested directly in the case of ISCOMS associated antigen using B cell KO mice. There are no specific models of dendritic cell deficiency in vivo available, but an alternative approach is to expand the dendritic cell numbers using the selective growth factor Flt3L. Preliminary experiments suggest that Flt3L does enhance immune responses and the activation of antigen-specific T cells after immunisation with ISCOMS (Allan Mowat personal communication). Therefore dendritic cells may be important in the establishment of ISCOMS immunity.

One cell that my studies seems to exclude in being central to the induction of immune responses to ISCOMS is the macrophage, as both II-12KO and yIFNKO mice had equally deficient activated macrophages in PEC after injection of ISCOMS, although yIFNKO mice had normal antigen-specific immunity despite this. In other studies, ISCOMS have been seen to accumulate within marginal metalophillic macrophages (MMM) in the spleen after i.v. injection [Claassen et al., 1995]. Depletion of these macrophages in vivo ablated T cell proliferative responses in the spleen, but did not significantly alter humoral immunity to ISCOMS [Claassen et al., 1995]. Macrophages are known to preferentially take up particulate antigens and have excellent antigen-presenting properties. Therefore the particulate nature of ISCOMS may target them to macrophages and also in the process of phagocytosis, activate them. In the presence of ISCOMS, macrophages have been shown to increase expression of MHC class II in vitro [Watson et al., 1992, Bergstrom et al., 1990], and I observed this phenomenon in vivo. However, in this laboratory, ablation of macrophages either by silica or toxin loaded liposomes did not significantly alter the generation of cell mediated responses [Matoy, 1996] which parallels my findings in the yIFNKO mice.

In order to address the mechanism by which ISCOMS exert their adjuvant effect several questions need to be addressed. Firstly, how do ISCOMS gain access to APC? One possibility is that ISCOMS directly associate with APC by binding to and stimulating receptors on the cell surface. As ISCOMS are very rich in carbohydrates because of the fact
that Quil A contains a mixture of triterpenoids [Higuchi et al., 1988], it is feasible that these may bind to receptors such as the mannose receptor found on macrophages and dendritic cells and thus be internalised [Aderem and Underhill, 1999]. Alternatively, because of their lipophilic nature, it is also possible that ISCOMS may simply diffuse through the plasma membrane and into cells.

The second important question is how do ISCOMS establish the early inflammatory response? Although, at the times I examined PEC histologically, there was no evidence of cell debris or dead cells, it is possible that the haemolytic nature of ISCOMS causes cell lysis, with release of inflammatory cytoplasmic contents into the local micro-environment, as well as ISCOMS particles themselves. This could recruit inflammatory cells, as well as dendritic cells, which have been shown recently to be able to phagocytose necrotic cells including macrophages followed by the priming of specific immune responses [Gallucci et al., 1999], may then be attracted to this site and phagocytose cell debris and ISCOMS. This possibility has recently been emphasised by observations of increased numbers of dendritic cells within 1 hour of administration of ISCOMS (Allan Mowat personal communication), which may reflect the recruitment of these cells very early to clear cell debris.

Thus I propose that ISCOMS are internalised by macrophages in vivo and that these cells are lysed due to the haemolytic nature of Quil A. The subsequent release of inflammatory cytoplasmic material, together with intact ISCOMS induces the release of chemoattractants and chemokines, and consequently the recruitment and degranulation of local mast cells followed by the release of other inflammatory molecules such as histamine. This process recruits further inflammatory cells which include dendritic cells and macrophages, which process and present the ISCOMS associated antigen and are induced to secrete large quantities of IL-12. The resulting release of γIFN then positively feeds back to increase the activation of macrophages and elevate still further the expression of surface MHC class II. IL-12 is also a direct stimulus to T cells and can induce the activity of CD8+ T cells. As a result, I predict that IL-12 derived possibly from dendritic cells may be the central factor in the ability of ISCOMS to prime such a wide range of specific immune responses in mice.
In conclusion, my results confirm and extend previous reports that ISCOMS generate wide ranging inflammatory cascade comprising recruitment of cells and release of inflammatory mediators. In addition, the mucosal and systemic immunogenicity of ISCOMS encompasses a wide range of immune effector responses, including both Th1 and Th2 dependent responses. However, the antigen-specific responses to ISCOMS are not limited by the absence of the majority of the innate factors thought to be critical for initiating these responses, γIFN, IL-4, IL-6 and iNOS respectively, but these results do indicate that there is a role for ISCOMS induced IL-12 and to a lesser extent IL-18 in the development of antigen-specific immune responses following ISCOMS immunisation. These findings distinguish ISCOMS from other mucosal adjuvant vectors such as Salmonella or CT and underline the complexity of the factors which may determine the induction of immune responses via mucosal surfaces. My results have identified key components of the innate immune response, namely IL-12, whose presence may crucial for the establishment of protective immunity by ISCOMS. The identification of such components has led to a better understanding of the mechanism by which ISCOMS exert their adjuvanticity, and hopefully may allow for their better exploitation in practical vaccine studies in the future.
Chapter 7

References

Abdi, K. and Herrmann, S. H. (1997) CTL generation in the presence of IL-4 is inhibited by free p40: evidence for early and late IL-12 function. *Journal of Immunology*, **159**: 3148.


synthesis of antigen specific complement fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. *European Journal of Immunology, 25*: 823.


Holst, M.A. and Raulet, D.H. (1989) IL-6 and IL-1 synergize to stimulate IL-2 production and proliferation of peripheral T cells. *Journal of Immunology*, **141**: 151.


responses in the murine lung to local immunization with influenza-A virus glycoproteins in
micelles and immunostimulatory complexes (iscoms). Scandinavian Journal Of Immunology,
27: 645.

mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo.
Annual Review of Immunology, 12: 207.

by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunology
Today, 20: 561.

Kamijo, R., Harada, H., Matsuyama, T., Bosland, M., Gerecitano, J., Shapiro, D., Le, J., Im,


vaccinated orally with surface sporozoite protein of Eimeria falciformis in ISCOMS.
Vaccine, 12: 798.

Kelsall, B. and Strober, W. (1996) Distinct populations of dendritic cells are present in the
subepithelial dome and T cell regions of the murine Peyer's patch. Journal of Experimental
Medicine, 183: 237.


Kohno, K. and Kurimoto, M. (1998) Interleukin 18, a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both. *Clinical Immunology and Immunopathology*, **86**: 11.


Kunimoto, D., Nordan, R. and Strober, W. (1989) IL-6 is a potent cofactor of IL-1 in IgM synthesis and of IL-5 in IgA synthesis. *Journal of Immunology*, **143**: 2230.


susceptible to infection with *Leishmania major* and mount a polarized Th2 cell response. *European Journal of Immunology, 26*: 1553.


cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. *Journal of Experimental Medicine*, 175: 779.


Scott, P. (1991) IFNγ modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. *Journal of Immunology, 147*: 3149.


Tripp, C.S., Wolf, S.F. and Unanue, E.R. (1993) Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe...
combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiological antagonist. *Proceedings of the National Academy of Science, USA*, 90: 3725.


Wynn, T.A., Eltoum, I., Oswald, I.P., Cheever, A.W. and Sher, A. (1994) Endogenous interleukin 12 (IL-12) regulates granuloma formation induced by eggs of *Schistosoma mansoni* and exogenous IL-12 both inhibits and prophylactically immunises against egg pathology. *Journal of Experimental Medicine, 179*: 1551.


Yang, X. and Brunham, R.C. (1998) Gene knockout B cell deficient mice demonstrate that B cells play an important role in the initiation of T cell responses to *Chlamydia trachomatis* (Mouse pneumonia) lung infection. *Journal of Immunology*, **161**: 1439.


220